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Abstract
Cyclic peptides possess desirable characteristics as potential pharmaceutical sca↵olds.
The cyanobactin family of cyclic peptide natural products boast diverse structures and
bioactivity. Exemplars are the patellamides, which have attracted attention due to
their ability to reverse the e↵ects of multi-drug resistance in human leukemia cells. In
addition to their macrocyclic architecture patellamides contain azol(in)e heterocycles
and d-amino acids. This structural complexity makes them challenging targets for
chemical synthesis. Understanding their biosynthesis will enable the development
of a biotechnological ‘toolkit’ for the synthesis of new pharmaceutical compounds.
Patellamides are ribosomally-synthesised and post-translationally modified peptides
(RiPPs) and much of their biosynthesis has been elucidated, however there are still
elements of their biosynthesis that are not yet fully understood.
PatA and PatG contain C-terminal domains of unknown function (DUFs). The
crystal structure of PatG-DUF has been solved and subsequent to biochemical and
biophysical investigation PatG-DUF was found not to constitute an essential part of the
biotechnological ‘toolkit’ and can be excluded from in vitro enzyme-based synthesis of
cyanobactin-like cyclic peptides.
The cyanobactin heterocyclases are able to introduce heterocycles into a peptide
backbone, seemingly irrespective of the neighbouring residues; however a molecular
rational governing substrate recognition is unknown. Additionally the mechanism of
heterocyclisaton is disputed. Analysis of crystal structures of LynD in complex with
cofactor and substrate (solved by Dr Jesko Koehnke) enabled the active site and
substrate recognition site to be located. A new mechanism for heterocyclisation has
been proposed. Guided by the substrate recognition observed in complex structures
a constituently active heterocyclase (AcLynD) has been engineered, which is able to
process short, leaderless peptide substrates.
Epimerisation in cyanobactin biosynthesis is believed to be spontaneous, but its precise
timing is uncertain. NMR analysis of selectively labelled peptide substrates processed by
the modifying enzymes, identified epimerisation to be spontaneous on the macrocycle,
regardless of whether the neighbouring heterocycles have been oxidised.
A one-pot in vitro synthesis of cyanobactins has been developed, and employed to create
a number of patellamide D analogues to ascertain structural-activity relationships.
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Introduction
1.1 Cyclic Peptides as Pharmaceuticals
Nature harbours a diverse array of bioactive cyclic peptides, many of which possess
desirable characteristics and are exploited as therapeutic agents [1–6] (Fig. 1.1). The
examples in Fig. 1.1 demonstrate the variability in size and chemical composition in
cyclic peptides o↵ered by nature, as well as the diversity of their clinical applications.
As potential pharmaceuticals, peptides exhibit a number of benefits over more traditional
small molecule compounds [7–9]. Their increased size and complexity dramatically
increases their specificity towards their biological targets, thus reducing undesired side
e↵ects — a common drawback of small molecule drug candidates [7,8]. In addition
they are able to disrupt protein-protein interactions (PPIs). PPIs typically involve
large surface areas lacking defined binding pockets, and are therefore more di cult to
target with small molecules, but are more amenable to interactions with peptides [8,10,11].
Underpinned by an enhanced knowledge and understanding of the molecular mechanisms
governing di↵erent disease pathways, the inhibition or stabilisation of specific PPIs
between subunits of essential multi-protein complexes are increasingly arising as
promising alternative pharmaceutical targets, highlighting the importance of this
advantage [12].
Cyclic peptides are of particular interest as they o↵er pharmacological advantages
over their linear counterparts [13,14]: A decrease in conformational flexibility of a
macrocycle results in a lower entropic penalty upon binding, thus increasing binding
1
Chapter 1. Introduction 2
Figure 1.1: Clinically available cyclic peptide drugs Examples of structurally
diverse, clinically available cyclic peptide drugs.
a nity [14]. Furthermore the absence of ionized termini facilitate easier passage across
lipid membranes [15,16], and provide resistance to exo-protease degradation [11]. These
advantageous properties of cyclic peptides go some way to address the shortcomings of
peptides compared with small molecules as potential drug molecules [9].
Given these desirable characteristics, the engineering of existing, and the design of novel
cyclic peptides, is an excellent route to new pharmaceutical compounds. However, like
other natural products, their complex architecture means that their chemical synthesis
is challenging and is often expensive and low yielding [6,17]. As a consequence, there is
significant interest in studying the biosynthesis of cyclic peptide natural products, with
the aim to utilise the e cient and green chemistry of enzymes to generate a diverse
range of novel pharmaceutical compounds.
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1.2 Biosynthesis of Cyclic Peptides
Originally it was believed that most cyclic peptide (as well as modified linear peptide)
natural products were the products of Non-Ribosomal Peptide Synthetases (NRPSs),
large modular protein complexes, where each module, through its associated domains, is
responsible for the incorporation (and subsequent modification if required) of a specific
amino acid into a growing peptide chain [18]. However, since the turn of the century a
growing number of highly modified cyclic and linear peptides have been found to be prod-
ucts of Post-Ribosomal Peptide Synthesis (PRPS) pathways [19,20]. These ribosomally-
synthesised and post-translationally modified peptides (RiPPs) are synthesised initially
by the ribosome as a longer precursor peptide, which undergoes extensive enzymatic
post-translational modification (PTM) to become the final product [19–21]. Although the
ribosome is canonically limited to the incorporation of proteinogenic amino acids into a
peptide, the numerous tailoring enzymes from various PRPS pathways are capable of a
wide range of modifications including, proteolysis of the precursor peptide, dehydration,
cyclodehydration (heterocyclisation), prenylation, methylation and macrocyclisation
amongst others, resulting in RiPPs displaying vast chemical and structural variation, as
well as a broad array of biological activities [19,20,22].
Exemplars of the RiPP family of natural products are the cyanobactins. Some examples
of cyanobactins, and the biosynthetic gene clusters and precursor peptides from which
they originate can be seen in Fig. 1.2. Cyanobactins, secondary metabolites of both free-
living and symbiotic cyanobacteria, are a class of cyclic, and to a lesser extent, linear
peptides, three to twenty amino acids in size, boasting a wealth of structural variation
and promising bioactivities [21]. Patellamides A, B and C have been reported to possesses
moderate antitumour activity, displaying IC50 values in the low µg mL-1 range against
a number of human cancer cell lines [23]. Moreover, patellamides B, C and D have been
shown to reduce the e↵ects of multidrug resistance (MDR) on leukemic cell lines [24,25].
The IC50 value for vinblastine against drug resistant CCRF-CEM human leukemic cells
decreases from 90 mM to 12 mM in the presence of 2.5 µg mL-1 patellamide B and
C [16,24]. Similarly the addition of 3.3 µM patellamide D to the multidrug resistant
CEM/VLB100 cell line causes the IC50 value of vinblastine, colchicine and adriamycin
to fall from 100 ng mL-1, 140 ng mL-1 and more than 1000 ng mL-1 to 1.5 ng mL-1, 50
ng mL-1 and 110 ng mL-1 respectively [16,25]. Encouraging antitumour activity has been
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reported for trunkamide A, displaying IC50 = 0.5 µg mL-1 against HT-29 human colon
carinoma and IC50 = 1 µg mL-1 against MEL-28 human melanoma cell lines [26]; and for
ulithiacyclamide with IC50 = 0.35 µg mL-1 and IC50 = 35 ng mL-1 against L210 murine
leukemia and KB cell lines respectively [26]. Antimalarial activity has been reported for
the aerucyclamide family, with aerucyclamides B, C and D displaying IC50 = 0.7, 2.3
and 6.3 µM respectively [26].
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Figure 1.2: Cyanobactins (a) Gene clusters from patellamide (pat), trunkamide
(tru), aestuaramide (lyn), microcyclamide (mic), cyanothecamide (cya) and
arthrospiramide (art) pathways. Gene clusters encode a N-terminal protease (A,
orange), heterocyclase (D, purple), precursor peptide (E, red), prenyl-transferase (F,
blue), oxidase (yellow), macrocyclase (G, green), two domains of unknown function
(turquoise), methyl-transferase (brown) associated proteins of unknown function
(black), transposase (grey) and hypothetical open reading frames (white). (b)
Sequence alignment of patellamide, trunkamide, aestuaramide, microcyclamide and
cyanothecamide precursor peptides. The core peptides (which are modified to become
the final products) are shown in red. Recognition elements for heterocyclisation,
N-terminal proteolysis and C-terminal proteolysis and macrocyclisation are shown
in purple, orange and green respectively. (c) examples of natural products from
the patellamide, trunkamide, aestruaramide, microcyclamide and cyanothecamide
pathways. The post-translational modifications are highlighted with the same colour
as the enzymes that perform the transformation.
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The details of RiPP biosynthesis, highlighting characteristics which make PRPS systems
promising targets for bioengineering with the intention of pharmaceutical development,
will be discussed using cyanobactins as an example, with particular focus on patellamide
biosynthesis [21,27,28]. Cyanobactin biosynthesis is exemplified by the patellamide case,
with many pathways sharing the same arrangement of the biosynthetic genes, high
homology between the biosynthetic enzymes, and even significant conservation of the
leader peptide and enzyme recognition sequences within the precursor peptides [21]
(Fig. 1.2). Consequently the subsequent discussion regarding the enzymatic details
of patellamide biosynthesis can be thought of as broadly applicable to cyanobactin
biosynthesis as a whole. Substantial di↵erences, where they arise, will also be discussed.
Despite these similarities, these pathways give rise to a diverse family of natural products
as highlighted in Fig. 1.2 [21,27], a feature which has attracted considerable attention.
1.3 Patellamides
Patellamides are cyclic octapeptides produced by Prochloron didemni, cyanobacteria
that live symbiotically within the ascidian Lissoclinum patella [28]. Distinctive structural
features include d-stereocentres, and thiazole and oxazoline heterocycles [27,28] (Fig. 1.3).
It is predicted that patellamides achieve a reduction in multidrug resistance, as described
previously (section 1.2) through competitive binding to, and thus inhibition of P-
glycoprotein (Pgp) [25]. Pgp is a transmembrane, ATP-dependent transport protein,
frequently overexpressed in tumour cells [29], and is responsible for the e✏ux of a
number of drug molecules, which ultimately leads to resistance [30]. Binding Pgp by
patellamides therefore restricts the exclusion of active pharmaceuticals and so increases
their e cacy in these resistant cell lines. The hypothesis that patellamide D targets
Pgp was initially supported by the observation that cyclosporin A (Fig. 1.1), another
cyclic peptide also binds Pgp [31]. More recently crystal structures of Pgp in complex
with two cyclic peptides: cyclic-tris-(R)-valineselenazole (QZ59-RRR) and cyclic-tris-
(S)-valineselenazole (QZ59-SSS) which are structurally related to patellamides (and
cyanobactins more generally) have been solved [32] (Fig. 1.4). This reinforces the idea of
an interaction between patellamide D and Pgp.
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Figure 1.3: Patellamides Patellamides A, B, C and D. Trademark structural features
include d-stereocentres, and thiazole and oxazoline heterocycles [27,28]
Chapter 1. Introduction 8
Figure 1.4: Pgp in complex with cyclic peptides QZ59-RRR and QZ59-SSS
(a) structure of cyclic-tris-(R)-valineselenazole (QZ59-RRR). (b) structure of cyclic-
tris-(S)-valineselenazole (QZ59-SSS). (c) QZ59-RRR and (d) QZ59-SSS bound at the
top of the internal chamber of Pgp (blue cartoon, PDB: 4M2S, 4M2T). Alternate view
of (e) QZ59-RRR and (f) QZ59-SSS. QZ59 compounds are shown as spheres coloured
by element, where carbon is magenta, nitrogen is blue, oxygen is red and selenium is
orange. N.B. The QZ59 compounds bind Pgp in slightly di↵erent locations and two
molecules of QZ59-SSS are bound, compared with one molecule of QZ59-RRR. Pgp is
shown as a blue ribbon.
1.4 Patellamide Biosynthesis
Patellamides, like other members of the cyanobactin and RiPP family of natural
products, are synthesised ribosomally as a precursor peptide, which undergoes a number
of enzymatic (and possibly non-enzymatic) chemical reactions during maturation to the
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final macrocyclic product [27,28]. Their biosynthesis can be attributed to a single operon
containing seven genes (patA-G) encoding proteins PatA through to PatG, including
the precursor peptide (PatE) as well as the tailoring enzymes [28]. The PatE amino acid
sequence can be seen in Fig. 1.5.
Figure 1.5: Patellamide precursor peptide PatE The gene product of patE,
the precursor peptide (PatE) from which patellamides are derived is shown. The
first 37 amino acids form the N-terminal leader peptide. Part of the leader peptide
forms the recognition sequence for the heterocyclase (purple). The N-terminal cleavage
recognition sequence (orange) and the C-terminal cleavage and macrocyclisation
signature (green) flank the core peptide sequences (red).
The first thirty-seven residues of PatE constitute the leader peptide, a common feature of
all RiPPs [20] (with bottromycins the only known exception, which contain a C-terminal
follower in place of the N-terminal leader peptide [33,34]). The leader peptide increases
the solubility of the precursor peptide and plays an important role in recognition of the
PTM enzymes, and so is thought to be a requirement for processing [22,35]. Additionally
it has been proposed that the leader peptide might act as a secretion signal, or perhaps
provide a more protective and regulatory function, assisting in the folding of the
precursor peptide, or inhibiting interaction with the PTM enzymes until biosynthesis of
the secondary metabolite is required [22,35]. However at present, little evidence exists
to support these proposals [22,35]. In the patellamide precursor, the leader peptide
is followed by two, eight-residue core peptides, which go on to become two separate
petellamides. Each core peptide is situated between an N-terminal protease sequence
and a C-terminal protease/macrocyclisation signature [36]. The core peptide sequence
itself is hypervariable [37].
Of the remaining genes in the operon patA, D, E, F and G are essential for in vivo
patellamide synthesis [28,38,39]. The genes patB and patC have been reported as non-
essential to synthesis and are at present of unknown function [28,38,39]. The gene products
of the essential patA, D, F and G, and their roles in patellamide maturation will be
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discussed in detail subsequently. A schematic summarising patellamide biosynthesis can
be seen in Fig. 1.6. Cyclodehydration of core peptide cysteine, and serine/threonine
residues generating thiazoline and oxazoline five-membered rings by PatD has been
identified as the first step [27,40,41]. Once complete, the heterocyclised precursor peptide is
cleaved at the N-terminus of the core peptide by PatA, removing the leader peptide [36,42].
The short, modified-precursor peptide is then simultaneously cleaved at the C-terminus
of the core peptide and macrocyclised by PatG [36,43,44]. PatG also oxidises thiazolines
to thiazoles [44]. The inversion of the stereochemistry of the two amino acids N-terminal
to the thiazoles has not been attributed to a gene product of the biosynthetic operon
and is generally thought to be spontaneous [45]. PatF has been identified as a prenyl-
transferase. Although PatF is reportedly essential for the production of patellamides in
vivo [46] it is not a requirement for their synthesis in vitro [47].
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Figure 1.6: Schematic of patellamide biosynthesis Heterocyclisation of cysteine
and serine/threonine residues to thiazolines and oxazolines respectively (purple) by
PatD has been identified as the first step. Once complete, the heterocyclised precursor
peptide is cleaved at the N-terminus of the core peptide, after the conserved recognition
motif (orange), removing the leader peptide. The resulting precursor peptide fragments
are macrocyclised by PatG, whilst simultaneously cleaving the core peptide from the
C-terminal conserved recognition signature (green). PatG also oxidised thiazolines to
thiazoles (yellow). It is not yet clear when during patellamide maturation oxidation
occurs, only that it must follow heterocyclisation. In addition, the amino acid residues
directly N-terminal to the thiazole heterocycles are epimerised. From our current
understanding it is unclear whether this is spontaneous or enzymatic, or when during
biosynthesis it occurs.
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1.4.1 PatD: Heterocyclisation
PatD is an ATP-dependent heterocyclase (cyclodehydratase), catalysing the formation
of oxazoline and thiazoline rings, from serine/threonine and cysteine residues respec-
tively [40,41,48]. In contrast, products of the trunkamide pathway contain only thiazoline
heterocycles [21,39], despite the trunkamide heterocyclase (TruD) sharing high sequence
homology (93 %) with PatD [40]. The reason for this di↵erence in reactivity is not
currently understood. The exact mechanism of heterocyclisation, particularly regarding
the role of ATP during turnover remains disputed. An initial hypothesis proposed by
McIntosh et al. was that both TruD and PatD function as molecular machines [48]. Later
work, from Dunbar et al. on the homologous heterocyclase complex, BalhCD, from linear
azole-containing peptide (LAP) biosynthesis, provided evidence for heterocyclisation
proceeding via a phosphorylation mechanism [49,50]. The structure of TruD determined
to 2.9 A˚ by Koehnke et al. revealed similarity between TruD and MccB, an adenylase
from the microcin C7 antibiotic biosynthesis pathway (Fig. 1.7). This observation
coupled with the observation that pyrophosphate is produced during turnover, lead
Koehnke et al. to propose that TruD (and thus PatD) operate by an adenylation
mechanism [51]. Therefore it is clear that further work is required to resolve these
mechanistic ambiguities. Plausible phosphorylation and adenylation mechanisms can
be seen in Fig. 1.7.
An attractive aspect of the cyanobactin heterocyclases from a biotechnological stand-
point is their ability to process cysteine (and in some cases serine and threonine)
seemingly irrespective of the immediately flanking residues [19,37,51]. The natural hyper-
variability of the cyanobactin core peptide sequences points to an interaction between the
heterocyclase enzyme and some of the highly conserved regions of the precursor peptide,
most likely within the leader peptide. If the leader peptide is removed from the precursor
peptide, prior to treatment with PatD/TruD, heterocyclisation was found to be slow and
ine cient [51]. A series of truncations and point mutations of the leader peptide of both
PatE and TruE helped to identify the minimal portion of the leader peptide thought to
be required for e cient processing by the heterocyclases [41,51,52]. This region, denoted
‘minimal leader’, spanning residues L26 through to L34 is therefore suspected to control
recognition between the enzyme and the substrate precursor peptide [51,52] (shown in
purple in Figs. 1.2, 1.5). In this way recognition is spatially distinct from catalysis,
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explaining the observed tolerance of cyanobactin heterocyclases towards a variety of
core peptide sequences. A molecular rational behind this substrate recognition was not
established.
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Figure 1.7: Heterocyclase mechanism and structure (a) Two possible
mechanism for heterocyclisation have been proposed. Both mechanisms proceed via
the reversible formation of a hemiorthoamide intermediate, which ultimately eliminates
to give a heterocycle. The proposed mechanisms di↵er regarding the utilisation of
the nucleotide in the activation of the hemiorthoamide intermediate with evidence
supporting an adenylation mechanism (top) and a kinase mechanism (bottom). (b)
X-ray crystal structure of TruD dimer (PDB: 4BS9) represented as a cartoon (purple
for one monomer and pink for the other). (c) structural comparison between domains 1
and 2 of TruD (purple) and MccB (green, PDB: 3H5A) and adenylase from C7 antibiotic
biosynthesis.
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1.4.2 PatA: N-terminal Core Peptide Cleavage
PatA is 75 kDa protein consisting of an N-terminal subtilisin-like serine protease domain
(PatApr) and a C-terminal domain of unknown function (PatA-DUF) [36]. The PatApr
domain catalyses the removal of the leader peptide from PatE, via proteolytic cleavage
between the recognition sequence, N-terminal to each core peptide, and the first residue
of the core peptide [36]. While the recognition sequence G(L/V)(D/E)(A/P)(S/P) is
highly conserved and necessary for PatApr activity, there appears to be no conservation
of the first residue of the core peptide [42]. The crystal structure of the protease domain
has been solved, independently by two labs [42,44] (Fig. 1.8). Modelling of the peptide
GLEASVT (P5-P20) into the active site of PatApr rationalised the conservation of the N-
terminal recognition signature throughout cyanobactin bionsynthesis, and the activity of
the enzyme regardless of the succeeding core peptide sequence [42] (Fig. 1.8). Hydrolysis
of the amide bond proceeds via nucleophilic attack by S218, part of an D-S-H catalytic
triad, typically found in subtilisin-like serine proteases [53]. Proteolysis in vitro was
reported to be very slow, with a turnover of <10 substrate molecules a day [36,42]. It
was suggested a slow turnover might be advantageous in vivo, allowing for complete
processing by the heterocyclase before the leader peptide is removed [48]. A recent study
has shown the relative rates of the proteolysis and heterocyclisation reactions can be
controlled by altering the redox potential of the reaction [54]. The precursor peptide
must be reduced to react with the heterocyclase (free cysteine is the substrate of the
heterocyclase), whereas non reducing conditions correlate with an increase in protease
activity [54]. If both PatA and ThcD (TruD homologue) are added simultaneously to
the precursor peptide in the presence of reducing agent, then the desired heterocyclised,
cleaved intermediate is produced as the major product. Conversely, in the absence of
reducing agent, the non-heterocyclised, cleaved intermediate is observed as the major
product, consistent with PatA acting before ThcD [54]. It has been proposed that it is
by controlling the redox potential, and thus the relative rates of the heterocyclase and
the N-terminal protease that cyanobacteria establish control of product formation in
vivo [54]. It is important to note that the PatApr domain is active in vitro in isolation,
and it doesn’t require the presence of the C-terminal DUF. It is currently unclear, what
e↵ect, if any, the DUF has on PatApr activity. The DUF will be discussed in more detail
separately.
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Figure 1.8: PatApr (a) X-ray crystal structure of PatApr (PDB: 3ZXX) shown as
an orange cartoon. (b) PatApr (orange) with modelled substrate (cyan sticks). PatApr
residues involved in substrate recognition are shown as orange sticks. Catalytic residues
are marked with an asterisk.
1.4.3 PatG: Oxidation and Macrocyclisation
PatG is a 131 kDa multi-domain protein. Metagenomic analysis identified a flavin
mononucleotide (FMN) binding site towards the N-terminus of PatG, indicative of
oxidase activity (PatGox) [44]. More often than not in cyanobactin biosynthesis, like
in the patellamide example, the oxidase domain is located at the N-terminus of the
G protein. However, there are examples, such as the cyanotheceamide biosynthetic
pathway, where the oxidase is found as a freestanding protein [26]. Oxidase activity was
confirmed when the cyanothecamide oxidase was shown to catalyse thiazoline oxidation
on a macrocyclic substrate, while the oxidase from the arthrospiramide pathway a↵ected
both linear and macrocyclic substrates in vitro [47]. However, it has not been confirmed
in nature. Interestingly, while other cyanobactins, including the tenuecyclamides and
microcyclamides, contain both oxazoles, and thiazoles, only patellamides containing
oxazolines and thiazoles have been identified [16,21,26]. It seems likely therefore, that
similarly to the heterocyclases, di↵erent oxidase domains from various cyanobactin
biosynthetic pathways, despite their high sequence homology are capable of di↵erent
chemistries. For example, through analysis of the products of aestuaramide (lyn),
cyanotheceamide (cya), arthrospiramide (art) and microcyclamide (mic) pathways (Fig.
1.2), it is possible that MicGox catalyses the oxidation of both thiazolines and oxazolines,
while Lyn, Cya and ArtGox (in addition to PatGox) only oxidase thiazolines (Fig. 1.9).
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Figure 1.9: Cyanobactin oxidation The N-terminal domain of the G enzymes (Gox)
is responsible for heterocycle oxidation. Reflecting the observed di↵erence in activity
of the D enzymes of di↵erent pathways, it is expected, through analysis of the products
of the patellamide, aestuaramide, cyanothecamide and microcyclamide pathways that
Pat, Lyn Cya and ArtGox catalyse thiazoline oxidation, while MicGox catalyses both
thiazoline and oxazoline oxidation.
In addition to an oxidase domain, PatG also contains a subtilisin-like serine protease
domain (PatGmac). Despite the similarity between the protease domains of PatA and
PatG [36], the enzymes act on di↵erent substrates, with PatG cleaving the core peptide
from the C-terminal (A/S)(Y/F)DG recognition motif, subsequent to the removal of
the leader peptide [43,55]. Furthermore, the PatG protease domain has been found to be
solely responsible for the macrocyclisation reaction [43,44,55].
The crystal structure of PatGmac in complex with substrate peptide VPAPIPFPAYDG
(P8-P40) was solved, providing valuable insight into substrate recognition [43] (Fig.
1.10). Recognition is achieved entirely through interactions between the enzyme and
the conserved ‘AYDG’ motif, and not with the core peptide [43]. The outcome is
a promiscuous enzyme that will accept a wide variety of substrates, with varying
compositions of the core peptide, including unnatural amino acids, providing the C-
terminal recognition element is present [55–58]. However there is one limitation: a
heterocycle (or a proline in undmodified substrates) is required at the final position (P1)
of the core peptide to angle the peptide away from steric clashes with the enzyme [43].
The PatGmac-peptide complex structure can also be used to hypothesise the mechanism
of macrocyclisation (Fig. 1.11). The reaction proceeds via attack of S783 on the C-
terminal carbonyl of the core peptide, creating an acyl-enzyme intermediate. The acyl-
enzyme intermediate has been observed by mass spectrometry [43]. At this point, the
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Figure 1.10: PatGmac structure (a) X-ray crystal structure of PatGmac
represented as a cartoon (green) with the macrocyclisation insert highlighted in blue.
(b) Close-up view of the active site of PatGmac (shown as surface) in complex with
VPAPIPFPAYDG substrate mimic. The N-terminal residues (VPA) are disordered
in the structure. The remaining core peptide residues (PIPFP) are shown as white
sticks, while the recognition element (AYDG) is shown as white spheres. This
representation shows that where the acyl-enzyme is formed is shielded from water by
the macrocyclisation insert (blue surface) and the AYDG peptide.
acyl-enzyme intermediate can be hydrolysed by either water, releasing linear peptide, or
by the free N-terminus of the core peptide, releasing the desired macrocyclic product.
The inherent cis conformation of the heterocycle at P1 orients the N-terminus of the
peptide for nucleophilic attack of the acyl-enzyme intermediate, resulting in head-to-
tail (N-C) cyclisation [43]. A large helix-loop-helix insertion (often referred to as the
macrocyclisation insert) adjacent to the active site shields the acyl-enzyme intermediate
from water, thus favouring macrocyclisation over hydrolysis [43]. It has also been
hypothesised that if the AYDG motif were to remain bound in the active site-post
cleavage, the steric bulk of these residues would assist in shielding the acyl-enzyme
intermediate [43].
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Figure 1.11: Macrocyclisation mechanism Proposed mechanism for macrocycli-
sation: The active site serine attacks the proline carbonyl adjacent to the AYDG motif
creating a characteristic acyl-enzyme intermediate, releasing AYDG. The incoming N-
terminus of the core peptide sequence displaces AYDG and hydrolyses the acyl-enzyme
intermediate forming the macrocycle.
Finally, PatG harbours a C-terminal domain of unknown function (PatG-DUF)
homologous to the DUF from PatA [44]. Like PatA, the protease domain of PatG is
active in vitro in the absence of the DUF, and so the role of the DUFs in patellamide
biosynthesis is to be investigated.
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1.4.4 PatF: An Inactive Prenyl-transferase
Sequence homology revealed the PatF family of PTM enzymes to be prenyl-transferase
enzymes [57,59,60]. Interestingly, while prenylation is a common modification found
in cyanobactins, no prenylated patellamides have been discovered [27]. Activity has
been demonstrated for the homologous cyanobactin prenyl-transferases TruF1 and
LynF [57,59], but PatF appears to be inactive [60] (Fig. 1.12). TruF1 catalyses the
forward-O-prenylation of serine and threonine residues, whereas LynF is responsible
for the reverse-O-prenylation of tyrosine, which spontaneously undergoes a Claisen
rearrangement to give a forward-C-prenylated product. [59] (Fig. 1.12). The structure
of PatF revealed that mutations of two catalytically important residues explain the
inactivity of PatF and thus the absence of prenylated natural products from the
patellamide pathway [60] (Fig. 1.12). Attempts to mutate PatF to restore activity resulted
in insoluble protein [60]. Whether PatF has another role in patellamide biosynthesis, and
if not, why it is conserved in the patellamide gene cluster is unknown [27].
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Figure 1.12: PatF: inactive prenyl-transferase (a) Example structures of a
serine-O-prenylated cyanobactin trunkamide A (catalysed by TruF1) and a tyrosine-
C-prenylated cyanobactin aestuaramide (catalysed by LynF). (b) LynF catalyses the
reverse-O-prenylation of tyrosine. A spontaneous Claisen rearrangement gives the
forward-C-prenylated product. (c) X-ray crystal structure of PatF (PDB: 4BG2)
represented as a cartoon (blue). (d) Overlay of PatF (blue) with known prenyl-
transferase DMATS (green). Important active site residues are shown as sticks. K136M
and H125D mutations (PatF numbering) are thought to impair substrate binding, thus
inactivating PatF [60].
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1.4.5 Epimerisation
Extensive structural analysis of patellamide D and lissoclinamides 4, 5 and 6, confirmed
that the amino acids directly N-terminal to the thiazole/thiazoline rings are epimerised
to d-stereocentres [61]. Additionally many of the related cyanobactins that contain
heterocycles have also been reported to contain d-amino acids, including trunkamide
A [62,63], lissoclinamide 7 [45,61] and the microcyclamides [64]. For the teneucyclamide and
trichamide families of cyanobactins, the presence of d-amino acids has been proposed,
but has not been confirmed in all products [65,66]. Since ribosomes are selective for l-
amino acids, epimerisation must be a PTM [45].
From our current understanding of the biosynthetic pathway, we cannot state definitively
when, during patellamide maturation, epimerisation takes place. Epimerisation can be
in theory either acid or base catalysed. While the ↵-carbon adjacent to the thiazoline is
not particularly acidic, perhaps favouring acid catalysis over base catalysis, thiazolines
are chemically unstable under acidic conditions and readily ring open to give cysteine [50].
Assuming then a base catalysed mechanism, epimerisation would seem favourable after
thiazoline formation, and prior to its oxidation to a thiazole, thus avoiding the need to
disrupt aromaticity to stabilise the build up of negative charge that occurs following
proton abstraction. Therefore the following base catalysed mechanism, where proton
abstraction is stabilised through conjugation onto the imine nitrogen seems viable [45]
(Fig. 1.13).
Figure 1.13: Epimerisation mechanism A base abstracts a proton at the ↵-carbon
adjacent to the thiazoline ring. This is stabilsed via conjugation and subsequent
protonation of the imine nitrogen. Re-protonation occurs at the ↵-carbon on the
opposite face.
Since it is not explicit whether oxidation directly succeeds heterocyclisation, follows
leader sequence removal, or only occurs on the cyclic peptide, the precise timing of
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epimerisation is uncertain. Furthermore it is unclear as to whether epimerisation is a
spontaneous or an enzymatic process in cyanobactin biosynthesis. Early work by Wipf
et al. demonstrated that if lissoclinamide 7 was synthesised with l-valine adjacent to
the thiazoline, it would epimerise to d-valine following treatment with pyridine [45] (Fig.
1.14), consistant with the ↵-carbon adjacent to a thiazoline being susceptable to non-
enzymatic epimerisation.
Figure 1.14: Epimerisation of lissoclinamide 7 Epimerisation of unnatural l-
isomer to the natural d-isomer using 5-10 equivalents of pyridine.
However, the required 5-10 equivalents of pyridine and temperatures of 60 °C to a↵ord
the correct isomer [45] do not reflect the physiological conditions of the cyanobacteria,
and so it cannot be considered proof of spontaneous epimerisation in nature. More
convincing was the observation by Salvatella et al. that an enantiomer of trunkamide A
synthesied with l-phenylalanine, when solubilised in a combination of 30 % d6-DMSO/70
% CDCl3 for a series of NMR experiments, epimerised to the natural d-enantiomer within
days [67] (Fig. 1.15). Analyses of solution structures of the isomers revealed trunkamide A
undergoes a significant conformational rearrangment following inversion of the F residue,
resulting in a less sterically hindered, planar structure and allows for two, new hydrogen
bonding interactions [67] (Fig. 1.15).
It was proposed that this increase in conformational stability of the macrocycle is
the driving force for the epimerisation reaction [67]. This agrees with epimerisation
being a spontaneous process, and that if it is, it most likely occurs on the macrocycle
and not on the linear peptide. It is di cult to rationalise a similar thermodynamic
driving force for a spontaneous epimerisation on the flexible linear peptide. Such a
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Figure 1.15: Epimerisation of trunkamide A Unnatural l-isomer spontaneously
epimerises to natural d-isomer within days. (a) 2D stick representation; (b) 3D solution
NMR structures determined by Salvatella et al. (figure taken from paper) [67]
‘conformational stability’ hypothesis might be su cient to explain the conservation
of d-stereocentres throughout the cyanobactin superfamily [21] and why the natural
compounds are isolated as single enantiomers and not diastereoisomers [45]. That said,
cyanobactins are structurally highly diverse, with known compounds of di↵erent ring
sizes and di↵erent constitutent amino acids. Therefore, it might not be that every
cyanobactin will experience the same conformational pressures favouring epimerisation,
as observed for trunkamide A. d-Stereocentres have so far always been reported
adjacent to thiazoline/thiazole heterocycles, and never next to oxazoline/oxazole
heterocycles, even though these residues are also potentially labile to epimerisation. Such
selectivity, whether chemical or regioselectivity, might be under control of an enzyme
catalyst. While there is evidence supporting a spontaneous epimerisation of synthetic
cyanobactins, the requirement of an epimerase in their biosynthesis has not been
explicitely ruled out. However no epimerase activity has been identified in any of the
biosynthetic enzymes, nor is epimerase activity predicted based on sequence homology of
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the remaining uncharacterised gene products in the biosynthetic cluster [27]. Epimerase,
racemase and isomerase enzymes are common place throughout biology, exhibiting a
vast diversity in structure and size, and subtle variation in their catalytic mechanisms,
especially concerning the amino acid combination utilised as acids and bases [68–72]. This
makes it di cult to predict epimerase activity amongst the uncharacterised proteins in
cyanobactin pathways. If epimerisation is catalysed by one of these uncharacterised gene
products, this would potentially represent a novel class of epimerase.
1.4.6 Proteins of Unknown Fucntion
PatA and PatG both contain homologous (56 % identical) C-terminal DUFs. In
patellamide biosynthesis, the presence of two DUFs and two epimerised amino acids
might correlate, raising the possibility of the DUFs catalysing epimerisation. The
conservation of the DUFs throughout cyanobactin biosynthetic pathways suggest they
play a role in their biosynthesis, but they do not appear necessary for their synthesis in
vitro [47]. Their role in biosynthesis is still to be determined.
In addition to the C-terminal domains of PatA and PatG, there exist two hypothetical
proteins of unknown function, PatB and PatC. Like the DUFs, these proteins are
associated to and conserved throughout cyanobactin biosynthetic pathways [26]. Neither
protein is necessary for their synthesis in vitro [47] or in vivo [28] and the reason for their
conservation is also unknown.
1.5 Exploiting the Advantageous Properties of Cyanobactin
Biosynthesis for the Development of Cyanobactin Ana-
logues for Biological Application
Despite the e cacious, clinically-relevant bioactivities of cyanobactins, coupled with
the pharmacological advantages of cyclic peptides as therapeutics (as discussed at
the beginning of this thesis (Section 1.1), the development of these compounds as
pharmaceutical lead compounds has been slow, largely due to a low availability of
material from their natural sources. Creating a large variety of macrocycles in su cient
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yields is paramount in ascertaining structural activity relationships of these bioactive
molecules, and for their subsequent development as drugs.
1.5.1 Chemical Synthesis
The typical approach is to turn to synthetic chemistry to access greater amounts
of material for subsequent testing. However, as with many natural products, their
complexity makes them challenging targets for de novo synthesis [17]. One of the most
e cient syntheses of cyanobactins was that of patellamide A by Garcia-Reynaga et
al. in 2008, forming patellamide A from a 14 step reaction with an overall yield
of 55 % [73]. While this synthesis boasts modest yields and relatively mild reaction
conditions, it utilises a patellamide A-specific starting point - a valine-thiazole dipeptide
for which the synthesis was previously established [74]. Therefore there is no guarantee
the synthetic strategy will be as e cient in making the other patellamides, or that it
will be applicable to the synthesis of diverse range of cyanobactins and cyanobactin-
like compounds. Although the diversity o↵ered through synthetic chemistry is generally
considered to be unlimited, the potential requirement to alter the synthetic strategy for
each macrocycle would prove expensive and time consuming.
1.5.2 in vivo Synthesis
A diverse range of cyanobactins can be produced in vivo, utilising cultured bacteria
as ‘chemical factories’. While so far attempts to culture Prochloron sp. have
been unsuccessful [75] products of the tru pathway have been produced recombinantly
in Escherichia. coli (E. coli) [38]. The promiscuity of the cyanobactin biosynthetic
enzymes mean that simply by engineering the TruE precursor peptide a huge variety
of compounds can be produced in a straightforward and cost e↵ective manner. An
extensive study by Ru↵ner et al. utilised a NNK (where N = A/C/G/T and K =
G/T) [76] mutagenesis strategy to modify the truE gene to assess the combinatorial
potential of the tru pathway [56]. In this library design, to account for the requirement
of a C-terminal heterocycle to facilitate macrocyclisation, cysteine was fixed at position
7 (N to C-terminal notation). In addition, proline was fixed at position 5, as it was
reasoned to be important for the structure of the final compound [56,67]. Even with
proline and cysteine fixed, a full degenerate XXXXPXC library contains 3.2 million
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possible sequences. In order to determine allowed sequences, that are processed by
the tru pathway, three double mutant (XXIAPFC, TSXXPFC and TSIXPXC) and a
quadruple mutant library (XSXXPXC) were designed, so that all positions other than 7
and 5 were randomised in at least a subset of libraries. These smaller libraries simplified
analysis, but still demonstrated the huge combinatorial potential of the tru pathway,
with >300 unique, new compounds [56]. Furthermore the modifying enzymes have been
shown to tolerate unnatural amino acids, expanding the accessible diversity [57]. The
non-proteinogenic amino acids are introduced using an orthogonal tRNA/aminoacyly-
tRNA synthetase pair that adds a specific unnatural amino acid in response to a nonsense
frameshift mutation [57]; however, currently only a limited number of unnatural amino
acids can be introduced incorporated, and only a single type of unnatural amino acid can
be incorporated into a single polypeptide chain [77]. In general, major drawbacks of these
methods are the low yields, with the macrocyclic products only being obtained in µg
L-1 quantities [57], and the di culty in their subsequent extraction from large volumes of
culture. However, a recent breakthrough in culture conditions, essentially the addition
of H2S, increased the cultured yield of patellins produced by the tru pathway, over
150 fold, and the addition of mevalonate increased the yield a further 18 fold [54]. The
e↵ect of these compounds was not, as first expected, due to an increase in the level of
expression of the substrate peptide, or PTM enzymes. Instead, the authors concluded
that sulfide regulated the activity of the enzymes, ensuring each one acted at the correct
point in the sequence of biosynthetic events [54]. Mevalonate is a known precursor
to dimethylallylpyrophosphate (DMAPP) [78], a substrate of the prenyl-transferase
enzymes [57,59,60], and so it was assumed the increase in the yield upon mevalonate
additon was due to an increase in activity of the prenyl-trasnferase. However, when the
pat pathway, which contains an inactive prenyl-transferase homologue, was expressed,
an increase in the cultured yield of patellins upon the addition of mevalonate was still
observed [54]. Therefore, the reason for the increase in yield, following supplementation
with mevalonate is unknown. If this approach is general, then it will transform in vivo
production.
1.5.3 in vitro Synthesis
Cyanobactin biosynthetic pathways can be reconstituted in vitro enabling the production
of natural and unnatural cyanobactins on a mg L-1 scale [47]. By using isolated substrate
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peptides and enzymes from multiple cyanobactin biosynthetic pathways, the in vitro
synthesis is robust and scalable. As with the in vivo synthesis, the use of biosynthetic
enzymes ensures the process is green and keeps synthetic costs to a minimum. The in
vitro synthesis makes use of engineered precursor peptides with varying core peptide
sequences. The modified precursor contains a single core peptide sequence and a C-
terminal His6 tag to aid purification. A lysine residue inserted between the N-terminal
recognition sequence ‘GLEAS’ and the start of the core peptide sequence facilitates the
use of trypsin as a more rapid alternative to PatA cleavage (Fig. 1.16). Such peptides
can be overexpressed in E. coli at high yields (50-200 mg L-1) [47]. The enzymes are also
accessible via straight forward expression and purification at high yields [47]. Diversity
can be created, not only through the use of various substrate peptides, but by combining
substrates with di↵erent combinations of enzymes from di↵erent pathways [47]. In this
way multiple products can be produced from a single precursor peptide (Fig. 1.16). Such
an engineered precursor peptide with the core peptide sequence ITACITFC (coding
for the natural product patellamide D) is usually employed as a standard substrate
throughout this thesis and is simply referred to as PatE0.
Chapter 1. Introduction 29
Figure 1.16: A schematic representation of the in vitro synthesis of azol(in)e
containing cyclic peptides A full description of the in vitro synthesis can be found
elsewhere (Chapter 5). Briefly: Engineered PatE0s with di↵ering core peptide sequences
(where X can be any amino acid (except lysine or arginine due to the use of trypsin
to remove the leader sequence)) can be processed with either a cysteine heterocyclase
(TruD/LynD) or a cysteine, threonine and serine heterocyclase (PatD/MicD). Only the
C-terminal cysteine needs to be conserved for subsequent processing by PatGmac - all
the other positions are in principle variable. The heterocyclised PatE0 is then purified
and incubated with trypsin to remove the leader sequence. The cleaved, heterocyclised
PatE0 is purified away from trypsin and macrocyclised by PatGmac. The purified
macrocycle can then be reacted with either ArtGox or CyaGox to to oxidise thiazolines
to thiazoles. In this way, using just the enzymatic steps described a minimum of four
macrocyclic products can be produced from a single precursor peptide starting material.
The ability to produce a wide variety of highly modified cyclic peptides in good yields, as
o↵ered by the in vitro synthesis method, provides a more facile route to further testing
and development, and might spark renewed interest and investigation into cyanobactins
as potential therapeutic compounds.
1.6 Aims and Objectives
Manipulation of cyaonobactin biosynthetic enzymes for the production of a diverse
range of azol(in)e containing macrocycles on a useful scale, as described for the in
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vivo and in vitro syntheses, requires a comprehensive understanding of the individual
enzymes involved. Much of cyanobactin biosynthesis has been characterised, however
some unknowns and uncertainties remain. These studies, through a combination of
structural biology, biochemical and biophysical characterisation, aim to address the
current unknowns in patellamide biosynthesis, with a focus on using any new insight
gained, coupled with our existing knowledge, to develop a biotechnological toolkit for
the synthesis of cyanobactins and ultimately diverse cyclic peptides more generally, thus
improving upon the existing in vitro synthesis.
There are three specific aspects of the biosynthesis that are investigated in this thesis:
(1) Investigation into the role of the C-terminal DUFs - What is their role in nature?
Are they involved in synthesis, either directly or indirectly? Do they constitute an
essential, or beneficial part of the biotechnological toolkit? (2) Detailed characterisation
of the heterocyclase enzyme - What is the mechanism of heterocyclisation? What
is the molecular rational governing substrate recognition of the heterocyclase? (3)
Investigation into epimerisation - When during synthesis does epimerisation occur? Is
it spontaneous or enzymatic? Can the stereochemistry of these residues be controlled?
Does an epimerisation step need to be built into the in vitro synthesis?
Finally, these studies aim to develop the in vitro synthesis further, in an attempt to
improve the e ciency and flexibility of the process. Ultimately the in vitro synthesis
will be tested for its applicability in producing a range of patellamide D analogues in an
attempt to determine structural activity relationships for Pgp inhibition.
Chapter 2
Structural and Biochemical
Characterisation of PatG-DUF
2.1 Introduction
The roles of the C-terminal domains of PatA and PatG in patellamide biosynthesis are
unknown and hence they are designated as Domains of Unknown Function (DUFs). The
high sequence homology between the domains implies their function is related (Fig. 2.1).
Figure 2.1: Sequence alignment of PatA-DUF and PatG-DUF The conserved
C-terminal DUFs of PatA and PatG share 56 % identity. Fully conserved residues are
shaded black and non-conserved residues are unshaded.
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Moreover both DUFs are highly conserved in all cyanobactin pathways, (some of which
can be seen in Figs. 2.2, 2.3), suggesting they have an important role in cyanobactin
biosynthesis.
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Figure 2.2: PatA-DUF homologues Sequence alignment between PatA-DUF and
homologues from related cyanobactin pathways. Fully conserved residues are shaded
black, partially conserved residues are shaded in grey, non-conserved residues are
unshaded.
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Figure 2.3: PatG-DUF homologues Sequence alignment between PatG-DUF and
homologues from related cyanobactin pathways. Fully conserved residues are shaded
black, partially conserved residues are shaded in grey, non-conserved residues are
unshaded.
Broadly speaking, three possibilities for the DUFs exist: (1) In all examples, the C-
terminal DUFs are associated with domains exhibiting protease activity. Therefore it is
possible the DUFs a↵ect proteolysis - either to accelerate reaction rates (PatApr turnover
is very low in isolation [42]), or to regulate activity. (2) PatG is a multi-domain protein,
containing an oxidase domain and a macrocyclase domain in addition to the C-terminal
domain of unknown function. The oxidase and macrocyclase domains catalyse two, very
di↵erent chemical reactions, and both domains are active in isolation [47]. Therefore it
is plausible that the DUFs exhibit intrinsic catalysis, chemically distinct from that of
their associated domains. In this case, epimerisation of the two residues N-terminal to
the thiazole heterocycles is the most likely candidate, as it is the only post-translational
modification that hasn’t currently been attributed to a gene product of the patellamide
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operon. (3) The DUFs might a↵ect patellamide biosynthesis indirectly. They could
provide a chaperone-like function, assisting in the pre-organisation of the precursor
peptide prior to biochemical modification. Alternatively they might be involved in host-
cell immunity, and/or export of the cyclic peptides from the host-cell. It is also possible
they are involved in mediating PPIs, providing a sca↵old for multi-enzyme complex
formation.
Since one of the on-going goals of the lab is to optimise the established in vitro
patellamide synthesis [47] for the production of a large variety of diverse patellamide-
like cyclic peptides on a mg scale, the first two hypothetical roles for the DUFs, as
described above, are the most important. As a consequence, the objective of this
chapter is to characterise the C-terminal domains of unknown function, focusing on
these first two hypothetical roles, to ultimately determinine whether the DUFs would
constitute an essential part of a biotechnological ‘toolkit’ for the in vitro synthesis
of cyanobactins. We turn to X-ray crystallography in an attempt to gain insight
through structural characterisation, and isothermal titration calorimetry (ITC) and
nuclear magnetic resonance spectroscopy (NMR) to investigate binding of the DUFs
with plausible substrates: the precursor peptide and intermediates formed during
biosynthesis. By expressing the DUFs alongside their associated domains, we can
investigate what e↵ect if any, the DUFs have on their activity.
2.2 Materials and Methods
N.B. References to PatG-DUFsp. and PatG-DUFdi. described in this methods section
refer to two di↵erent constructs of PatG-DUF with a slightly di↵erent amino acid
sequence as discussed in section 2.3.1 and Fig. 2.7.
2.2.1 Expression and Purification of Native and SeMet PatG-DUF
The C-terminal domain of PatG from Prochloron sp. (PatG-DUF; amino acid residues
914-1186) was cloned from full-length patG into pEHISTEV plasmid with an N-terminal
His6 tag and a Tobacco etch virus (TEV) protease site [79]. A vector map can be seen in
Fig. 2.4. The protein was expressed in E. coli BL21 (DE3) cells grown in Luria-Bertani
(LB) medium supplemented with 50 µg mL-1 kanamycin. Cultures were incubated at 37
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°C, 200 rpm until OD600 = 0.6. Cells were subsequently induced with 1 mM isopropyl-
thiol- -d-galactoside (IPTG) and further incubated at 18 °C, 200 rpm overnight. l-
Selenomethionine-labelled (SeMet) PatG-DUFsp. was expressed from E. coli BL21 (DE3)
cells grown in minimal medium supplemented with glucose-free nutrient mix (Molecular
Dimensions), 50 µg mL-1 kanamycin and 5 % glycerol. This medium was inoculated with
overnight culture grown in LB, which had been washed three times in minimal medium.
After 15 min growth at 37 °C, 60 mg L-1 l-selenomethionine was added. The cultures
were returned to 37 °C and incubated until OD600 = 0.6, at which point 100 mg L-1
lysine, phenylalanine, threonine and 50 mg L-1 isoleucine and valine were added. After
incubation for a further 20 min, expression was induced by the addition of 1 mM IPTG,
and the cells were incubated at 18 °C for 24 h. For both native and SeMet variants, the
cells were harvested by centrifugation (4000g, 4 °C, 15 min).
Cell pellets were resuspended in G-DUF lysis bu↵er (Appedix A) supplemented with
0.4 mg DNAse (Sigma-aldrich) per gram of wet cell pellet and cOmplete EDTA-free
protease-inhibitor tablets (Roche; 1 per 50 mL resuspension). The cells were lysed via
passage through a cell disruptor at 207 MPa (Constant Systems) and the cell debris was
removed via centrifugation (40 000g, 4 °C, 20 min). The supernatant was loaded onto
a pre-equilibrated Ni-Sepharose 6 Fast Flow column (GE Healthcare) at 4 °C, and the
column was washed with G-DUF lysis bu↵er. The protein was eluted from the column in
G-DUF elution bu↵er (Appendix A). The elution was passed over a desalt column (Desalt
16/10, GE Healthcare) in desalt bu↵er supplemented with 10 % glycerol (Appendix A).
TEV-protease was added at a mass:mass ratio of 1 mg TEV to 10 mg of protein and
the sample was incubated for 2 h at room temperature to remove the N-terminal His6
tag. The digested sample was passed over a second Ni-Sepharose 6 Fast Flow column
and the flow-through was collected and loaded onto a Highload 16/60 Superdex 200 gel-
filtration column (GE Healthcare) equilibrated in gel filtration bu↵er supplemented in 10
% glycerol (Appendix A). The purity of the protein was analysed by SDS-PAGE, and its
identity confirmed by LC-ESI-MS. Analysis of the mass spectrum of SeMet PatG-DUFsp.
confirmed the successful incorporation of the five expected SeMet residues. Native and
SeMet PatG-DUFsp. were concentrated to 4.75 mg mL-1 for crystallography, using a 10
000 MWCO vivaspin centrifugal concentrator (Generon).
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Figure 2.4: Vector map of PatG-DUF
2.2.2 Mutagenesis of PatG-DUFsp. to PatG-DUFdi.
Mutagenesis of PatG-DUFsp. was performed using established protocols [80].
2.2.3 CD Spectroscopy
Near-UV CD spectra were recorded on a Jasco J-18 spectro-polarimeter with PatG-
DUFsp. and PatG-DUFdi. samples in gel filtration bu↵er supplemented with 10 %
glycerol.
2.2.4 Crystallography
Crystal screens were set up with the sitting-drop vapour di↵usion method using a
Gryphon robot (Art Robbins). The protein was screened against sparse-matrix screens
composed of a range of known crystallisation conditions at 20 and 4 °C [81]. Di↵raction-
quality crystals were grown in a condition containing 0.04 M potassium phosphate, 16 %
PEG 8000 and 20 % glycerol. Crystals of SeMet PatG-DUFsp. grew in the same condition
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as native protein. A single SeMet PatG-DUFsp. crsystal was cryoprotected in mother
liquor and flash-cooled in liquid nitrogen. A single wave-length anomalous dispersion
(SAD) data set was collected at the Se K absorption edge at 100 K on beamline IO2
at Diamond Light Source. The structure was solved uising AutoSol and the chains were
built into electron density using AutoBuild from the PHENIX crystallography suite [82].
The structure was manually rebuilt in Coot [83] and refined using REFMAC5 [84]. TLS
restraints were generated for refinement using the TLSMD server [85] and the structure
was validated using MolProbity [86]. All sequence alignments were created using Clustal
Omega [87] and presented using ALINE [88]. All structural images were generated using
PyMol [89].
2.2.5 Expression and Purification of PatE0 and 15N-PatE0
For biochemical characterisation an engineered PatE variant was used, denoted PatE0.
PatE0 has a single core peptide with the sequence ITACITFC (corresponding to the
natural product patellamide D) and a C-terminal His6 tag. The full PatE0 amino
acid sequence is as follows: MDKKNILPQQGQPVIRLTAGQLSSQLAELSEEALGDA-
GLEASKITACITFCAYDGELEHHHHHH. PatE0 was cloned into pBMS23CHIS by Dr
Wael Houssen (University of Aberdeen). A vector map can be seen in Fig. 2.5.
PatE0 was expressed in E. coli BL21 (DE3) grown in LB medium supplemented with
100 µg mL-1 ampicillin. Cultures were incubated at 37 °C, 200 rpm until OD600 = 0.6.
Cells were subsequently induced with 1 mM IPTG and further incubated at 37 °C, 200
rpm for 5 h. 15N-PatE0 was expressed in E. coli BL21 (DE3) cells grown in minimal
medium prepared with 15NH4Cl (Sigma-aldrich) and supplemented with glucose-free
nutrient mix (Molecular Dimensions), 100 µg mL-1 ampicillin and 5 % glycerol. This
medium was inoculated with overnight culture grown in LB and washed three times in
minimal medium. The cultures were incubated at 37 °C until OD600 = 0.6, induced with
0.5 mM IPTG and incubated at 30 °C overnight. Cells were harvested by centrifugation
(4000g, 4 °C, 15 min).
Cell pellets were re-suspended in urea lysis bu↵er (Appendix A) and lysed by sonication
at 15 microns (SoniPrep 150, MSE) with a pulse time of 30 s and a total on time of 4
min per 100 mL lysate solution. The lysate was cleared by centrifugation (40 000g, 20
°C, 20 min), and the supernatant loaded onto a Ni-Sepharose 6 Fast Flow column (GE
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Healthcare). The column was washed with urea lysis bu↵er and peptide was eluted with
urea elution bu↵er (Appendix A). The peptide elution was incubated in the presence of
10 mM dithiothreitol (DTT) for 2 h prior to passage down a Highload 16/60 Superdex 75
gel filtration column (Ge Healthcare) pre-equilibrated in gel filtration bu↵er. The purity
of the peptide was analysed by SDS-PAGE, and its identity confirmed by MALDI-TOF-
MS.
Figure 2.5: Vector map of PatE0
2.2.6 Expression and Purification of PatD
Codon optimised full-length PatD with an N-terminal thrombin-cleavable His6 tag was
purchased from DNA2.0 in the pJexpress 411 vector. It was expressed from E. coli BL21
(DE3) cells, grown in autoinduction medium at 20 °C for 48 h [90]. Cells were harvested
by centrifugation (4000g, 4 °C, 15 min). Cell pellets were resuspended in general lysis
bu↵er (Appedix A) supplemented with 0.4 mg DNAse (Sigma-aldrich) per gram of wet
cell pellets and cOmplete EDTA-free protease-inhibitor tablets (Roche; 1 per 50 mL
resuspension). The cells were lysed via passage through a cell disruptor at 207 MPa
(Constant Systems) and clarified by centrifugation (40 000g, 4 °C, 20 min). Cleared
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lysate was applied to Ni-Sepharose 6 Fast Flow column (GE Healthcare) equilibrated in
general lysis bu↵er. The protein was washed with general lysis bu↵er, then eluted using
general elution bu↵er (Appendix A). The elution was then passed over a Highload 16/60
Superdex 200 gel filtration column (GE Healthcare) equilibrated in gel filtration bu↵er.
2.2.7 Heterocyclisation of 15N-PatE0 using PatD
Pure 15N-PatE0 (100 µM) was incubated in the presence of PatD (5 µM), ATP (5
mM), and MgCl2 (5 mM) in gel filtration bu↵er at 27 °C overnight to ensure complete
heterocyclisation. Following incubation, heterocyclised 15N-PatE0 was isolated via size
exclusion chromatography by passage down a Highload 16/60 Superdex 75 gel filtration
column (GE Healthcare) equilibrated in gel filtration bu↵er. The reaction was monitored
by MALDI-TOF-MS; a loss of 18 Da corresponding to the loss of water, was observed
for each heterocycle formed.
2.2.8 ITC Data Collection and Analysis
ITC experiments were performed using a VP-ITC instrument (MicroCal) in gel filtration
bu↵er at 20 °C. Both PatE0 and PatG-DUFdi. were dialysed into freshly prepared gel
filtration bu↵er for 2 days (changing to fresh bu↵er after the first day) at 4 °C to ensure
that the bu↵ers for the experiment were matched. A cell solution of 40 µM PatG-DUFdi.
and a syringe solution of 600 µM PatE0 were prepared (using the dialysis bu↵er to dilute
the samples) and degassed at 18 °C for 15 min. The PatE0 solution was titrated into the
PatG-DUFdi. solution as follows: an initial injection of 2 µL followed by injections of 5
µL at a speed of 0.5 µL min-1 with a delay of 4 min between injections. The syringe
was stirred at 307 rpm for the duration of the experiment. The raw data were processed
using the MicroCal Origin software. The baseline was adjusted and the integrations
were performed manually.
2.2.9 NMR Binding Experiments
NMR experiments were performed at 10 °C in a Bruker AVANCE III 500 MHz
spectrometer equipped with a 5 mm TXIz probe. The instrument was run using
the TopSpin software (Bruker). The sample for binding experiments consisted of 100
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µM 15N-PatE0 in gel filtration bu↵er supplemented with 5 % D2O, and a 1H-15N
HSQC spectrum was recorded. Aliquots of 1.6 mM PatG-DUFdi. were added to final
concentrations of 50, 100 and 200 µM and HSQCs were recorded after each addition. The
spectra were overlaid using TopSpin to identify changes (if any) in the spectra subsequent
to addition of PatG-DUFdi.. The 1H-15N HSQC sepctra were acquired with Water-gate
supression [91] at 1024 x 128 points and a digital resolution of 9.8 and 19.0 Hz for the
1H and 15N dimensions respectively. The experiments were repeated using a modified
PatE0 containing four heterocycles under the same conditions. This resulted in a poorer
signal-to-noise ratio and therefore the experiment was repeated using 250 µM modified
15N-PatE0 and aliquots of 2 mM PatG-DUFdi. were added to final concentrations of 125,
250 and 500 µM.
2.2.10 Expression and Purification of PatGmacDUF
PatGmacDUF (amino acid residues 515 - 1191) was cloned into pEHISTEV plasmid by
Dr Jesko Koehnke. A vector map can be seen in Fig. 2.6. The protein was expressed in E.
coli BL21 (DE3) cells grown in LB medium supplemented with 50 µg mL-1 kanamycin.
Cultures were incubated at 37 °C, 200 rpm until OD600 = 0.6. Cells were subsequently
induced with 1 mM IPTG and further incubated at 18 °C, 200 rpm overnight. Cells
were harvested by centrifugation (4000g, 4 °C, 15 min).
Cell pellets were resuspended in general lysis bu↵er (Appedix A), supplemented with
0.4 mg DNAse (Sigma-aldrich) per gram of wet cell pellet and cOmplete EDTA-free
protease-inhibitor tablets (Roche; 1 per 50 mL resuspension). The cells were lysed via
passage through a cell disruptor at 207 MPa (Constant Systems) and the cell debris was
removed via centrifugation (40 000g, 4 °C, 20 min). The supernatant was loaded onto
a pre-equilibrated Ni-Sepharose 6 Fast Flow column (GE Healthcare) at 4 °C, and the
column was washed with general lysis bu↵er. The protein was eluted from the column
in general elution bu↵er (Appendix A). The elution was passed over a desalt column
(Desalt 16/10, GE Healthcare) in desalt bu↵er 2 (Appendix A). TEV-protease was added
at a mass:mass ratio of 1 mg TEV to 10 mg of protein and the sample was incubated
for 2 h at room temperature to remove the N-terminal His6 tag. The digested sample
was passed over a second Ni-Sepharose 6 Fast Flow column and the flow-through was
loaded onto a MonoQ column (GE Healthcare) equilibrated in desalt bu↵er 2. Protein
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was eluted from the MonoQ column through a linear NaCl gradient. Finally the protein
was passed down a Highload 16/60 Superdex 200 gel-filtration column (GE Healthcare)
equilibrated in gel filtration bu↵er supplemented in 10 % glycerol (Appendix A).
Figure 2.6: Vector map of PatGmacDUF
2.2.11 Expression and Purification of PatGmac
PatGmac was expressed from pEHISTEV vector and purified as described (section 5.5.2).
2.2.12 Measuring Macrocyclisation Rate by HPLC
ITMeOxACThHITMeOxACThHAYDGE substrate peptide was generated as described (sec-
tion 5.2.4) and purified via passage down a Highload 16/60 Superdex 30 gel filtration col-
umn (GE Healthcare). Macrocyclisation of pure ITMeOxACThHITMeOxACThHAYDGE
was carried out as described (section 5.2.4). Reaction progress was monitored using
an Agilent infinity 1260 series RP-HPLC equipped with a MWD detector and a single
quadropole MS using a Nucleodur C4 (Macherey-Nagel) column (10 µm x 4.6 x 250
mm). 50 µL samples were taken at 0, 2, 4, 6, 8, 10, 12, 24, 48 and 72 h. Samples were
Chapter 2. Structural and Biochemical Characterisation of PatG-DUF 43
eluted from the column using an aqueous 5 mM ammonium carbonate - MeCN gradient
with a flow rate of 1 mL min-1 as follows: 0 - 3 min 5 % MeCN, 3 - 20 min 5 - 95 %
MeCN, 20 - 22 min 95 % MeCN, 22 - 23 min 95 - 5 % MeCN.
2.3 Results and Discussion
2.3.1 Cloning, Expression and Purification of PatG-DUF
Due to the high sequence homology between the C-terminal domains of unknown
function of PatA and PatG (Fig. 2.1), the decision to initially focus on PatG-DUF
was arbitrary. In an attempt to isolate and subsequently characterise the domain, a
truncated construct (amino acid residues 914-1186) of the C-terminus was designed based
on sequence homology (figure 2.3) and cloned into pEHISTEV vector. This construct
(PatG-DUF) was cloned from gDNA isolated from Prochloron sp. that were previously
isolated from Pacific reef samples. The exact strain could not be determined and the
amino acid sequence of this PatG-DUF construct (hereafter referred to as PatG-DUFsp.)
di↵ers at three points (E958D, R959Y and V1037M) from the deposited amino acid
sequence of PatG isolated from Prochloron didemni (accession No. AAY21556.1; Fig.
2.7). It is unclear as to whether these di↵erences arose as a result of natural variance
amongst species or a cloning artefact.
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Figure 2.7: Sequence alignment of PatG-DUF cloned from DNA isolated
from Procholoron sp. (PatG-DUFsp.) and PatG-DUF isolated from P.
didemni (PatG-DUFdi.). Sequence di↵erences are highlighted in green.
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Consequently PatG-DUFsp. was modified by site-directed mutagenesis to generate PatG-
DUF with the sequence from P. didemni (hereafter referred to as PatG-DUFdi.). Any
protocols, results and discussion that are applicable to both PatG-DUFsp. (E958, R959
and V1037) and PatG-DUFdi. (D958, Y959 and M1037) constructs will still be referred
to more generally, as PatG-DUF.
PatG-DUF, subsequent to iterative rounds of optimisation of the expression and
purification conditions (data not shown) was expressed and purified as described (section
2.2.1 and 2.2.2). Both PatG-DUFsp. and PatG-DUFdi. behaved in an identical fashion,
eluting from the gel filtration column as two separate peaks (Fig. 2.8). The first peak,
eluting at approximately 55 mL corresponds with a high order multimer (>600 kDa) and
was not expected to be biologically relevant. The second peak, eluting at approximately
90 mL contains pure PatG-DUF, as determined by SDS-PAGE and LC-ESI-MS, yielding
5 mg L-1 culture. Comparison with standards (Bio-Rad) confirm that PatG-DUF elutes
from the gel filtration column as a monomer (Fig. 2.8).
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Figure 2.8: PatG-DUF purification (a) Highload 16/60 Superdex 200 gel filtration
chromatogram of PatG-DUFsp. (green) and Bio-Rad gel filtration standards (grey); (b)
elution volume and molecular weight of gel filtration standards (Bio-Rad); (c) LC-ESI-
MS of PatG-DUFsp. processed to 0.1 Da; (d) LC-ESI-MS of PatG-DUFdi. processed to
0.1 Da; (e) SDS-PAGE of PatG-DUFsp. (lane 2) and PatG-DUFdi. (lane 3) compared
with Mark12TM molecular weight marker (lane 1).
Both PatG-DUFsp. and PatG-DUFdi. were dialysed into gel filtration bu↵er supple-
mented with 10 % glycerol and a Near-UV CD spectra were recorded (Fig. 2.9). These
spectra revealed no significant di↵erence in the overall tertiary structure between the
two variants and so we concluded that either sequence would be suitable for structural
characterisation.
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Figure 2.9: Near UV CD-spectra of PatG-DUFsp. and PatG-DUFdi. PatG-
DUFsp. (green) and PatG-DUFdi. (blue) are overlaid. A blank containing only bu↵er is
shown in red. The CD-spectra overlay well, suggesting the sequence variations (three-
point mutations) do not alter the tertiary structure of the domain.
Crystallography was carried out on PatG-DUFsp. as it had been purified first, and gave
crystals. We carried out biophysical and biochemical studies with PatG-DUFdi. as we
felt these data would be more informative, with a known database match.
2.3.2 Crystallography of PatG-DUFsp.
Pure PatG-DUFsp. at 4.75 mg mL-1 was subjected to crystallisation trials using a range
of sparse-matrix screens [81]. After three days crystals were formed in a precipitant
composition of 0.04 M potassium phosphate, 6 % PEG 8000 and 20 % glycerol (Fig.
2.10). A single crystal was picked and a native data set was collected in-house to 2.1 A˚
(Fig. 2.10, Table 2.1).
Determination of electron density, and thus the crystallographic structure of the protein
from X-ray di↵raction data requires knowledge of the amplitudes and the phases of the
scattered waves [92]. While the amplitudes can be calculated from the intensity of the
reflections in the di↵raction pattern, the phase information is lost in the experiment [93].
If a structurally similar model exists, initial phases can be estimated by placing the
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Figure 2.10: PatG-DUFsp. crystallography (a) Image of PatG-DUFsp. crystals
taken from Rigaku Minstrel imager. (b) UV image of crystals taken from Rigaku
Minstrel imager. (c) Single crystal di↵raction to 2.1 A˚ recorded in house.
Table 2.1: Data collection statistics for PatG-DUFsp. native data set.
Statistics are average values; values for the highest resolution shell are included in
parentheses.
PatG-DUFsp. native data set
Wavelength (A˚) 1.54
Space group P21 21 2
Unit-cell parameters (A˚, °) a = 64.2, b = 95.5, c = 40.3
↵ =   =   = 90.0
Resolution (A˚) 38.3-2.10 (2.16-2.1)
I/ I 12.9 (4.3)
Rmerge (%) 8.8 (36.8)
Completeness (%) 99.3 (95.7)
Multiplicity 5.0 (4.2)
model of the known protein into the unit cell of the new protein crystal, in a process
called molecular replacement [92]. However in the case of PatG-DUFsp., the structure
has not been determined for any of its sequence homologues, so no such model exists.
Therefore the structure cannot be determined using the native dataset already collected.
Phase information had to be obtained experimentally, in this case by the use of single
wavelength anomalous dispersion (SAD).
Di↵erent elements absorb X-rays at specific wavelengths. This absorption drops
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sharply at wavelengths just bellow their emission wavelengths, a feature known as
the element’s absorption edge. If the wavelength of the incident X-ray is close to an
element’s absorption edge, the element will exhibit anomalous dispersion [92]. Anomalous
dispersion (sometimes called anomalous scatter) results in a break down in Friedel’s
law, and so reflections hkl are no longer equal in intensity to reflections -h-k-l [92]. This
di↵erence between Friedel pairs can be used to locate the atom responsible for the
anomalous scattering within the unit cell, providing phase information for this atom,
which can be used to calculate the phases of the reflections of the protein [92,93].
The absorption edge of light atoms, such as carbon, nitrogen and oxygen is away from
the wavelength of X-rays used in crystallography, and so they do not contribute to
anomalous dispersion within a protein unit cell [85]. However the absorption edge of
heavier atoms is within this range, and their incorporation into a unit cell would provide
the anomalous scattering necessary to solve the crystal structure [92,93].
The most common and e cient method to introduce heavy atoms into the protein
crystal is to replace all the methionine residues with selenomethionine (SeMet), an
analogue containing a selenium atom in place of the sulfur. This provides an isomorphous
crystal with exploitable anomalous dispersion characteristics. This can be achieved
by the expression of protein in E. coli in a minimal medium where the l-methionine
is entirely replaced with l-selenomethionine. Inhibition of methionine biosynthesis by
adding large concentrations of leucine, isoleucine, phenylalanine, lysine and threonine
shortly before induction enhances the chance of complete selenomethionine incorporation
during protein expression [94].
Purification of SeMet PatG-DUFsp. was identical to that of native protein. However as
is anecdotally typical with SeMet incorporation, a lower yield of 0.46 mg L-1 of culture
was observed. LC-ESI-MS analysis confirmed all five selenium residues in PatG-DUFsp.
had been successfully replaced with SeMet (Fig. 2.11).
The lower peak at 30 758.7 Da represents an impurity, which has not yet been identified.
However no significant impurity was observed by SDS-PAGE analysis (Fig. 2.11) and
the impurity did not a↵ect crystalisation. SeMet PatG-DUFsp. was concentrated to
4.75 mg L-1 and screened for crystallisation. After three days crystals were observed in
the same precipitant conditions as the native protein. The largest crystal was picked,
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Figure 2.11: SeMet PatG-DUFsp. production (a) SDS PAGE analysis showing
purified SeMet PatG-DUFsp.. (b) LC-ESI-MS of SeMet PatG-DUFsp. (Mass = 31
293.8 Da). A mass increase compared to the mass of the native protein (31 056.5
Da) corresponds with incorporation of all five possible selenomethionine residues. The
smaller peak (30758.7 Da) corresponds to an impurity that hasn’t presently been
identified.
which di↵racted to 1.72 A˚ under synchrotron radiation. Data collection and refinement
statistics can be seen in Table 2.2.
The SeMet PatG-DUFsp. crystal belonged to the space group P212121 and contained one
monomer in the asymmetric unit. The structure has a fold comprising of seven ↵-helices
and thirteen  -strands. Analysis with secondary structure matching at the European
Bioinformatics Institute and TopSearch both suggest the fold is novel, with the closest
matches being a series of unrelated enterotoxins, giving r.m.s.d. values of between 3 and
4 A˚ over ⇠80 residues [95,96].
The refined model contains residues 920-1064 and 1077-1184 (residue numbering
corresponds to full-length PatG). The missing residues are at the N- and C-termini
of the model and in a connecting loop between ↵-helices 5 and 6, and are presumed to
be disordered. The model includes a single disulfide bond between C1136 and C1142
(Fig. 2.12). Regarding the sequence di↵erences between PatG-DUFsp. and PatG-DUFdi.
(Fig. 2.7): E958 and R959 are located on the surface, whilst V1037 is located on the edge
of a hydrophobic pocket near the surface (Fig. 2.12). None of these sequence alterations
would seem likely to alter the structure, which is consistent with the near-UV CD spectra
(Fig. 2.9).
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Examination of the identified anomalous scattering atoms revealed the Se atoms of
the four ordered methionine residues (the fifth selenomethionine at the start of protein
sequence is not visible in the model and presumed disordered). However, an additional
anomalous signal was observed at the interface of one monomer and its symmetry mate.
This signal corresponded with a significant sphere of unaccounted-for electron density,
which was coordinated in a tetrahedral arrangement by residues E977, H1087, H1090
and D1088* from the symmetry mate (PatG-DUF*sp.) creating a dimer. Based on the
anomalous signal, coupled with this coordination, the electron density was attributed to
a Zn2+ ion. Since zinc was not deliberately added to any of the purification bu↵ers, or
crystallisation conditions, it is presumed Zn2+ is bound in the cell. An equivalent Zn2+
binding site in the symmetry mate was also observed (Fig. 2.12).
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Table 2.2: Data collection and refinement statistics for SeMet PatG-DUFsp.
An anomalous data set was collected using a single crystal on a beamline I02 at the
Diamond Light Source. Statistics are average values; values for the highest resolution
shell are included in parentheses.
SAD data set
Wavelength (A˚) 0.9797
Space group P21 21 2
Unit-cell parameters (A˚, °) a = 64.1, b = 95.2, c = 40.2
↵ =   =   = 90.0
Resolution (A˚) 53.2-1.7 (1.8-1.7)
I/ I 12.1 (3.4)
Rmerge (%) 14.6 (89.6)
Completeness (%) 99.9 (100)
Multiplicity 14.0 (11.3)
Anomalous completeness 99.9 (99.9)
Anomalous multiplicity 7.3 (5.7)
Refinement
R-factor (%) 17.5 (23.9)
Rfree (%) 20.0 (29.5)
R.m.s.d., bond lengths (A˚) 0.005
R.m.s.d., bond angles (°) 0.932
No. of non-H atoms
Protein atoms 2109
Solvent atoms 269
Heterogen atoms 1
B factors A˚2
All 26.0
Protein 25.1
Ligand (Zn2+) 15.9
Water 32.8
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Figure 2.12: X-ray crystal structure of PatG-DUFsp. (a) PatG-DUFsp.
represented as a cartoon. The disulfide bond between C1136 and C1142 is shown
as orange sticks and the Zn2+ is shown as a grey sphere. PatG-DUFsp. amino acids
which di↵er from those in PatG-DUFdi. are highlighted as spheres for clarity. (b) X-ray
crystal structure of the PatG-DUFsp. dimer represented as a cartoon. (c) Enlargement
of the Zn2+ coordination site. E977, H1087, D1088 and H1090 are shown as green
sticks, and E977*, H1087*, D1088* and H1090* are shown as cyan sticks. Di↵erence
electron density (Fo-Fc) contoured at 3  with phases calculated from a model that was
refined without Zn2+ present is shown as a blue isomesh.
Analysis with PISA - software that enables the exploration of macromolecular inter-
faces [97] reveals that there are almost no contacts between the amino acid residues at
the interface, and that removing the Zn2+ ions in silico reduces the complex formation
significance score to 0.056, indicating Zn2+ is crucial in mediating dimer interactions.
Since Zn2+ was not added externally, its presence in the crystal could suggest that
the dimer is present in solution. However PatG-DUF eluted from the gel filtration
column as a monomer (Fig. 2.8), preventing a firm assignment of dimer versus monomer.
Interestingly the residues involved in Zn2+ binding are not all conserved in PatA-
DUF (Fig. 2.13). While the H1087Y substitution might still coordinate Zn2+, the
H1090R substitution would not. Additionally these residues are not well conserved
in the majority of PatG-DUF homologues (with notable exceptions being TruG-DUF
and ArtG-DUF) or in any of the PatA-DUF homologues (Fig. 2.13). Consequently we
cannot make any claims regarding the biological relevance of a dimeric assembly for the
DUF domain.
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Figure 2.13: Truncated DUF sequence alignments (a) PatG-DUF and PatA-
DUF, (b) PatG-DUF and its homologues, (c) PatA-DUF and its homologues. The
residues involved in Zn2+ coordination in PatG-DUF are highlighted with red stars.
2.3.3 Cloning, Expression and Purification of PatA-DUF
In an attempt to isolate stable, homogenous PatA-DUF for structural characterisation, a
construct of the C-terminal domain based on the PatG-DUF construct that had already
been used in structural studies was designed (figure 2.1), and cloned into pEHISTEV
plasmid. As a set of preliminary expression experiments, PatA-DUF was expressed from
a set of 10 mL E. coli BL21 (DE3) cultures in LB, incubated until OD600 = 0.6 and
induced with 0.1, 0.5 or 1 mM IPTG and expressed at 15, 25 or 37 °C overnight. This
small-scale expression test confirmed induction with 0.1 mM IPTG at 15 °C yields the
greatest amount of protein (Fig. 2.14).
However in these experiments the majority of the protein did not bind the Ni beads,
with a large amount of the sample present in the flow-through (Fig. 2.14). This might
be because the protein is aggregated in solution and so the His6 tag is unaccessible
to the Ni beads. A variety of bu↵er conditions were tested, but none resulted in
a noticeable improvement (data not shown). Therefore PatA-DUF was cloned into
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Figure 2.14: PatA-DUF expression SDS-PAGE of PatA-DUF expression test:
Flowthrough and Elution from Ni column loaded with lysate from E. coli BL21 cells
induced with 0.1, 0.5 and 1.0 mM IPTG and incubated at 15, 25 and 37 °C overnight.
pEHISSUMOTEV, a vector containing a TEV-cleavable Small Ubiquitin-like Modifier
(SUMO) tag preceded directly at its N-terminus by a His6 tag. SUMO tags have
been shown to enhance protein expression, and promote correct protein folding [98].
Additionally, the covalent attachment of the ⇠12 kDa tag should su ciently extend
the His6 tag from the core of the protein to promote binding to the Ni column. Initial
signs were promising with yields >100 mg L-1 of culture eluting from the Ni column.
However, once the tag was removed the protein eluted from the gel filtration column in
the void volume, implying the sample was entirely aggregated (Fig. 2.15).
Figure 2.15: PatA-DUF purification Gel Filtration chromatograph of PatA-DUF
after removal of the SUMO tag. PatA-DUF elutes as a single peak in the void volume
inplying the entire protein sample is aggregated.
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At present, all attempts to purify PatA-DUF have been unsuccessful. Consequently,
given the high homology between the C-terminal domains of PatA and PatG, all
subsequent attempts to identify a role for the domains have focused on the biochemical
and biophysical characterisation of PatG-DUF.
2.3.4 Investigating Potential Binding Partners for PatG-DUFdi.
The X-ray crystal structure for PatG-DUFsp. is novel, and so provides no immediate
insight as to why the DUFs are conserved throughout cyanobactin biosynthetic
pathways. In an attempt to elucidate the function of this domain, and importantly,
determine whether it has a direct role in patellamide biosynthesis, a number of potential
binding partners for PatG-DUF were explored. Obvious targets to test include the
patellamide precursor peptide PatE, the modified precursor biosynthetic intermediates,
and the final macrocyclic product. If binding is observed, subsequent experiments can be
designed to test hypotheses regarding the function of the domain. A modified precursor
peptide PatE0 was used in place of the natural sequence.
Initial binding experiments were performed using ITC. Titrating PatE0 into a solution of
PatG-DUFdi. reproducibly results in a weak, but detectible, titration curve, indicative
of a binding interaction (Fig. 2.16). However analysis of the data yields unlikely
stoichiometries of around ten molecules of PatG-DUFdi. binding to one molecule of
PatE0. Furthermore, close inspection of the cell solution revealed heavy precipitation at
the end of the experiment. Therefore it seems likely that the exothermic signal observed
arises from protein aggregation rather than a genuine binding interaction between PatE0
and PatG-DUFdi..
To resolve the ambiguity of the ITC data, binding experiments between PatG-DUFdi.
and PatE0 were performed using NMR spectroscopy. Using 15N labelled PatE0 a 1H-
15N-HSQC spectrum was recorded in the absence, and presence of 0.5, 1.0, and 2.0
molar equivalents of PatG-DUFdi. (Fig. 2.17), where a binding event would give rise to
significant changes in the chemical shift of the N-H cross peaks.
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Figure 2.16: ITC of PatG-DUFdi. and PatE0 ITC data of PatE0 titrated into
PatG-DUFdi. solution. The top panel shows raw data representing heat evolved in
response to injections, the bottom panel shows the integrated heats of injections (⇤)
and the best fit (-) to the one-site model (Origin).
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Figure 2.17: NMR of 15N-PatE0 + PatG-DUFdi 1H-15N-HSQC of 15N-PatE0
(blue), with 0.5 (green), 1.0 (purple) and 2.0 (red) equivalents of PatG-DUFdi..
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Figure 2.18: NMR of 15N-PatE0 + PatG-DUFdi 1H-15N-HSQC of 15N-PatE0
before (blue) and after (red) addition of 2.0 equivalents of PatG-DUFdi.
.
The spectra of pure 15N PatE0 in the absence (blue) and presence of 2.0 equivalents
of PatG-DUFdi. (red) have been overlaid for clarity (Fig. 2.18), and clearly show an
identical chemical shift pattern, showing that PatG-DUFdi. does not bind the unmodified
precursor peptide.
The NMR experiments were repeated using 15N PatE0 that had ben processed with
PatD, introducing four heterocycles (two thiazolines and two oxazolines) within the
context of the core peptide (Fig. 2.19). As before, the addition of up to 2.0 equivalents
of PatG-DUFdi. to the modified PatE0 resulted in an identical NMR spectrum to that of
pure heterocyclised PatE0 (Fig. 2.20), indicating that the heterocycle-containing peptide
does not bind PatG-DUFdi. either. The known disorder of the leader peptide in PatE0 [51]
would suggest that blocking of PatG-DUFdi. binding by the leader peptide is unlikely. At
present, we are unable to produce labelled cleaved precursor or macrocycle in su cient
quantities and purity for NMR experiments.
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Figure 2.19: NMR of heterocyclised 15N-PatE0 + PatG-DUFdi 1H-15N-
HSQC of heterocyclised 15N-PatE0 (blue), with 0.5 (green), 1.0 (purple) and 2.0 (red)
equivalents of PatG-DUFdi..
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Figure 2.20: NMR of heterocyclised 15N-PatE0 + PatG-DUFdi overlaid
Heterocyclised 1H-15N-HSQC of 15N-PatE0 before (blue) and after (red) addition of
2.0 equivalents of PatG-DUFdi..
2.3.5 Investigating the E↵ect of PatG-DUF on Macrocyclisation
To investigate what e↵ect, if any, the DUF has on peptide macrocyclisation, a new
construct encompassing both the macrocyclisation and DUF domains of PatG, (hereby
referred to as PatGmacDUF) was cloned into the pEHISTEV plasmid by Dr Jesko
Koehnke and expressed and purified as described (section 2.2.10). The 74 kDa
PatGmacDUF eluted from the gel filtration column as a single peak at approximately
80 mL, corresponding to a monomer (Fig. 2.21), yielding 1.5 mg L-1 culture of pure
protein, as assessed by SDS-PAGE (Fig. 2.21).
The rate of macrocyclisation was monitored using HPLC to follow the consumption
of the ITMeOxACThHITMeOxACThHAYDGE substrate peptide by both PatGmac and
PatGmacDUF at 0, 2, 4, 6, 8, 10, 12, 24, 48 and 72 h time intervals. Start and end-points
of the macrocyclisation reaction were established as 100 and 0 % of substrate respectively.
No linear product was observed, so it can be assumed that complete consumption of
substrate corresponds with complete product formation. Very little deviation between
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Figure 2.21: Purification of PatGmacDUF (a) Superdex S200 gel filtration
chromatogram of PatGmacDUF. (b) SDS-PAGE analysis of PatGmacDUF compared
with Mark12TM molecular weight marker. Identity was confirmed by MS.
the rates of macrocyclisation by PatGmac and PatGmacDUF was observed, and by 24
h both constructs have processed 90 % of the starting material, and both reactions were
essentially complete (<1 and <5 % for PatGmac and PatGmacDUF respectively) by 48
h (Fig. 2.22).
Figure 2.22: Rate of macrocyclisation by PatGmac and PatGmacDUF
Consumption of ITMeOxACThHITMeOxACThHAYDGE substrate during the macrocy-
clisation reaction over time by PatGmac (blue) and PatGmacDUF (green).
Any increase in the initial rate of macrocyclisation (0 - 12 h) observed upon the inclusion
of PatG-DUF compared with PatGmac in isolation (although likely not significant) is
o↵set by a much lower soluble protein yield following purification of PatGmacDUF
compared with PatGmac (1.5 mg L-1 and >200 mg L-1 respectively) [43]. The increase
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in activity is not su cient to justify the use of PatGmacDUF as an alternative to the
original PatGmac construct for biotechnological application.
2.4 Conclusions
The patellamide proteins PatA and PatG contain C-terminal domains of unknown
function, which are 56 % identical and are conserved in related cyanobactin biosynthetic
pathways. X-ray crystallography revealed the structure of PatG-DUFsp. to be a novel
fold, and although a dimer is observed in the crystal, the residues involved in Zn2+
coordination (which is required for dimerisation) are not well conserved in PatA-DUF
or in homologues from other pathways. Consequently, it is di cult to speculate as to
the functional importance of the dimer. We have been unable to detect any binding
of PatG-DUFdi. to linear substrates (simple peptides or peptides with heterocycles),
indicating that these are unlikely to be substrates or ligands of the DUFs. The pitfall in
using one technique to assess binding was shown by the reproducible, but functionally
meaningless ITC binding curves that we observed. Further study is required with
macrocyclic peptide before we can entirely rule out any binding between DUFs and
patellamide substrates. It remains possible that the dimerisation of the domain indicates
an interaction between DUFs, potentially leading to homodimers of PatA/PatG or even
heterodimers of PatA and PatG. To investigate whether the DUFs a↵ect the activity
of their associated domains a construct containing both the macrocyclisation and the
C-terminal DUF of PatG was designed. No significant enhancement of activity was
observed for PatGmacDUF over PatGmac in vitro to o↵set the far lower soluble yield
of PatGmacDUF compared with PatGmac, limiting its potential for biotechnological
application. If the DUFs have no enzymatic role, which our lack of binding data would
suggest, coupled with the observation that the protease domains of PatA and PatG are
active in isolation, which is not significantly altered by the presence of the DUFs, it is
interesting as to why they are conserved throughout cyanobactin biosynthesis. However,
importantly, it also suggests that the DUFs can be excluded from in vitro enzyme-based
synthesis systems. This simplifies the design of a biotechnological ‘toolkit’ for bioactive
cyclic and linear peptides.
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2.5 Future Work
Although the work in this chapter demonstrates that the DUFs are not required for
the synthesis of cyanobactins in vitro a role for the DUFs is yet to be determined.
E↵orts to identify a role for DUFs should begin by monitoring for a possible binding
interaction between PatG-DUF and short, leaderless peptides and macrocyclic peptides.
Additionally, it remains possible that the DUFs are sca↵old for multi-protein complexes,
and this is to be investigated.

Chapter 3
Structure-guided
Characterisation and Engineering
of the Heterocyclase
3.1 Introduction
The incorporation of heterocycles within a peptide backbone, significantly alters
the peptide’s physiochemical properties, giving rise to more medicinally favourable
characteristics, including increased membrane permeability, and reduced conformational
flexibility, which can both improve oral bioavailability and target a nity [99]. Therefore,
enzymes o↵ering a straightforward and site-selective installation of heterocycles into
a peptide backbone are a desirable and applicable biotechnology. The cyanobactin
heterocyclase enzymes (D enzymes) catalyse the ATP-dependant cyclodehydration of
cysteine, and in some cases serine/threonine residues, forming thiazoline and oxazoline
heterocycles within the context of the cyanobactin core peptide. These enzymes show
high substrate tolerance, selectively modifying these residues, largely irrespective of
their neighbouring residues, suggesting substrate recognition is spatially distinct from
catalysis. The importance of the highly conserved leader peptide in substrate processing
is well documented, and is thought to be involved in recognition [41,51,52]. However at
the time of writing the molecular rational underpinning this recognition is unknown.
Additionally, at present, the precise utilisation of ATP during turnover is contentious,
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with evidence supporting its involvement in substrate activation via both the ↵ and
 -phosphate [50,51].
In this chapter, we make use of X-ray crystal structures of the cyanobactin heterocyclase
LynD (highly homologous to PatD) from the aestuaramide pathway (Lyngbya sp.)
in complex with various substrate peptides and nucleotides (determined by Dr Jesko
Koehnke) to provide insight into substrate recognition and the mechanism of heterocy-
clisation. Analysis of the crystal structures reveal the orientation of the nucleotide bound
at the active site is not consistent with an adenylation mechanism [51]. Consequently the
utilisation of ATP as a cofactor is looked at in more detail. The complex structures
also provide direct evidence for the role of the leader peptide in substrate recognition,
rationalising the observed cis and trans activation of the heterocyclase [41] by the leader
peptide, and the sequence of the ‘minimal leader’ required for complete processing [51,52].
Using these data, a novel LynD has been engineered, capable of a↵ecting a short peptide
lacking the leader peptide, with wild-type-like activity.
3.2 Materials and Methods
3.2.1 Expression and Purification of LynD, AcLynD and LynD Mu-
tants
Codon-optimised full-length LynD (Lyngbya sp. PCC-8106) with an N-terminal His6
tag and TEV protease site was purchased from DNA2.0 in the pJexpress 411 plasmid.
Mutagenesis was performed by Dr Andrew Bent using established protocols [80]. For
biochemical characterisation all proteins were expressed and purified as described
(section 2.2.6).
3.2.2 Expression and Purification of PatE0 and PatE0 mutants
PatE0 and PatE0 mutants were expressed and purified as described (section 2.2.5).
Mutagenesis was performed by Dr Andrew Bent using established protocols [80].
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3.2.3 Synthesis of a Detectable Full-length Leader Peptide
To generate full-length leader peptide, the PatE0 sequence was mutated at four positions
(D2Y, K3E, K4E and R16E) using standard protocols [80]. The resulting quadruple
mutant (PatE04) full amino acid sequence is as follows: MYEENILPQQGQPVIELT-
AGQLSSQLAELSEEALGDAGLEASKITACITFCAYDGELEHHHHHH. PatE04 was ex-
pressed and purified as described for PatE0 (2.2.5) and subjected to heterocyclisation
tests to ensure normal processing. The mutations K3E, K4E and R16E enable full-
length leader to be retained following digestion of PatE04 with trypsin (Sigma-aldrich)
and the D2Y mutation allows the leader peptide to be visualised during purification
from the trypsin reaction and quantified. PatE04 was digested with 1/100 trypsin at 37
°C, 300 rpm for 3 h and subsequently applied to a Ni-Sepharose Fast Flow column (GE
Healthcare) equilibrated in gel filtration bu↵er. The flow-through was collected and was
confirmed to contain full-length PatE04 leader peptide by MALDI-TOF-MS. The pure
sample was concentrated to 1 mM.
3.2.4 Heterocyclisation Reactions
Standard heterocyclisation reaction conditions are as follows: 100 µM PatE0 (and
variants) were incubated with 5 µM enzyme, 5 mM ATP, 5 mM MgCl2 in gel filtration
bu↵er at 37 °C for 16 h. Reactions set up for analysis of ATP hydrolysis by 31P NMR
were prepared using 220 µM ATP and 1 mM DTT in place of 1 mM TCEP (from gel
filtration bu↵er); the reaction was incubated at 37 °C for 2 h. To investigate the activity
of LynD and variants towards leaderless substrates, 5 µM enzyme was incubated with
100 µM synthetic ITACITFCAYDG in the presence and absence of 5.5 µM synthetic
LAELSEEAL (minimal leader) or full-length PatE04 leader peptide. The reactions were
otherwise performed under standard conditions. Synthetic peptides were purchases from
Peptide Protein Research Ltd. Samples were analysed either by LC-ESI-MS or MALDI-
TOF-MS.
3.2.5 Comparative Time-Course Experiments
To assess the relative rates of heterocyclisation under various conditions, reactions were
monitored at regular intervals using MALDI-TOF-MS. In each case reactions of PatE0
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or ITACITFCAYDG were prepared as described (3.2.4) and incubated at 37 °C prior
to the addition of LynD (wild-type, mutants and fused), allowing a 0 time point to be
recorded. Time points for each reaction were as follows: for PatE0 with LynD (standard
conditions) and ITACITFCAYDG with LynD fusion, the reaction was monitored after
1, 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 min. For ITACITFCAYDG with LynD
in the absence and presence of either the minimal leader LAELSEEAL peptide or full-
length PatE04 leader peptide, the reaction was monitored after 15, 30, 60, 120, 240
and 1440 min. For PatE0 with wild-type LynD and LynDK409A with 500 µM ATP the
reaction was monitored after 10, 30, 60, 120 and 360 min. Reactions were set up in
triplicate and each sample was analysed by MALDI-TOF-MS in triplicate (nine spectra
recorded per time point). For each time point the total ion count for each species (0, 1
and 2 heterocycles) was recorded and averaged, and the percentage of each species was
calculated. Plotting the percentage of species containing 1 and 2 heterocycles against
time allowed a visual comparison for the rate of the reaction relative to the wild-type
reaction (PatE0 + LynD).
3.2.6 ITC Data Collection and Analysis
ITC experiments were performed using a VP-ITC instrument (MicroCal) in gel filtration
bu↵er supplemented with 5 mM MgCl2. LynD and PatE0 (and their respective mutants)
were dialysed into freshly prepared bu↵er overnight at 4 °C to ensure the bu↵ers for
the experiment were matched. For substrate binding experiments a cell solution of
10 µM LynD (and mutants) and a syringe solution of 150 µM PatE0 (and mutants)
were prepared by diluting protein and peptide with dialysis bu↵er. For nucleotide
binding experiments, the cell concentration was increased to 20 µM, and the ATP/AMP
concentration in the syringe solution was 300 µM. Substrate and ATP experiments were
performed at 20 °C and AMP experiments were performed at 25 °C. Cell and syringe
solutions were degassed for 15 min at 18 and 23 °C respectively. The titration method
was as follows: one injection of 2 µL followed by injections of 5 µL at 0.5 µL min-1, with
a delay of 4 min between injections. A stirring speed of 307 rpm was used throughout.
Raw data were processed using MicroCal Origin software, the baseline was adjusted
and the integration limits were set manually. Data were fitted to the one-site model
(Origin), setting the stoichiometry to 1.
Chapter 3. Structure-guided Characterisation and Engineering of the Heterocyclase 69
3.2.7 31P NMR Experiments
31P NMR spectra were acquired using 1,024 scans on a Bruker AVANCE III 500 MHz
spectrometer equipped with a room temperature BBFO+ probe. Composite pulse
sequence ‘waltz-64’ was used for 1H power-gates broadband decoupling.
3.2.8 Selective 18O-PatE0
PatE0 was selectively 18O labelled at the carbonyl of the residues preceding the
cysteine residues based on a protocol described in the study of BalhD [50]. PatE0
was heterocyclised as described (section 3.2.4) and the reaction mixture was purified
using size-exclusion chromatography (Highload 16/60 Superdex 75, GE Healthcare).
Pure heterocyclised-PatE0 was concentrated to 0.5 mL and dried to a powder using
a Thermo Savent Speed Vac. To accomplish selective 18O labeling, the dried sample
was resuspended in H218O supplemented with 0.1 % formic acid to hydrolyse the
heterocycles, and incubated at 20 °C. The ring opening was followed using MALDI-
TOF-MS. Once complete, selectively labelled 18O-PatE0 was dialysed into gel filtration
bu↵er (containing 1 mM DTT in place of 1 mM TCEP). To ensure all traces of acid and
H218O were removed, the sample was dialysed 3 x 1:1000 (2 x 2 h followed by overnight).
The dialysed sample was recovered, diluted to 7.5 mL in urea lysis bu↵er supplemented
with 10 mM DTT and passed through a Highload 16/60 Superdex S75 size-exclusion
column (GE healthcare) pre-equilibrated in gel filtration bu↵er containing 1 mM DTT
in place of 1 mM TCEP to yield pure 18O-PatE0, as confirmed by MALDI-TOF-MS.
3.2.9 LC-ESI-MS of 18O-PatE0 pyrophosphate
Purification of pyrophosphate was achieved by passing the reaction mixture through a
protein concentrator with a 5 kDa cuto↵. The flow-through was applied to CaptoQ
resin (GE Healthcare) and washed with 15 column volumes of dH2O. Pyrophosphate
was eluted with 1M sodium acetate, pH 7.0. Accurate mass measurements were carried
out on an ABSciex 5600 mass spectrometer with a nanospray source. Samples were
diluted 50 % with acetonitrile and infused at 1 µL min-1 using the built-in syringe pump.
Negative ionization spectra were collected from 60-400 m/z in MS mode. Mass/charge
(m/z) ratios of 176.9 and 178.9 were isolated in Q1 and fragmented with collision energy
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of 30 V in Q2, and the fragments were measured from 50-200 m/z on the TOF analyser.
The TOF was externally calibrated with a mixture of periodate (190.8847 m/z) and
sulfanilic acid (172.0074 m/z).
3.2.10 Preparation of Test Substrates for AcLynD
PatE0 variants with seven (PatE0-IACIMAC) and nine (PatE0-IITACIMAC) core peptide
residues, and one with three cysteine residues (PatE0-ICACITFC) in the core peptide
were cloned, expressed and purified as described for PatE0 (section 2.2.5). Each peptide
was digested with 1/100 trypsin at 37 °C, 300 rpm for 3 h and subsequently purified
using size-exclusion chromatography (Highload 16/60 Superdex S30, GE Healthcare) in
gel filtration bu↵er containing an additional 1 mM TCEP (2 mM total).
3.3 Results and Discussion
The cyanobactin heterocyclase LynD from the aestuaramide pathway (Lyngbya sp.) is a
close homologue of the patellamide heterocyclase PatD. To date, only products from
the aestuaramide pathway containing thiazole heterocycles have been identified [100],
suggesting LynD would display TruD-like activity, processing only cysteine residues
within a core peptide (compared to PatD, which additionally processes serine and
threonine residues) [40]. However, since the core peptides from which the aesuaramides
are derived, lack serine and threonine residues, this hypothesis needed to be tested.
While the core peptide sequence of the aesuramide and patellamide precursor peptides
are varied, the conserved recognition elements and leader peptide from the two pathways
are highly similar, and so it is expected that PatE0 would be a substrate of LynD (Fig.
1.2).
Incubation of LynD with PatE0 in the presence of ATP/Mg2+ overnight (to ensure
completion), resulted in a species with a mass loss of 36 Da as identified by LC-
ESI-MS, corresponding with two heterocyclisation events (Fig. 3.1). Iodoacetamide
(IAA), a molecule that forms adducts with free cysteine was added to the heterocyclised
product, and no mass increase was detected by LC-ESI-MS, confirming the loss of 36 Da
corresponded with the modification of the two cysteine residues within the core peptide
(Fig. 3.1).
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Figure 3.1: PatE0 + LynD LC-ESI-MS of (a) PatE0, (b) PatE0 + LynD and (c)
PatE0 + LynD + Iodoacetamide (IAA). The loss of 36 Da (two water molecules) coupled
with the lack of mass increase following incubation with iodoacetamide, consistent with
the two core peptide cysteine residues have undergone cyclodehydration, forming two
thiazoline heterocycles.
3.3.1 Structure of LynD Complexes
X-ray crystallography of LynD in complex with variants of substrate peptide PatE0 and
various nucleotides were pursued by Mr Hannes Ludewig and Dr Jesko Koehnke. Three
complex structures were solved by Dr Jesko Koehnke: LynD-AMP-PatE0, 2.86 A˚, (PDB:
4V1U); LynD-ATP-PatE0C51A, 2.14 A˚, (PDB: 4V1T); LynD- , -imido-ATP-PatE0C51A
(LynD-AMP-PNP-PatE0C51A), 3.01 A˚, (PDB: 4V1V). All three complexes contained
two monomers in the asymmetric unit, with each monomer composed of three domains,
which form an antiparallel dimer through head-to-tail association of domains 1 and 2,
as seen for TruD (PDB: 4BS9) [51]. The LynD complex structure is overall tighter than
that seen for the apo TruD structure; particularly domains 3 from each monomer are
much closer together in the complex structure (Fig. 3.2). All three complex structures
are highly similar, with low C↵ r.m.s.d. values ( 1.06 A˚) between the three structures.
The following discussion refers to the highest-resolution LynD-ATP-PatE0C51A structure,
except when specified. In this model LynD residues 6-143, 151-229, 240-336 and 342-
775 in chain A and residues 4-226, 240-336 and 343-775 in chain B are ordered. The
missing residues are presumed disordered. A Zn2+ is coordinated in domain 2 in the
same manner as TruD [51]. The structure allows us to locate both the active site and
substrate recognition site. The nucleotide at the active site is in domain 3, whereas
the leader peptide is bound at the interface between domain 1 from one monomer and
domain 3 from another (Fig. 3.2). Simple distance constraints dictate that processing
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of the core peptide must occur in the same domain 3 that binds the leader peptide. The
nucleotide in this domain is approximately 26 A˚ away from the closest ordered residue
of the leader peptide, su ciently close to position the subsequent core peptide near to
this nucleotide. Conversely the shortest accessible route from the leader peptide to the
alternate nucleotide gives a total distance of over 70 A˚; the precursor peptide is not long
enough to reach this nucleotide. Therefore the dimer is a functional requirement (Fig.
3.2).
Figure 3.2: X-ray crystal structures of LynD complexes (a) Cartoon
representation of LynD-ATP-PatE0C51A complex showing dimeric assembly. LynD
(purple) is comprised of the same 3 domains as seen for TruD [51]. A structural Zn2+ ion
(grey sphere) is coordinated in domain 2 and the nucleotide (yellow spheres) is bound
in domain 3. The ordered residues of PatE0C51A (cyan cartoon) is bound between
domain 1 of one LynD monomer, and domain 3 of another. The second monomer
is shown using the same colour scheme as the other, but using faded colours. (b)
Cartoon representation of LynD-AMP-PNP-PatE0C51A (LynD monomers are shown in
purple and light pink). The nucleotide nearest to the last ordered residue of PatE0C51A
(therefore the catalytic nucleotide for that peptide), is located in the same domain
3 which makes contacts with the leader peptide, indicating the dimer is a functional
requirement. A clear path from the last ordered residue of PatE0C51A to AMP-PNP
can be seen. AMP-PNP is shown as yellow stick. Magnesium ions in the active shown
as grey spheres.
3.3.2 Nucleotide Binding Site
The nucleotide binding site, and thus the active site of LynD is located within domain
3 (residues 316-775). This is inconsistent with the hypothesis that the cyanobactin
heterocyclase enzymes are adenylating enzymes, which was in part proposed due
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to structural similarity between the cyanobactin heterocyclase TruD, and MccB, an
adenylase required for the biosynthesis of the antibiotic microcin C7, which would require
ATP to be bound in domain 2 (although the authors did note that the ATP binding site of
MccB is not fully conserved in TruD) [51]. Domain 3 of LynD is structurally homologous
to the E. coli YcaO domain [101] (C↵ r.m.s.d. of 2.4 A˚ over 282 residues) and binds the
nucleotide in the same location. The adenosine ring is bound through cation-⇡ stacking
interactions with R344 on one face, and makes van der Waals interactions with S419 and
T351 on the other. Additionally it forms hydrogen bonds through the N7 and N1 atoms
with residues Q415 and N536 respectively (Fig. 3.3). The lack of extensive hydrogen
bonding around the ring is consistent with the ability of the D enzymes to use other
nucleotide triphosphates [51]. The O20 and the O30 atoms of the ribose hydrogen bond
with the main chain of A534 and the side chain of E426 respectively. The ↵-phosphate
makes a salt bridge with R636 and hydrogen bonds with Q544 and S419. In the LynD-
ATP-PatE0C51A structure, a discontinuation of the nucleotide electron density caused
us to reassign the complex more accurately as having bound ADP and phosphate (Pi)
(Fig. 3.3). It is presumed the Pi mimics the  -phosphate of ATP. It is unclear as to
whether the hydrolysis of ATP to ADP and Pi in the crystal structure is mechanistically
relevant, but if so it would be consistent with substrate activation via a phosphorylation
mechanism [49,50]. The precise positions of the   and  -phosphates vary slightly between
the ADP-Pi and the AMP-PNP structures, but their similarities are informative. In
both complexes a Mg2+ ion, coordinated by E640, binds the   and  -phosphates and a
second Mg2+ ion, coordinated by E548, binds the  -phosphate. In the ADP-Pi structure
the second Mg2+ bridges the   and  -phosphates (Fig. 3.3). This structure also contains
a third Mg2+ ion, coordinated by E423, which also bridges the   and  -phosphates. In
addition to the metal ions, the  -phosphate makes salt bridges with R636 and K409,
and the  -phosphate forms a salt bridge with R552 and R427 (Fig. 3.3).
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Figure 3.3: LynD nucleotide binding site (a) LynD-ADP-Pi-PatE0C51A, (b)
LynD-AMP-PNP-PatE0C51 and (c) LynD-AMP-PatE0 complex structures. Di↵erence
electron density (F0-Fc) contoured at 3   with phases calculated from a model that
was refined without nucleotide or metal ions present, shown as a blue isomesh. (d)
Residues involved in binding of adenosine and ribose moeity of ADP shown as sticks.
(e) Residues involved phosphate and metal ion coordination shown as sticks. Colouring
for all images are as follows: Nucleotide atoms are coloured yellow for carbon, blue for
nitrogen, red for oxygen and orange for phosphorous. Protein atoms follow the same
colour scheme, except carbons are purple. Metal ions are shown as grey spheres.
3.3.3 Orientation of Nucleotide Binding
Heterocyclisation of cysteine, serine and threonine proceeds via attack on the nucleotide
triphosphate by a hemiorthoamide intermediate. However these complex structures
reveal that the orientation of the nucleotide within the active site, relative to the
incoming substrate is such that the ↵-phosphate is occluded from attack by the
hemiorthoamide (Fig. 3.4), thus precluding an adenylation mechanism [51].
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Figure 3.4: Occlusion of ↵-phosphate The ↵-phosphate is occluded from attack
of the reacting hemiorthoamide intermediate. (a) Incoming precursor peptide threads
through to the active site, through the channel as shown, approaching the  -phosphate.
(b) Close-up view of the nucleotide in the active from the perspective of the incoming
peptide. From this angle shielding of the ↵-phosphate clearly precludes an adenylation
mechanism. One monomer of LynD is shown as a purple cartoon. Domain 3 of the other
monomer is represented with a pink surface. The precursor peptide is shown as a cyan
cartoon. Nucleotide phosphates are shown as sticks coloured orange for phosphorous
and red for oxygen. Metal ions are shown as grey spheres.
To ensure that the observed orientation of the nucleotide is mechanistically relevant and
to eliminate any possibility that it is an artefact of crystallisation, residues identified
as nucleotide binding were mutated, and the mutants were tested for their ability to
bind ATP or AMP and process substrate PatE0. Binding experiments were performed
using ITC and can be seen in Fig. 3.5. The activity of each mutant was monitored using
MALDI-TOF-MS. A summary of the binding and activity data can be seen in Table 3.1.
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Figure 3.5: Nucleotide binding ITC data for ATP and AMP titrated into LynD
and LynD mutant solutions. The top panel shows raw data representing heat evolved
in response to injections, the bottom panel shows the integrated heats of injections (⇤)
and the best fit (-) to the one-site model (Origin).
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Table 3.1: Nucleotide binding and processing of LynD mutants.
Nucleotide KD (µM)
Enzyme ATP AMP
No. of heterocycles
(PatE0)
LynD 50.25 14.41 2
LynDK409A No binding No binding 2
LynDK409E No binding No Binding 1
LynDE423R No binding 5.65 0
LynDR427E No binding 23.04 1 and 2
LynDR636E No binding No binding 0, 1 and 2
LynDR636A N/A No binding 0, 1 and 2
Both the K409A and K409E mutants completely abolished binding of ATP and AMP to
LynD as determined by ITC experiments (Fig. 3.5, Table 3.1). Therefore the ability of
each mutant to process PatE0 substrate was unexpected (Table 3.1). The K409A mutant
resulted in complete substrate turnover, converting both cysteine residues to thiazolines,
while the K409E mutant slowed processing, catalysing only one cyclodehydration under
standard conditions (Table 3.1). These data imply that both the K409A and K409E
mutants do bind ATP, but only very weakly, below the detection limits of ITC, and
that our standard reaction conditions contain su cient ATP (5 mM) to facilitate
catalysis. Consequently the ability of the K409A mutant to process substrate PatE0 was
investigated again, using a lower ATP concentration (500 µM), and the heterocyclisation
reaction was monitored over time using MALDI-TOF-MS. By plotting the amount of
product formed over time, as identified by MALDI-TOF-MS under these new reaction
conditions, it becomes obvious that the K409A mutation impairs processing, forming
both heterocycles more slowly compared with wild-type enzyme (Fig. 3.6).
The R636E and R636A mutations inhibit binding of both ATP and AMP to LynD (Fig.
3.5). Unfortunately the ITC experiment between LynDR636A and ATP reproducibly
resulted in the complex ITC curve as shown (Fig. 3.5), and could not be easily
interpreted, and at present we are unable to explain this result. Both mutants
significantly a↵ect substrate processing, resulting in a mixture of products containing
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Figure 3.6: LynDK409E heterocyclisation rate Relative rates of the
heterocyclisation reaction between PatE0 and LynD + 5 mM ATP (blue), PatE0 and
LynD + 500 µM ATP (red) and PatE0 and LynDK409E + 500 µM (green) analysed by
MALDI-TOF-MS. The top graph shows the time taken to form the 1st heterocycle and
the bottom graphs shows the time taken to form the 2nd heterocycle. Each experiment
was set up in triplicate and each measurement was repeated three times; thus each
time-point is an average of nine measurements. Errors are plotted as +/- 1 s.d..
0, 1 and 2 heterocycles. These data support the idea that R636 coordinates the ↵-
phosphate, as observed in the crystal structure.
The E423R and the R427E mutations also impair substrate processing, forming 0
heterocycles, and a mixture of 1 and 2 heterocycles respectively, under standard reaction
conditions. Interestingly, while both mutations completely abolish ATP binding, AMP
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still binds to each mutant (Fig. 3.5, Table 3.1). The E423R mutant binds AMP with
higher a nity, and the R427E mutant shows only slightly weaker a nity than the wild-
type enzyme (Table 3.1). The ability of the E423R and the R427E mutants to bind AMP,
but not ATP, confirm the involvement of these residues in the coordination of   and
 -phosphates as predicted by the crystal structure, indicating the observed orientation
of the nucleotide in the active site is correct, and not an artefact of crystallisation.
Consequently these data, strongly suggest heterocyclisation does not proceed via the
previously proposed adenylation mechanism [51].
3.3.4 Nucleotide Utilisation
Simply ruling out an adenylation mechanism for heterocyclisation does not by extension
confirm the alternative hypothesis, that substrate is activated via a kinase mechanism,
as proposed for the LAP heterocyclase BalhD [49,50]. An adenylation mechanism was
not proposed solely because of structural homology between TruD and an adenylating
enzyme, but due to the direct observation (by 31P NMR) that AMP and pyrophosphate
(PPi) and phosphate (Pi) are produced during turnover [51]. While the presence of AMP
could be explained by the degradation of ADP following substrate phosphorylation by
ATP; a kinase mechanism is not su cient to explain the presence PPi [51]. Additionally,
in the TruD study, at no point was ADP detected [51]. It is unlikely the cyanobactin
and the LAP classes of heterocyclase operate via di↵erent mechanisms, so we decided
to look at the utilisation of ATP in the cyclodehydration reaction in more detail, in an
attempt to resolve these mechanistic ambiguities.
Using 31P NMR, LynD, was observed to produce AMP, PPi and Pi both in the absence
of substrate (similarly to the E. coli YcaO domain [101]) and in the presence of substrate
PatE0 (like TruD [51]). ADP was not detected (Fig. 3.7).
For TruD, the production of AMP, PPi and Pi was correlated to the appearance of
heterocycles, and not just background ATP hydrolysis [51]. It was assumed that the Pi
arose due to the degradation of PPi under experimental conditions and that AMP and
PPi were the mechanistically relevant biproducts of cyclodehydration [51].
To investigate this further, we sought to follow on from an experiment described in the
BalhD study, which utilised 18O at the carbonyl of the residues directly preceding the
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Figure 3.7: 31P NMR spectra of LynD reactions 31P NMR spectra of LynD +
ATP + PatE0 reaction (green), LynD + ATP background reaction (orange), Pi (pink),
PPi (blue), AMP (teal), ADP (red) and ATP (purple). Comparison between LynD
reactions and standards show LynD hydrolises ATP to AMP, PPi and Pi. No ADP is
detected.
cyclisable cysteines, and determined the role of ATP in substrate activation due to the
incorporation of the 18O in Pi, as identified by an isotope shift of the Pi peak in a 31P
NMR spectrum [50]. To generate such a selectively 18O-PatE0 variant, PatE0 was first
heterocyclised as described, purified and lyophilised. The dried sample was re-solubilised
in H218O supplemented with 0.1 % formic acid, and incubated at 20 °C to hydrolise the
heterocycles and accomplish selective 18O labelling. The ring opening was followed by
MALDI-TOF-MS, a mass increase of 40 Da (relative to the heterocyclised material)
indicated successful incorporation of 18O into both carbonyl positions (Fig. 3.8). Once
ring opening was complete, the sample was extensively dialysed into gel filtration bu↵er
to remove all traces of acid and H218O. Unexpectedly the sample formed a gel during
dialysis. Full solubilisation of the material required the addition of 8 M urea, which was
subsequently removed via passage over a gel filtration column, yielding pure 18O-PatE0.
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Figure 3.8: Acidic ring opening of heterocyclised PatE0 (a) Mechanism of acidic
ring opening of thiazoline heterocycles. (b) MALDI-TOF-MS of heterocyclised PatE0
(6953 Da). (c) MALDI-TOF-MS after ring opening by acidic H218O (6993 Da).
The 31P NMR experiment was repeated using the selectively labelled18O-PatE0 sub-
strate. The result reflected that seen by Dunbar et al. in the BalhD study, whereby the
heavy oxygen from the substrate carbonyl is incorporated into phosphate, as identified
by an isotope shift of the Pi peak in roughly 60:40 16O : 18O [50] ratio. Once again
AMP and PPi were also detected in the 31P NMR spectrum (Fig. 3.9). The same
16O/18O isotope shift was not observed for AMP, providing further evidence against an
adenylation mechanism (Fig. 3.9), while the PPi peak appears to have broadened (Fig.
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3.9). Addition of pyrophosphotase to the NMR tube increased the total amount of Pi
2.7-fold (eliminating PPi). Although the close proximity of the 16O/18O peaks results in
some overlap, making it di cult to accurately integrate each peak, the ratio of 16O/18O
Pi did not appear appreciably altered (Fig. 3.9). If PPi production only arose due to
background hydrolysis of ATP by LynD, then the PPi would only contain 16O. In this
instance, addition of pyrophosphatase would only increase the 16O Pi peak, but not the
18O. The contrary increase of both the 16O and 18O-Pi peaks equally, is consistent with
the presence of 18O in PPi.
Figure 3.9: 31P NMR spectrum of 18O-PatE0 31P NMR spectrum of LynD +
ATP + 16O-PatE0 (blue) overlaid with 31P NMR spectrum of LynD + ATP + 18O-
PatE0 (red). (a) Close up of the AMP peak. (b) Close up of the Pi peak; the peak is
split in two because of the small but detectable chemical shift di↵erence between 16O-Pi
and18O-Pi.(c) Close up of the PPi peak; the PPi peak appears broader in the presence
of 18O-PatE0. (d) 31P NMR spectrum of LynD + ATP + 18O-PatE0 before (red) and
after (green) the addition of pyrophosphatase. After the addition of pyrophosphatase
the PPi peak disappears and the Pi peak grows in intensity. (e) Close up of the Pi
peak before (red) and after (green) the addition of pyrophosphotase. (f) Integration of
16O-Pi and18O-Pi peaks, showing the proportion of each species is approximately the
same following incubation with pyrophosphatase.
To provide further insight, we purified PPi from the 18O-PatE0 heterocyclisation reaction
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mixture using anion exchange chromatography and analysed the purified sample using
LC-ESI-MS (Fig. 3.10). These data revealed 16O and 18O-PPi in approximately equal
amounts ( m/z = 176.942 and 178.9466 respectively; Fig. 3.10). The lower than expected
18O : 16O ratio could be explained by H216O exchange with PPi under the LC-ESI-MS
conditions, which has previously been seen for Pi [102].
Figure 3.10: MS of PPi purified from heterocyclisation reaction with 18O-
PatE0 (a) 16O and 18O-PPi (m/z = 176.9421 and 178.9466 respectively) are observed
in roughly equal amounts. The peak at m/z = 177.0387 is a contaminant (formula
C6H10O4P (the 12C/13C isotope pattern is seen)) and is not related to PPi and
is observed in the 16O-PPi control. (b) MSMS fragmentation of PPi showing the
typical fragmentation pattern: loss of water (m/z = 158.9258) and fragmentation
into PO3- (m/z = 78.9591). (c) MSMS fragmentation of PPi purified from the 18O-
PatE0 heterocyclisation reaction. Loss of H2O and H218O (m/z = 160.9299 and
158.9259 respectively) and fragmentation into PO218O- (m/z = 80.9633) indicates 18O
is incorporated in PPi during heterocyclisation
.
However the identification of 18O-PPi by LC-ESI-MS, confirmed by MSMS (Fig. 3.10)
complements our 31P NMR data implying 18O from the carbonyl of the peptide
substrate is transferred onto PPi during turnover. A feasible explanation of these
data is a pyrophosphorylation mechanism, where the hemiorthoamide attacks the  -
phosphate, breaking the ↵- -phosphate bond to give AMP and 18O pyrophosphorylated
hemiorthoamide, which subsequently eliminates 18O-PPi (Fig. 3.11). The 18O-PPi then
breaks down spontaneously under the reaction conditions to give 18O-Pi and 16O-Pi.
Although less common than a kinase mechanism, precedent for such a mechanism in
nature exists, with the best-known example of an enzyme of this class being ribose-
phosphate-diphosphokinase, which catalyses the pyrophosphorylation of the 10OH of
ribose 5-phosphate [103]. Arguing against this hypothesis is the lack of structural
homology between LynD and ribose-phosphate diphosphokinase. Furthermore, in all
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Figure 3.11: Plausible pyrophosphorylation mechanism for heterocyclisa-
tion In a reversible step a hemiorthoamide intermediate is formed. The hemiorthoamide
intermediate subsequently attacks ATP at the  -phosphate, cleaving the ↵- -phosphate
bond and AMP is released. In an irreversible step the PPi is eliminated from the
activated hemiorthoamide intermediate, yielding the heterocyclised product and PPi.
our LynD structures the nucleotide is oriented such that the  -phosphate is still more
accessible to the hemiorthoamide intermediate than the  -phosphate (Fig. 3.4).
To test the hypothesis of a pyrophosphorylation mechanism, the ability of LynD to
facilitate heterocyclisation in the presence of non-hydrolisable methylene bridged ATP
analogues was investigated. Incubation of LynD with  , -methylene-ATP (AMPPCP)
completely abolishes turnover, while ↵, -methylene-ATP (AMPCPP) supports the first
heterocyclisation event with a rate comparable to that of ATP, but is significantly slower
than ATP for the second heterocyclisation event (Fig. 3.12). These data disprove the
pyrophosphorylation mechanism as proposed (Fig. 3.11). The activity of the ↵, -
methylene bridged analogue implies that scission of the ↵, -phosphate bond is not
a requirement for turnover, while the inactivity of the  ,  analogue confirms that
heterocyclisation must proceed via attack of hemiorthoamide at the   position of ATP.
A kinase mechanism is consistent with the observed activity of these ATP analogues,
but does not account for the incorporation of 18O in PPi.
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Figure 3.12: The e↵ect of ATP analogues on substrate processing (a) LC-ESI-
MS of PatE0 (m/z = 6990) + LynD + ATP analogues. Complete substrate processing
is evident by a loss of 2 water molecules ( - 36 Da, m/z = 6954). (b) Relative rates
of heterocyclisation reaction between PatE0 and LynD + 5 mM ATP (blue) and PatE0
and LynD + 5 mM AMPCPP (red) analysed by MALDI-TOF-MS. The top graph
shows the time taken to form the 1st heterocycle, and the bottom graph shows the
time taken to form the 2nd heterocycle. Each experiment was set up in triplicate and
each measurement was repeated three times; thus each time-point is an average of nine
measurements. Errors are plotted as +/- 1 s.d..
Rationalising all the data leads us to propose what we believe to be a novel mechanism
of substrate activation: we suggest that the reacting intermediate is first activated
via phosphorylation, and the resulting O-phosphorylated hemiorthoamide subsequently
attacks ADP, which is activated for cleavage by the Mg2+ ions coordinated at the active
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site, to yield AMP and O-PPi (Fig. 3.13). This second step, is not an occasional side
reaction since ADP is not detected and 18O is transferred into PPi e ciently. An
immediate shortfall of this proposal is the heterocyclisation activity in the presence of
AMPCPP, which should preclude the second phosphorylation. However this second
phosphorylation event could be achieved by release of the AMPCPP hydrolysis product
AMPCP (ADP analogue), followed by binding a new molecule of AMPCPP to supply
a second  -phosphate. Release and rebinding of the cofactor in this way could explain
the slower rate of heterocyclisation observed for AMPCPP compared with ATP (Fig.
3.12). Unfortunately, a non-negligible rate of background hydrolysis of the nucleotide
has thus far precluded our attempts to accurately perform the stoichiometry experiments
necessary to confirm this hypothesis. Further work towards testing this mechanism, and
attempts to unify all the observed data are ongoing.
Figure 3.13: Proposed heterocyclisation mechanism The hemiorthoamide
attacks the  -phosphate of ATP, cleaving the  , -phosphate bond giving ADP.
The ADP is not released from the enzyme, and is attacked by the phosphorylated
hemiorthoamide intermediate at the  -phosphate to give AMP. In an irreversible step
the PPi is eliminated from the activated hemiorthoamide intermediate, yielding the
heterocyclised product and PPi.
3.3.5 Leader Peptide Recognition
In all three LynD complex structures, only residues Q21-G35 of the leader peptide of
PatE0 are ordered, and are located at the interface between domain 1 from one LynD
monomer and domain 3 from another (Fig. 3.14). This ordered region of the leader
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peptide in the structures corresponds with the residues thought to govern substrate
recognition, as identified by multiple biochemical studies, providing rational to the
‘minimal leader’ [41,51,52]. Residues Q21-S23 adopt a coil, S24-E28 a helical turn, S30-
A33 a  -strand, and L34-G35 a coil. The  -strand adds to the antiparallel  -sheet in
domain 1 (Fig. 3.14). This extended  -sheet interaction is similar to that observed in
the lantibiotic dehydratase substrate complex [104]. In addition to the  -sheet hydrogen
bonds, the chain of PatE0 E28 and E31 make hydrogen bonds and salt bridges with the
main chain of LynD Q37 and the side chains of Y39 and R74. Residues L26 and L29
of PatE0 are found in hydrophobic pockets of domain 1 making van der Waals contacts
with Y67 and Y70. The leader peptide makes contacts with domain 3 of LynD through
a salt bridge between PatE0 E32 and LynD R399 and hydrophobic interactions between
PatE0 L34 with V217 and L398 of LynD. The specific contacts made between the leader
peptide and domain 3 of LynD are responsible for the ordering of a region that was not
observed in the apo structure of TruD [51].
Figure 3.14: Leader peptide binding by LynD Ordered residues of PatE0 are
shown as a cyan cartoon and subunit A and subunit B of LynD are shown as purple and
pink cartoons respectively. Residues directly involved in binding are shown as sticks.
Numbering of PatE0 residues is shown in italics for clarity. Salt bridge interactions are
shown with dashed lines.
To validate the importance of the residues identified in the crystal structures in substrate
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binding, a series of mutants of LynD and PatE0 were made and their binding interactions
measured using ITC (Fig. 3.15). Furthermore the e↵ect of each mutant on substrate
processing was monitored using MALDI-TOF-MS. A summary of the binding and
activity data is shown in Table 3.2.
Figure 3.15: LynD substrate binding ITC data for PatE0 and PatE0 mutants
titrated into LynD and LynD mutant solutions. The top panel shows raw data
representing heat evolved in response to injections, the bottom panel shows the
integrated heats of injections (⇤) and the best fit (-) to the one-site model (Origin).
LynD binds PatE0 with a KD = 1.49 µM (Fig. 3.15). This is consistent with the low
µM binding observed between TruD and PatE2 [51]. The PatE0 L26R, L29R and E31R
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Table 3.2: LynD and PatE0 mutations and their e↵ects on binding and processing.
Enzyme Peptide KD (µM)
No. of
heterocycles
(PatE0)
LynD PatE0 1.49 2
LynD PatE0L26R No binding 2
LynD PatE0L29R No Binding 1 and 2
LynD PatE0E31R No Binding 1 and 2
LynD PatE0E32R 18.35 2
LynDY67D PatE0 12.92 2
LynDY67D PatE0L26R 15.22 2
LynDR74E PatE0 No binding 2
LynDR74E PatE0E31R No binding 1 and 2
LynDR399E PatE0 10.74 2
LynDR399E PatE0E32R 8.55 2
mutations reduce binding to wild-type LynD below the detection limits of ITC, with the
later two mutations a↵ecting processing by LynD under our standard reaction conditions,
forming a mixture of 1 and 2 heterocycles (Fig. 3.15, Table 3.2). PatE0E32R shows weaker
binding to LynD, with a KD = 18.35 µM, but is completely processed by LynD under
our standard conditions (Fig. 3.15, Table 3.2). The LynD Y67D, R74E and R399E
mutations all reduce binding a nity to PatE0, but retain catalytic activity (Fig. 3.15,
Table 3.2). In pairing the LynD mutants with their corresponding PatE0 mutants, such
that the interacting enzyme and substrate residues again have opposite charge (or charge
introduced in the case of LynDY67D and PatE0L26R) we sought to investigate whether
binding could be restored. However these coupled mutations had little or no e↵ect on
the binding a nity between enzyme and substrate, compared with the single mutation
experiments. Interestingly LynDR74E struggled more to accept PatE0E31R as a substrate
than wild-type PatE0, producing a mixture of 1 and 2 heterocycles within the time-frame
of our assay (Fig. 3.15, Table 3.2). These data confirm the importance of the residues
identified in the crystal structures in substrate recognition.
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3.3.6 Activation of LynD by the Leader Peptide
The cyanobactin heterocyclases TruD and PatD have been shown to process leaderless
peptide substrates in vitro, but ine ciently; they cannot process all of the potentially
heterocyclisable residues within the peptide [41,51]. Thus the leader peptide was
deemed important for full activity of the heterocyclase, and not a prerequisite
for heterocyclisation. Using a short, leaderless peptide substrate ITACITFCAYDG
(mimicking the core peptide and C-terminal macrocyclisation element of PatE0),
LynD catalysed a single cyclodehydraton reaction after overnight incubation, which
is consistent with previous reports [51] (Fig. 3.16). An elegant study by Y. Goto et
al. had shown that full processing of all heterocyclisable residues in a short peptide
substrate by PatD can be recovered through addition of exogenous leader peptide [41].
Here, we show that addition of full-length PatE04 leader (up to but not including the
core peptide) and minimal leader (LAELSEEAL) peptides both restore processing by
LynD, converting both cysteine residues in ITACITFCAYDG to thiazolines, but at a
slower rate compared to LynD and full-length PatE0 (Fig. 3.16). The increase in activity
is more pronounced for the full-length leader peptide than for the minimal leader peptide
(Fig. 3.16).
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Figure 3.16: The roles of substrate leader in promoting catalysis (a) LC-
ESI-MS analysis of ITACITFCAYDG (m/z = 1277.6) incubated with TruD, LynD +/-
full-length leader peptide overnight. When the substrate peptide is incubated with just
TruD or LynD only 1 heterocycle is formed (m/z = 1259.4). Addition of exogenous
full-length leader peptide restores processing by LynD, such that 2 heterocylces are
formed following an overnight incubation. (b) Relative rates of various leader peptide-
activated heterocyclisation reactions analysed by MALDI-TOF-MS: LynD + PatE0
(blue), LynD + minimal leader + ITACITFCAYDG (purple), LynD + full-length leader
+ ITACITFCAYDG (red) + LynD + ITACITFCAYDG (orange). The top graph shows
the time taken to form the 1st heterocycle, and the bottom graph shows the time
taken to form the 2nd heterocycle. Each experiment was set up in triplicate and each
measurement was repeated three times; thus each time-point is an average of nine
measurements. Errors are plotted as +/- 1 s.d..
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Guided by structural analysis, residues Q21 to A37 of the leader peptide were fused to
the N-terminus of LynD to construct a self-activating enzyme (AcLynD). A six-pair ‘GA’
linker was introduced between the last residue of the leader peptide and the first residue
of LynD to promote correct folding of the leader peptide into the enzyme binding site.
This engineered enzyme expressed at a higher yield than native enzyme, and processed
both cysteine residues in ITACITFCAYDG substrate at a similar rate to wild-type LynD
with full-length PatE0 (Fig. 3.17).
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Figure 3.17: Activity of AcLynD on ITACITFCAYDG (a) MALDI-TOF-MS
analysis of ITACITFCAYDG (m/z = 1277.6) incubated with AcLynD overnight. The
substrate is fully processed by AcLynD to give a product containing 2 heterocycles. (b)
Relative rate of AcLynD + ITACITFCAYDG (green) compared with LynD + PatE0
(blue) and LynD + ITACITFCAYDG (orange) analysed by MALDI-TOF-MS. The top
graph shows the time taken to form the 1st heterocycle, and the bottom graph shows
the time taken to form the 2nd heterocycle. Each experiment was set up in triplicate
and each measurement was repeated three times; thus each time-point is an average of
nine measurements. Errors are plotted as +/- 1 s.d..
To investigate whether the AcLynD exhibits a high substrate tolerance as seen for the
wild-type enzyme, a variety of short test peptide substrates were generated in house,
by mutating the core peptide of PatE0 and removing the leader peptide with trypsin
prior to the heterocyclisation reaction. In this way three test peptides were produced,
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which contain a core peptide sequence, the macrocyclisation signature (AYDG) and a C-
terminal extension (ELEHHHHHH (ELE-H6)) derived from the original PatE0 sequence:
a peptide with a seven residue core peptide (IACIMACAYDGELE-H6), a peptide with
a nine residue core peptide (IITACIMACAYDGELE-H6) and a peptide with three
cysteine residues within the core peptide (ICACITFCAYDGELE-H6). The three test
peptides were incubated with AcLynD and native LynD under standard conditions. Both
IACIMACAYDGELE-H6 and IITACIMACAYDGELE-H6 were completely processed
by AcLynD, while ICACITFCAYDGELE-H6 gave a mixture of 3 and 2 heterocycles
(Fig. 3.18). AcLynD showed a significant increase in activity compared with native
LynD, which only generated 1 heterocycle in all three substrates (Fig. 3.18). Although
ICACITFCAYDGELE-H6 was not processed to completion under standard conditions,
indicating the need for optimisation, these data emphasise the advantageous ability of
AcLynD to process short leaderless substrates with a much greater e ciency than the
native enzyme.
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Figure 3.18: Activity of AcLynD with various short leaderless substrate
peptides MALDI-TOF-MS analysis of AcLynD + (a) IACIMACAYDGELE-H6 (b)
IITACIMACAYDGELE-H6 and (c) ICACITFCAYDGELE-H6. The top panel shows
the substrate peptide on its own, the middle panel shows the substrate peptide processed
by LynD and the bottom panel shows the substrate peptide processed by AcLynD.
AcLynD can be thought of as an ‘activated’ enzyme, and its activity compared with
wild-type enzyme is summarised by the cartoon schematic seen in Fig. 3.19.
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Figure 3.19: Cartoon schematic of LynD and AcLynD The LynD dimer
undergoes a conformational rearrangement (purple and pink) following binding of
PatE0 (black) generating an ‘active’ enzyme. In the absence of a leader peptide the
conformational rearrangement is not possible and heterocyclisaton of the core peptide is
ine cient. Covalent attachment of the leader peptide to the enzyme (cyan) in AcLynD
mimics the ‘activated’ native LynD, allowing e cient wild-type-like processing of the
core peptide.
3.4 Conclusions
The cyanobactin heterocyclase enzymes (D enzymes) are responsible for the ATP-
dependent post-translational conversion of cysteine (and in some cases serine and
threonine) residues to thiazoline (and oxazoline) heterocycles within the cyanobactin
precursor peptide [40]. A key feature of these enzymes is their ability to separate substrate
recognition from catalysis, allowing them to process numerous precursor peptides
containing varied core peptide sequences, ultimately leading to diverse products, as long
as recognition elements within the leader peptide are conserved [51,52]. This low substrate
specificity makes the D enzymes attractive enzymes for biotechnological development.
The crystal structures of heterocyclase LynD, from the aestuaramide pathway (Lyngbya
sp.), in complex with various substrate peptides and nucleotides were solved, allowing
both the active site and the substrate recogniton site to be located.
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These complex structures revealed the ↵-phosphate of ATP, bound in domain 3 (the
conserved YcaO domain [49,101]) of LynD, is shielded from incoming substrate peptide,
and thus heterocyclisation cannot proceed via an adenylation mechanism. While
the exposed  -phosphate supports a kinase mechanism, a kinase mechanism cannot
explain the observation that LynD, as with TruD, hydrolyses ATP to AMP and PPi
during turnover [51]. In an extension of the selective 18O labelling studies of the
LAP heterocyclas BalhD, 18O from the carbonyl of the residue directly preceding the
cyclisable-cysteine was shown to be e ciently transferred into PPi, confirming PPi is
a mechanistically relevant bi-product of heterocyclisation, and does not solely arise
due to background hydrolysis of ATP. The non-hydrolysable ATP analogue AMPCPP
supported catalysis but at a slower rate than that seen for ATP, however the AMPPCP
analogue abolished catalysis, indicating heterocyclisation occurs through attack of the
substrate of the  -phosphate of ATP. A plausible mechanism, unifying all these data
was proposed, where the cysteine thiol cyclises onto the neighbouring carbonyl carbon,
creating a hemiorthoamide intermediate, which subsequently attacks the  -phosphate of
ATP at the active site. At this point the resulting ADP is not released from the enzyme
active site, but attacked at the  -phosphate (or a second equivalent of nucleotide in
the case of the AMPCPPP analogue) by the activated phosphorylated hemiorthoamide,
creating a pyrophosphorylated hemiorthoamide, which eliminates to give the thiazoline
product, and PPi.
The substrate binding site was located at the interface of domain 1 from one monomer
of LynD and domain 3 from the other, so the dimer is a functional requirement.
Binding of the substrate brings about a significant conformational rearrangement of
the enzyme and the holoenzyme dimer is packed together much more tightly compared
with the apo TruD structure. Furthermore the rearrangement upon binding results in
the ordering of a number of previously disordered residues within domain 3, including a
helix-strand-helix motif that forms part of the entrance to the nucleotide binding site.
As expected, substrate binding is dominated through interactions between LynD and
the leader peptide, with only residues Q21-G35 of the leader peptide ordered in all the
complex structures. The ordered region overlaps well with those residues thought to play
an important role in substrate recognition as identified through numerous biochemical
studies [41,51,52] and rationalises the previously described ‘minimal leader’ [51].
Similarly to TruD, LynD is capable of installing a single heterocycle, at the C-terminus
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of a core peptide of a leaderless substrate. Upon addition of exogenous ‘minimal’ leader
or full-length leader peptide, the processing ability of LynD is restored, cyclising both
cysteine residues in the leaderless substrate. The e ciency of this trans activation of
LynD towards leaderless substrates was significantly increased by fusing the important
leader peptide residues to the N-terminus of LynD, creating an ‘activated’ enzyme:
AcLynD. AcLynD has been shown to e ciently process multiple leaderless substrates,
and at a rate comparable to that of the native enzyme with the full-length PatE0
substrate. The ability to dispose of the leader peptide is highly advantageous from
a biotechnological perspective, as it allows for the synthesis of diverse cyanobactin
analogues in vitro, starting from shorter, thus more economic substrates. Furthermore,
shorter peptides are more amenable to chemical synthesis, allowing for the incorporation
of non-natural amino acids, o↵ering an explosion in diversity. Moreover AcLynD,
and homologues thereof are potentially capable of installing heterocycles in substrates,
unrelated to cyanobactins, vastly increasing their potential biotechnogical application.
3.5 Future Work
The heterocyclisation mechanism proposed in this chapter is the only feasible mechanism
we can see that consolidates all the data acquired to date. However this mechanistic
hypothesis remains to be tested. If the stoichiometry of both ATP and AMPCPP
required for the heterocyclisation reaction can be accurately determined, this will address
whether two phosphorylation events are necessary for heterocycle formation, and provide
evidence that the proposed mechanism is plausible.
Expansion of the AcLynD technology to homologues able to e ciently modify serine
and threonine residues has since been carried out, with AcMicD and AcPatD constructs
having been cloned by Ms Ying Ge. Work towards optimising the activity, and
investigation into the substrate tolerance of the AcD enzymes, and thus the potential
limitations of the technology are ongoing.
Chapter 4
Investigation into Cyanobactin
Epimerisation
4.1 Introduction
Biology is chiral. Amino acids (except glycine) and thus proteins are inherently chiral.
It follows therefore, that the chirality of a drug molecule is critically important to
its biological activity [105,106]. Despite the same chemical structure, stereoisomers of
chiral drugs can exhibit significant di↵erences in their pharmacological properties, as
well as di↵erences in the way they are metabolised [106]. Single enantiomer drugs can
display enhanced target selectively, thus reducing o↵-target toxicity, compared with
racemic mixtures. [105]. Most famously, the lack of enantiomeric purity of the sedative
Thalidomide led to the unexpected and tragic teratogenic side e↵ects, that has been
described as a medical disaster [107]. Consequently, in the preparation of pharmaceutical
compounds it is imperative that the stereochemistry of chiral centres of the final
compounds are characterised, and when possible produced as single enantiomers, either
during synthesis or as a result of purification [105,106].
Several cyanobactins have been confirmed to contain d-stereocentres, and although
not proven, they are likely widely distributed throughout the family [45,61–66]. The
conservation of these epimerised residues suggests they may be important for activity.
Epimerisation during cyanobactin biosynthesis has been proposed to be a spontaneous
process [45,67], although the involvement of enzymes in this process has not been formally
105
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excluded. Furthermore, it is not known at what point during cyanobactin biosynthesis
the epimerisation reaction occurs. If it is a spontaneous process, it would seem
likely to occur on the macrocycle as a means to relieve steric pressure and form a
thermodynamically stable conformation [67]. Addtionally d-stereocentres have not been
observed in the related linear azoline containing peptides (LAPs) [20]. Cyanobactin
products made in vitro give rise to CD-spectra that is identical to that of the natural
products, and on this basis it was concluded epimerisation had occurred spontaneously
under the reaction conditions used in the laboratory [47]. Nevertheless it is important
to characterise the epimerisation reaction, to definitively address the uncertainties
surrounding the reaction, and determine whether an epimerisation step needs to be
built into future developments of the in vitro synthesis. Once the epimerisation reaction
has been characterised, it may be possible to control the epimerisation of select residues,
increasing the diversity accessible through the in vitro synthesis.
Epimerisation reactions at a carbon centre require hydrogen exchange and so can usually
be studied using 1H NMR and related techniques. For epimerisation events where proton
abstraction and addition is mediated via water, dissolving the molecule in D2O will
result in a loss of proton peaks in the NMR spectrum as the labile hydrogen is replaced
with solvent deuterium (spin = 1). Such an experiment is straightforward for small
molecules, which do not contain many hydrogen atoms, and thus individual atoms
can be monitored. However epimerisation of cyanobactins could arise directly after
heterocyclisation of the 60 + residue precursor peptide. The derivatives of PatE used
in the in vitro synthesis (PatE0) contain >450 hydrogen atoms. Scanning a 1H NMR
spectrum for the loss of two, individual proton peaks resulting from an epimerisation
reaction would be at best challenging, as can be seen in the 1H NMR spectrum of PatE0
(Fig. 4.1). Regions of characteristic chemical shifts have been highlighted.
In theory structural information of larger peptides, such as PatE0, can be resolved
using 3D triple resonance (1H, 13C, and 15N) NMR experiments [108]. By compiling
this information, it should be possible to identify the ↵C protons as cross peaks in a 1H-
13C-HSQC spectrum, and subsequently observe whether they disappear due to exchange
with solvent deuterium. The unfolded nature of PatE results in a narrow dispersion of
cross peaks in 2D spectra, resulting in overlapping cross peaks [51], and so complicates
the detection of the two peaks of interest. The AcD enzymes (chapter 3) are capable of
processing short, leaderless substrates, which are easily accessible via chemical synthesis.
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Figure 4.1: PatE0 1H NMR spectrum PatE0 contains 478 hydrogens. The
resolution is not su cient to identify individual proton resonances.
Isotopically labelled amino acids can be incorporated into the peptide synthesis to
generate starting material where the epimerisable residues are selectively labelled. Using
13C-alanine (A*) the selectively-labelled starting peptide ITA*CITA*CAYDGE was
synthesised (BioSyn). This peptide will have only two peaks in a 1H-13C-HSQC spectrum
(↵CH and  CH3) and so analysis of the epimerisation reaction is greatly simplified. A
reaction scheme using the starting peptide ITA*CITA*CAYDGE can be seen in Fig.
4.2.
1H-13C-HSQC NMR of the substrate ITA*CITA*CAYDGE can be used to monitor
epimerisation on the linear peptide following heterocyclisation by the AcD enzymes,
and following macrocyclisation and oxidation, by PatGmac and ArtGox respectively, by
conducting the enzymatic transformations in D2O bu↵er. Loss of the ↵CH cross peak
in the 1H-13C-HSQC spectrum confirms H/D exchange has occurred, which is indicative
of epimerisation. The presence of the  CH3 provides an internal control.
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Figure 4.2: Reaction scheme using the starting peptide
ITA*CITA*CAYDGE ITA*CITA*CAYDGE is heterocyclised using AcMicD
macrocyclised by PatGmac and oxidised by ArtGox. Red asterisk indicate 13C.
Wavy bonds indicate that epimerisation can occur theoretically at any point following
heterocyclisation and so the precise stereochemistry is unknown.
4.2 Materials and Methods
4.2.1 Expression and Purification of Biosynthetic Enzymes
AcMicD was expressed from pJexpress 411 and purified as described (section 5.2.2).
PatGmac was expressed from pEHISTEV and purified as described (section 5.2.2).
ArtGox was expressed from pEHISSUMOTEV and purified as described (section 5.2.2).
PatG-DUFdi. was expressed from pEHISTEV and purified as described (section 2.2.1).
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4.2.2 Preparation of Deuterated Conditions for NMR Experiments
A 2.5 mM stock solution of synthetic ITA*CITA*CAYDGE (Biosyn) was prepared in
D2O. A stock of one-pot reaction bu↵er/D2O (Appendix A) was prepared by dissolving
all components in D2O. Stock solutions of 100 mM ATP and 1 M MgCl2 were prepared
in one-pot reaction bu↵er/D2O. Biosynthetic enzymes were exchanged into one-pot
reaction bu↵er/D2O prior to their addition to the reaction mixture.
4.2.3 Heterocyclisation of ITA*CITA*CAYDGE
Synthetic ITA*CITA*CAYDGE was incubated with AcMicD as described (section
5.2.4). Heterocyclised products were purified via size exclusion chromatography by
passage down a Highload 16/60 Superdex 30 gel filtration column (GE Healthcare).
4.2.4 Macrocyclisation of ITMeOxA*CThHITMeOxA*CThHAYDGE
Pure ITMeOxA*CThHITMeOxA*CThHAYDGE was incubated with PatGmac as described
(section 5.2.4).
4.2.5 Oxidation of cyclo[ITMeOxA*CThHITMeOxA*CThH]
To oxidise thiazolines to thiazoles, 10 µM ArtGox and 200 µM FMN were added to the
macrocyclisation reaction mixture, and incubated at 27 °C for 3 h.
4.2.6 Incubation of Macrocyclic Products
To investigate spontaneous epimerisation, macrocyclic products were extracted from the
one-pot reaction mixtures using an equal volume of d10-nBuOD, evaporated to dryness
using a Thermo Savent Speed Vac, resolubilised in D2O supplemented with 5 % d6-
DMSO incubated at 27 °C.
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4.2.7 1H-13C HSQC NMR measurements
For NMR experiments, 300 µL samples were transferred to a Shigemi NMR tube
(CortecNet) matched to the appropriate solvent (D2O or d6-DMSO). NMR experiments
were performed at 22 °C on a Bruker Ultrashield 700 sprectrometer. The instrument
was ran and the data analysed using TopSpin software (Bruker).
4.2.8 Measuring Macrocyclisation Rate by HPLC
Macrocyclisation rate experiment was performed as described (section 2.4.12).
4.3 Results and Discussion
4.3.1 Investigating Epimerisation on Linear Peptide
A sample of ITA*CITA*CAYDGE (100 µM) was prepared in one-pot reaction bu↵er/D2O
(Appendix A) and a 1H-13C HSQC NMR spectrum was recorded (Fig. 4.3).
Figure 4.3: ITA*CITA*CAYDGE 1H-13C HSQC NMR spectrum Spectrum
was recorded in one-pot reaction bu↵er/D2O. Integrals for the ↵CH and  CH3 peaks
are shown in brackets
Despite the peptide containing two labelled alanine residues, both the residues are in
highly similar chemical environments, such that the signals overlap, and the 1H-13C
HSQC NMR spectrum contains only two, easily identifiable cross-peaks: ↵CH at 4.08,
49.5 ppm and  CH3 at 1.11, 16.2 ppm.
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Two heterocyclisation reactions of ITA*CITA*CAYDGE were prepared using AcMicD in
one-pot reaction bu↵er, one made up in H2O and the other in D2O. The heterocyclised
products of each reaction were purified via size exclusion chromatography to remove
ATP, which is added in excess to the reaction and might complicate the 1H-13C
HSQC NMR spectrum. The pure products, ITMeOxA*CThHITMeOxA*CThHAYDGE
were concentrated to 500 µL, dried to a powder under vacuum and resolubilised to
100 µM in d6-DMSO for NMR analysis (Fig. 4.4).
Figure 4.4: ITMeOxA*CThHITMeOxA*CThHAYDGE 1H-13C HSQC NMR
spectra from samples prepared in (a) H2O and (b) D2O. Both spectra contain clear
↵CH and  CH3 cross-peaks. Integrals for the ↵CH and  CH3 peaks are shown in
brackets. Spectra were recorded in d6-DMSO
Following the heterocyclisation reaction, the ↵CH cross-peak shifted slightly upfield in
the hydrogen dimension to 4.7 ppm, which is consistant with heterocyclisation of the
neighbouring cysteine [51]. The retention of the ↵CH cross-peak in the D2O sample
indicates that epimerisation was not concurrent with the heterocyclisation reaction. A
second batch of pure ITMeOxA*CThHITMeOxA*CThHAYDGE, transformed by AcMicD
in one-pot bu↵er/D2O was prepared and divided into two samples. One sample was
incubated at 100 µM in one-pot bu↵er/D2O and the other in one-pot bu↵er/D2O with
the addition of 20 µM PatG-DUFdi., a possible epimerase candidate. The samples were
incubated at 27 °C for 48 h before recording 1H-13C HSQC NMR spectra (Fig. 4.5).
The 1H-13C HSQC NMR spectra of ITMeOxA*CThHITMeOxA*CThHAYDGE contain a
clear ↵CH cross peak following 48 h incubation in both the presence and the absence
of PatG-DUFdi.. Although the integral of the ↵CH peak relative to the  CH3 is lower
than before, the same ratio between the integrals is observed for a control reaction with
PatG-DUFdi. in H2O (Fig. 4.5), indicating that the loss of the ↵CH signal is not a result
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Figure 4.5: ITMeOxA*CThHITMeOxA*CThHAYDGE incubations 1H-13C
HSQC NMR spectra (a) one-pot bu↵er/D2O and (b) one-pot bu↵er/D2O + 20 µM
PatG-DUFdi.. (c) Control sample of PatG-DUFdi. incubation in one-pot bu↵er/H2O.
All three spectra contain clear ↵CH and  CH3 cross-peaks. Integrals for the ↵CH
and  CH3 peaks are shown in brackets. Spectra were recorded in one-pot reaction
bu↵er/D2O. The control sample was recorded in d6-DMSO.
of H/D exchange. The reason for the loss in signal is unknown. It is assumed the one-pot
bu↵er conditions (pH 9.0) are su ciently basic to abstract the labile alanine ↵CH after
incubation for two days if epimerisation is spontaneous. Therefore, these data indicate
that epimerisation is not spontaneous on the linear peptide following heterocyclisation,
and that PatG-DUFdi. does not function as an epimerase, at least under the conditions
tested.
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4.3.2 Epimerisation of the Macrocycle
Pure ITMeOxA*CThHITMeOxA*CThHAYDGE was incubated with PatGmac in one-pot
reaction bu↵er/D2O under standard conditions (section 5.2.4). After 1 week a 1H-13C
HSQC NMR spectrum was recorded (Fig. 4.6).
Figure 4.6: ITMeOxA*CThHITMeOxA*CThHAYDGE + PatGmac 1H-13C
HSQC NMR spectrum ↵CH is no longer visible. Spectrum was recorded in one-pot
reaction bu↵er/D2O.
The absence of the ↵CH cross-peak, while the  CH3 is still present shows that H/D
exchange has occurred at this position, and suggests the stereocentre has epimerised.
These data imply that either epimerisation takes place spontaneously once the macro-
cycle has formed, or that it is someway catalysed by PatGmac, either as a mechanistic
consequence of the macrocyclisation reaction, or as a separate reaction. To determine
which is correct, it is necessary to understand the relative rates of the macrocyclisation
and epimerisation reactions. The rate of macrocyclisation was investigated using HPLC
to follow consumption of the unlabelled substrate ITMeOxACThHITMeOxACThHAYDGE
as described (section 2.2.12). From this experiment it is clear that 90 % of the starting
material had been consumed after 24 h, and that the reaction was essentially complete
(<1 % starting material) by 48 h (Fig. 4.7). A new macrocyclisation reaction of the
labeled ITMeOxA*CThHITMeOxA*CThHAYDGE was prepared and monitored by 1H-13C
HSQC NMR at 0, 5, 24, 48, 72, 96, 120 and 144 h (Fig. 4.7). Overtime the intensity
of the ↵CH cross-peak is significantly reduced, while the intensity of the  CH3 remains
constant. While the macrocyclisation reaction can be considered 90 % complete by 24
h, the intensity of the ↵CH cross-peak does not decrease as rapidly, and continues to
decrease up to 144 h. This observed delay between macrocyclisation and epimerisation
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demonstrates that epimerisation is not a mechanistic consequence of macrocyclisation.
These data indicate that it either occurs spontaneously once the macrocycle has been
formed, or it is catalysed by PatGmac in a completely separate reaction.
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Figure 4.7: Rate of macrocyclisation vs epimerisation (a) Consumption of
ITMeOxACThHITMeOxACThHAYDGE substrate during the macrocyclisation reaction
over time. The reaction is essentially complete by 48 h. (b) 1H-13C HSQC NMR spectra
of ITMeOxA*CThHITMeOxA*CThHAYDGE + PatGmac at various time intervals. A
close of the  CH3 and ↵CH cross-peaks are shown for clarity (c) Full-size 1H-13C
HSQC NMR spectra of the first (0 h) and last (144 h) time point. (d) Table showing
integrals of ↵CH and  CH3 peaks at each time point.
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To investigate whether PatGmac is responsible for epimerisation, the experiment was
repeated, but this time the macrocycle was extracted from the reaction mixture using
d10-n-BuOD after 24 h (as described in section 5.3.3) and exchanged back into one-
pot reaction bu↵er in the absence of enzyme. A 1H-13C HSQC NMR spectrum was
recorded and signal for the ↵CH was still clearly visible (Fig. 4.8). The sample was
then incubated at 27 °C for a further 24 h and a second 1H-13C HSQC NMR spectrum
was recorded. Comparing the two spectra, it is clear that the ↵CH cross-peak is much
smaller following the 24 h incubation (figure 4.7), confirming that H/D exchange is not
catalysed by PatGmac, and so it is a spontaneous reaction.
Figure 4.8: Epimerisation of the macrocycle in the absence of PatGmac
(a) 1H-13C HSQC NMR spectra of the extracted cyclo[ITMeOxA*CThHITMeOxA*CThH]
(left) and cyclo[ITMeOxA*CThHITMeOxA*CThH] after 24 h incubation in one-pot
reaction bu↵er (right). Integrals for the ↵CH and  CH3 peaks are shown in brackets
(b) Close-ups of the  CH3 and ↵CH cross-peaks.
Exchange of the ↵CH signal observed in these experiments is not proof of epimeri-
sation. In nature it is expected that epimerisation of these labile stereocentres
results in a more thermodynamically stable conformation of the macrocycle, and
thus the epimerisation reaction is unidirectional [67]. Consequently if epimerisation of
cyclo[ITMeOxA*CThHITMeOxA*CThH] has occurred then the deuterium which has been
incorporated into the cyclic peptide would not be expected to exchange back. To
test this, a sample of extracted cyclo[ITMeOxA*CThHITMeOxA*CThH], which had been
incubated in one-pot bu↵er/D2O to allow for H/D exchange, was evaporated to dryness,
and resolubilised in one-pot bu↵er/H2O and incubated at 27 °C. After 1 week the sample
was dried and resolubilised in d6-DMSO and a 1H-13C HSQC NMR spectrum was
recorded (Fig. 4.9). Despite prolonged incubation in H2O no exchange of molecular
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deuterium with solvent hydrogen was observed, indicating that following the observed
H/D exchange, the macrocycle exists in a thermodynamically stable conformation, with
a high kinetic energy barrier preventing back exchange, suggesting epimerisation has
indeed occurred.
Figure 4.9: Irreversible H/D exchange 1H-13C HSQC NMR spectra of
the extracted cyclo[ITMeOxA*CThHITMeOxA*CThH] following incubation in one-pot
bu↵er/H2O for 1 week. The ↵CH cross-peak is not visible indicating H/D exchange
does not reoccur under these conditions. The spectrum was recorded in d6-DMSO
.
All the experiments were conducted at pH 9.0. To explore the e↵ect of pH on the
epimerisation reaction a sample of extracted macrocycle was resolubilised in one-pot
reaction bu↵er at pH 7.6 and a 1H-13C HSQC NMR spectrum was recorded (Fig. 4.10).
As before the ↵CH is clearly visible. The sample was incubated at 27 °C and further
1H-13C HSQC NMR spectra were recorded after 24 h and 6 d (Fig. 4.10). Although
little change was observed after 24 h, after 6 d the ↵CH signal had completely vanished,
suggesting epimerisation is slower at pH 7.6 but not precluded.
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Figure 4.10: Epimerisation at pH 7.6 1H-13C HSQC NMR spectra of the extracted
(a) cyclo[ITMeOxA*CThHITMeOxA*CThH], (b) cyclo[ITMeOxA*CThHITMeOxA*CThH]
after 24 h, and (c) 6 d incubation in one-pot reaction bu↵er/D2O pH 7.6. Integrals for
the ↵CH and  CH3 peaks are shown in brackets.
It has been proposed that, on the natural compounds, epimerisation occurs after
heterocyclisation, but prior to oxidation [45]. If true, then by oxidising the thiazoline hete-
rocycles quickly after macrocyclisation, it might be possible to trap the adjacent residues
in the l-conformation. To test this, pure ITMeOxA*CThHITMeOxA*CThHAYDGE was
incubated with PatGmac in one-pot reaction bu↵er/D2O under standard conditions.
After 24 h, 10 µMArtGox and 200 µM FMN were added, and the reaction was incubated
for 3 h. The oxidised macrocyclic product, cyclo[ITMeOxA*CThzITMeOxA*CThz] was
extracted using d10-n-BuOD and exchanged back into one-pot reaction bu↵er/D2O and
a 1H-13C HSQC NMR spectrum was recorded (Fig. 4.11). The sample was incubated
for a further 24 h and a second 1H-13C HSQC NMR spectrum was recorded (Fig.
4.11). Similarly to the reduced compound, the intensity of the ↵CH cross-peak of
cyclo[ITMeOxA*CThzITMeOxA*CThz] decreases after 24 h incubation, indicating H/D
exchange is still possible on the oxidised compound.
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Figure 4.11: Epimerisation of the oxidised macrocycle (a) 1H-13C
HSQC NMR spectra of the extracted cyclo[ITMeOxA*CThzITMeOxA*CThz] (left)
and cyclo[ITMeOxA*CThzITMeOxA*CThz] after 24 h incubation in one-pot reaction
bu↵er/D2O(right). Integrals for the ↵CH and  CH3 peaks are shown in brackets.
(b) Close-ups of the  CH3 and ↵CH cross-peaks.
Surprisingly the thermodynamic driving force of the favourable conformation that
results from the epimerisation reaction is su ciently strong, such that epimerisation
is spontaneous and inevitable.
4.4 Conclusions
The 1H-13C HSQC NMR experiments described in this chapter are the first attempt
to definitively address the uncertainties in cyanobactin epimerisation, including when
during cyanobactin synthesis epimerisation takes place, and whether it is a spontaneous
or enzymatic process. Understanding cyanobactin epimerisation is crucial when
attempting to characterise natural products, as well as analogues made in a laboratory.
Furthermore, it is important to know whether an epimerisation reaction needs to be
built into the one-pot in vitro synthesis method (chapter 5).
Although the 1H-13C HSQC NMR experiments technically monitor for exchange of labile
↵C hydrogen with solvent deuterium, it is assumed this correlates with epimerisation.
No H/D exchange, and thus we concluded no epimerisation, was observed on the
heterocyclised linear peptide. This fits with the ‘conformational stability’ hypothesis
(section 1.4.5) as it is di cult to expect one conformation (l or d) to be significantly
favoured over the other on a flexible linear peptide. PatG-DUFdi. was tested as possible
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epimerase candidate. Although PatG-DUFdi. had been shown previously not to interact
with full length PatE0 or a heterocyclised derivative, an interaction of PatG-DUFdi.
with a leaderless peptide substrate had not been ruled out (Chapter 2). Incubation
of ITMeOxA*CThHITMeOxA*CThHAYDGE yielded an identical result with and without
PatG-DUFdi, confirming PatG-DUFdi does not catalyse epimerisation on the linear
peptide.
Loss of the ↵CH cross-peak in 1H-13C HSQC NMR spectra following macrocycli-
sation indicated epimerisation was either spontaneous on the macrocycle or catal-
ysed by PatGmac; the latter was ruled out when H/D exchange was observed on
cyclo[ITMeOxA*CThHITMeOxA*CThH] in the absence of PatGmac at both pH 9.0 and
pH 7.6. Furthermore, this exchange was found to be irreversible following incubation
of the ↵C-D containing cyclo[ITMeOxA*CThHITMeOxA*CThH] in bu↵ered H2O. This
indicates that the initial H/D exchange did correlate with epimerisation, resulting
in an irreversible formation of a thermodynamically favourable conformation, which
is consistant with the pre-stated ‘conformational stability’ hypothesis (section 1.4.5).
Interestingly, exchange was still observed following oxidation of thiazoline to thiazole,
emphasising the strength of this thermodynamic driving force. These data indicate
that patellamide D produced via the one-pot in vitro synthesis method (chapter 5)
should be authentic, and that an epimerisation reaction should not need to be built
into the synthesis. Furthermore the persistence of the epimerisation reaction, for
stereocentres adjacent to thiazole moieties as well as thiazoline heterocycles mean that
the stereochemistry of the final compounds produced via the one-pot in vitro synthesis
method is controlled by the conformation of the final product.
4.5 Future Work
Under the current one-pot in vitro synthesis reaction conditions, it does not seem
possible to produce patellamide analogues where the d-amino acids are replaced with
l-amino acids. Given the conformational driving force of the reaction, it is possible
that factors altering conformation of the cyclic peptide, also a↵ect the propensity
for the cyclic peptide to undergo epimerisation. For example, what is the e↵ect of
di↵erent numbers, and combinations of heterocycles around the macrocycle? What is
the e↵ect of N -methylation? What is the e↵ect of the epimerisable side-chain? These
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experiments were conducted using alanine, the most innocuous chiral amino acid. It
seems likely that amino acids with bulkier side-chains would experience more steric
pressure, and accordingly a faster rate of epimerisation. What is the e↵ect of the
macrocycle ring size - does there become a point where the macrocycle is su ciently
large that residues adjacent to thiazoline/thiazole, depending on their side chain, do not
experience significant steric pressure, and so do not epimerise? A number of further
experiments are to be conducted in an attempt to answer these questions and ascertain
some rules governing the spontaneity of the epimerisation reaction. In addition it
should be possible to model these compounds in silico, which might provide supporting
data for the experiments performed in this chapter, and begin to address remaining
uncertainties.

Chapter 5
One-pot in vitro Synthesis of
Diverse Cyclic Peptides
5.1 Introduction
The cyanobactin superfamily of highly modified cyclic peptide natural products exhibits
a range of interesting bioactive molecules, which could potentially be exploited as
therapeutic agents [21]. However, since the first cyanobactins were isolated in the
early 1980s [109], their pharmaceutical development has been slow, owing to a low
availability of natural material, coupled with technically challenging and expensive
syntheses [17]. The enzymes responsible for cyanobactin biosynthesis display low
substrate specificity, and are highly tolerant towards substitutions within a precursor
peptide’s core peptide [27,40,42–44,47,51,59]. It is hypothesised that this promiscuity can
be exploited to design novel cyanobactin analogues, enabling the determination of
structure-activity relationships. Ultimately bespoke macrocycles, displaying enchanced
e cacy when compared to their natural counterparts, can be engineered. Cyanobactin
biosynthesis has been reconstituted in vitro, making use of various enzymes from di↵erent
cyanobactin pathways to produce natural and unnatural azol(in)e containing cyclic
peptides on a milligram scale [47]. Using the in vitro method, engineered PatE precursor
peptides, containing various core peptide sequences, can be combined with di↵erent
cyanobactin processing enzymes, generating multiple products from a single precursor
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peptide. To date, this method has been used to produce 17 macrocycles, containing 6-9
residues, representing 11 out of the 20 canonical amino acids [47].
A major drawback of the current in vitro synthesis is the use of trypsin. Although trypsin
o↵ers a rapid alternative to PatA, the non-specific nature of its proteolysis prevents the
use of positively charged amino acids in the core peptide sequence and its use demands
multiple purification steps, a↵ecting the yield and the e ciency of the whole process. The
ability of AcLynD to process short, leaderless substrates negates this problem. AcMicD
and AcPatD (homologues of AcLynD) were cloned (by Ms Ying Ge, PhD student),
capable of processing serine and threonine residues in addition to cysteine residues in
short leaderless substrates. Using the AcD enzymes an e cient one-pot synthesis method
was developed. The ease and e ciency of this method to produce the macrocycle
cyclo[ITMeOXACThzITMeOxACThz] (1) from a synthetic peptide with the sequence
ITACITACAYDGE is compared to the original in vitro synthesis using a PatE0 variant
with the same core peptide sequence (PatE0-ITACITAC). For characterisation of the in
vitro synthesis products, the previous purification procedures were optimised, including
the incorporation of a simple, preliminary two-phase extraction method to separate cyclic
peptide products from enzymes, cofactors and linear peptides. Additionally, a robust
method for quantitation of purified cyclic peptide products was developed. The one-
pot synthesis method is easily scalable and the ability to use short synthetic substrates
greatly increases the diversity available through an in vitro synthesis, while the use
of enzymes keeps the process green and cost-e↵ective. The one-pot in vitro synthesis
has been employed to generate a library of structurally-diverse compounds, suitable
for obtaining structure-activity relationships in collaboration with Dr Andrew Bent,
Scottish Enterprises and Ripptide-Pharma.
5.2 Materials and Methods
5.2.1 Expression and Purification of PatE0-ITACITAC
A variant of PatE0 with the core peptide sequence ITACITAC (PatE0-ITACITAC) was
cloned into PBMS23CHIS by Dr Andrew Bent. The full PatE0-ITACITAC amino
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acid sequence is as follows: MDKKNILPQQGQPVIRLTAGQLSSQLAELSEEALGDA-
GLEASKITACITACAYDGELEHHHHHH. PatE0-ITACITAC was expressed and puri-
fied as described (section 2.5).
5.2.2 Expression and Purification of Biosynthetic Enzymes: LynD,
MicD, PatGmac, ArtGox, AcLynD, AcMicD and AcPatD
LynD was expressed from the pJexpress 411 plasmid (DNA 2.0) as described (section
3.2.3). MicD was expressed from the pJexpress 411 plasmid (DNA 2.0) as for LynD.
PatGmac was cloned into the pEHISTEV vector (a kind gift from Dr Huanting Liu)
by Dr Jesko Koehnke and was expressed as described for LynD. ArtGox was cloned
into the pEHISSUMOTEV (a kind gift from Dr David Owen) by Dr Andrew Bent
and expressed with a SUMO tag as described for LynD, however the auto-induction
media was supplemented with 50 µM riboflavin. AcLynD was cloned and expressed as
described (section 3.2.3) AcMicD, AcPatD were cloned into pJexpress 411 (DNA 2.0) by
Ms Ying Ge and expressed as described for LynD. Vector maps for AcLynD, AcMicD,
AcPatD, PatGmac and ArtGox can be seen in Fig. 5.1.
All enzymes were purified as follows: cell pellets were resuspended in general lysis bu↵er
(Appendix A) supplemented with 0.4 mg DNAse (Sigma) per gram of wet cell pellets,
and cOmplete EDTA-free protease inhibitor tablets (Roche; 1 per 50 mL resuspension).
The cells were lysed via passage through a cell disruptor at 207 MPa (Constant Systems)
and clarified by centrifugation (40 000g, 4 °C, 20 min). Cleared lysate was passed through
a Ni-Sepharose 6 Fast Flow column (GE Healthcare) equilibrated in general lysis bu↵er.
The bound protein was washed with lysis bu↵er and eluted in general elution bu↵er
(Appendix A). The eluted protein was dialysed (3 x 300 mL, 4 °C) into one-pot storage
bu↵er (Appendix A), concentrated to 1 mM and stored as 1 mL alliquots. For ArtGox
general lysis and elution bu↵ers were supplemented with 50 µM FMN; the SUMO tag
was not removed during purification.
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Figure 5.1: Biosynthetic enzyme vectors (a) AcLynD, (b) AcMicD, (c) AcPatD,
(d) PatGmac, (e) ArtGox.
5.2.3 in vitro Synthesis of cyclo[ITMeOXACThzITMeOxACThz] (1) from
PatE0-ITACITAC
5.2.3.1 Heterocyclisation of PatE0-ITACITAC using MicD
Pure PatE0-ITACITAC was incubated in the presence of MicD (5 µM), ATP (5 mM) and
MgCl2 (5 mM) in gel filtration bu↵er at 37 °C overnight. The reaction was monitored by
MALDI-TOF-MS; a loss of 18 Da, corresponding to the loss of water, was observed for
each heterocycle formed. Once the reaction was confirmed to be complete, the product
PatE0-ITMeOXACThHITMeOxACThH (2) was isolated via size exclusion chromatography
by passage down a Highload 16/60 Superdex 75 gel filtration column (GE Healthcare)
equilibrated in gel filtration bu↵er. Pure 2 was concentrated to 10 mg mL-1.
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5.2.3.2 Removal of Leader Peptide using Trypsin
Pure 2 was incubated with 1:100 trypsin (Sigma-aldrich) at 37 °C, 300 rpm for 4 h.
Following incubation, cleaved peptide was isolated using a Ni-Sepharose 6 Fast Flow
column (GE Healthcare), and eluted using gel filtration bu↵er supplemented with 250
mM imidazole. The eluted fraction was passed down a Highload 16/60 Superdex 30 gel
filtration column (GE Healthcare), pre-equilibrated in peptide column bu↵er (Appendix
A) to separate cleaved ITMeOXACThHITMeOxACThHAYDGELEH6 (3) from non-cleaved
2 and to remove imidazole. Purified 3 was concentrated to 300 µM. Successful proteolysis
was confirmed using MALDI-TOF-MS.
5.2.3.3 Macrocyclisation with PatGmac
Pure 3 (100 µM) was incubated with PatGmac (20 µM) in peptide column bu↵er
supplemented with DMSO (5 %) and NaCl (350 mM), at 37 °C for 1 week. Reaction
progress was monitored using MALDI-TOF-MS.
5.2.3.4 Oxidation of cyclo[ITMeOXACThHITMeOxACThH] (4) with ArtGox
Once macrocyclisation was complete, ArtGox (20 µM) and FMN (200 µM) were added
to the reaction mixture and the reaction was incubated at 37 °C for 16 h to give 1.
5.2.4 One-pot Synthesis of 1 from Synthetic ITACITACAYDGE
(BioSyn)
Synthetic ITACITACAYDGE (110 µM) was heterocyclised by incubation with AcMicD
(30 µM), ATP (10 mM), MgCl2 (10 mM) and DTT (0.5 mM) at 27 °C for 16 h
in one-pot reaction bu↵er (Appendix A). Complete heterocyclisation was confirmed
by MALDI-TOF-MS. Once complete the modified peptide was diluted to a reacting
concentration of 90 µM as PatGmac (50 µM), DMSO (5 %) and NaCl (350 mM) were
added to the reaction mixture. The reaction mixture was incubated at 27 °C for 48 h,
and macrocyclisation was monitored using MALDI-TOF-MS. To oxidise thiazolines to
thiazoles, ArtGox (5 µM) and FMN (200 µM) was added and the reaction mixture was
incubated at 27 °C for a further 4 h to give 1. To oxidise both thiazolines and oxazolines
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to thiazoles and oxazoles, 40 µM ArtGox and 1 mM FMN were added to the reaction
mixture, and the reaction was incubated at 27 °C for 48 h to give 12. To produce only
thiazoline/thiazole heterocycles the substrate was incubated with AcLynD (5 µM), ATP
(5 mM), MgCl2 (5 mM) and DTT (0.5 mM) at 27 °C for 16 h in one-pot reaction bu↵er.
Macrocyclisation and oxidation reactions were performed as described. All peptides in
Table 4.2 were processed as described.
5.2.5 Extraction of Macrocycles using n-BuOH
Extraction of the macrocyclic product from the reaction mixture was achieved by adding
an equal volume of n-butanol (n-BuOH) to the reaction mixture. The two phases
were separated by centrifugation (4000g, 10 min). The organic phase was collected
and the aqueous phase was extracted a further two times with equal volumes of n-
BuOH. Using MALDI-TOF-MS, macrocycle was always identified the organic fraction
from the first extraction, and sometimes from the second and third extractions. After
three extractions, macrocyclic products were never identified in the aqueous phase. The
n-BuOH fractions that contained product were evaporated to dryness using a rotary
evaporator, and the crude compound was resolubilised in a 1:1 mixture of methanol and
water for HPLC analysis and purification.
5.2.6 HPLC Purification of Macrocycles
Analytical RP-HPLC was performed on an Agilent infinity 1260 series equipped with a
MWD detector and a single quadropole MS using a Nucleodur C18 (Macherey-Nagel)
column (10 µm x 4.6 x 250 mm). Semi-preparative RP-HPLC was performed on an
Agilent infinity 1260 series equipped with a MWD using a Nucleodur C18 (Macherey-
Nagel) column (10 µm x 16 x 250 mm). Samples were eluted from the column using an
aqueous 5 mM ammonium carbonate - MeCN gradient with a flow rate of 1 mL min-1.
For cyclic peptide products containing two heterocycles (thiazoline/thiazole/proline) or
less, the following gradient was used: 0 - 5 min 5 % MeCN, 5 - 40 min 5 - 95 % MeCN,
40 - 45 min 95 % MeCN, 45 - 48 min 95 - 5 % MeCN. For cyclic peptides containing
four or three heterocycles (thiazoline/thiazole/oxazoline/oxazole/proline), the following
gradient was used: 0 - 5 min 5% MeCN, 5 - 8 min 5 - 50 % MeCN, 8 - 55 min 50 - 95
% MeCN, 55 - 60 min 95 % MeCN, 60 - 62 min 95 - 90 % MeCN. The retention time
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of compounds were identified by MS and UV detection at 220 nm using the analytical
system. Fractions containing pure cyclic peptide were collected manually using UV
detection at 220 nm using the semi-preparative system.
5.2.7 NMR Quantitation
All qNMR experiments were performed at 25 °C on a Bruker AVANCE III 500 MHz
spectrometer equipped with a room temperature BBFO+ probe. Data acquisition was
done with 16 scans, 10.00 compensate 90 ° pulse and a 30 s delay. The instrument was
run and the data was analysed using TopSpin software (Bruker).
5.2.8 Pgp-GloTM Assay
The Pgp-GloTM assay detects the e↵ect of compounds on the ATPase activity of
recombinant human Pgp in a membrane fraction, by utilising the light-generating
ATP-dependant reaction of firefly luciferase (Fig. 5.2). ATP is incubated with Pgp;
after a defined time the reaction is stopped and luciferase and luciferin are added to
the reaction mixture. The luciferase consumes any remaining unmetabolised ATP to
produce oxyluciferin, resulting in a detectable luminescence signal. Compounds that
stimulate Pgp ATPase activity, i.e. substrates of Pgp transport, result in an increased
consumption of ATP by Pgp, and thus a reduction in oxyluciferin production and the
concomitant luminescence signal. Conversely, those compounds that inhibit ATPase
activity give rise to an increased luminescence signal.
The Pgp-GloTM assay supplies two control compounds: sodium orthovanadate (Na3VO4)
and verapamil. Na3VO4 is a selective inhibitor of Pgp, and completely abolishes ATP
activity [110]. Any ATPase activity in the presence of Na3VO4 is attributed to minor
non-Pgp contaminants in the membrane fraction. The di↵erence in luminescence signal
between the Na3VO4 treated and untreated Pgp determines the basal Pgp ATPase
activity. Comparison of the basal ATPase activity with the activity determined following
treatment of Pgp with a test compound, allows compounds to be identified as stimulatory
or inhibitory. Verapamil is supplied as a known substrate of, and thus a stimulator of
Pgp ATPase activity [111]. By treating Pgp with a test compound in conjunction with
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Figure 5.2: Pgp-GloTM assay The image was taken from the Pgp-GloTM Assay
technical bulletin.
verpamil, the ability of a test compound to inhibit verapamil stimulated Pgp ATPase
activity can be investigated.
Screening and dose-response curves were performed according to manufacturer’s instruc-
tions, however a longer ATP incubation time of 3 h was used.
5.3 Results and Discussion
5.3.1 in vitro Synthesis of cyclo[ITMeOXACThzITMeOxACThz] (1)
Full-length PatE0-ITACITAC was expressed and purified as described (section 2.5)
yielding 50 mg L-1 culture. Purity was assessed by SDS-PAGE and identity confirmed
by MALDI-TOF-MS (Fig. 5.3).
Pure PatE0-ITACITAC was heterocyclised with MicD as described (section 5.2.3). The
reaction was monitored by MALDI-TOF-MS and the product was purified by size-
exclusion chromatography. A mass decrease of 72 Da (m/z = 6842) relative to the
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Figure 5.3: PatE0-ITACITAC purification (a) SDS-PAGE analysis of purified
PatE0-ITACITAC (b) MALDI-TOF-MS of purified PatE0-ITACITAC (6913.4 Da).
starting material indicates both threonine and cysteine residues have been heterocyclised
giving PatE0-ITMeOXACThHITMeOxACThH (2) (Fig. 5.4).
Figure 5.4: PatE0-ITACITAC + MicD MALDI-TOF-MS of PatE0-ITACITAC +
MicD reaction mixture following 16 h incubation at 27 °C.
To remove the leader sequence, 2 was incubated with trypsin as described (section
5.2.4). After 4 h the proteolysis reaction was purified via size exclusion chromatography
to separate ITMeOXACThHITMeOxACThHAYDGELEH6 (3) from trypsin and full length
2. The presence of 3 was confirmed by MALDI-TOF-MS (Fig. 5.5). However MS
analysis of purified 3 (2322.0 Da) revealed a prominent contamination peak at m/z =
1362.8 (Fig. 5.5). Trypsin can cleave C-terminal to any lysine or arginine in a peptide
sequence, and so it was expected that the contamination at m/z = 1362.8 corresponds to
a fragment of the leader peptide NILPQQGQPVIR (1361.8 Da). Therefore a Ni a nity
chromatography step was incorporated into the purification procedure prior to size
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exclusion step and was found to su ciently purify 3 from the undesired NILPQQPVIR
peptide (Fig. 5.5).
Figure 5.5: 2 + trypsin (a) MALDI-TOF-MS of 3 (2322.0 Da) purified via size
exclusion chromatography. A significant contamination with m/z = 1362.8 corresponds
tocorrespond to leader peptide fragment NILPQQGPVIR (1361.8 Da). (b) MALDI-
TOF-MS of 3 purified by Ni a nity chromatography, showing the contaminating leader
peptide fragment has been removed. The dashed box shows an enhanced view of the
product peaks.
Pure 3 was incubated with PatGmac as described (section 5.2.5). The reaction was
analysed by MALDI-TOF-MS after three days. (Fig. 5.6).
The presence of cyclo[ITMeOXACThHITMeOxACThH] (4) (m/z 705.4) coupled with the
reduction in the intensity of the peak corresponding to 3 (m/z = 2323.0), confirmed the
macrocyclisation reaction had progressed. The large peak at m/z = 1618.7 corresponds
to the expected side product of the reaction: AYDGELEH6 (1617.7 Da). The adjacent
peak at m/z = 1547.6 corresponds to the loss of the N-terminal alanine residue from the
side product, but the reason for this is unknown. The reaction was incubated at 37 °C
until no starting material was observed by MALDI-TOF-MS (typically 1 week).
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Figure 5.6: 3 + PatGmac MALDI-TOF-MS of 3 + PatGmac. Starting material
(2322.0 Da) and 4 (704.4 Da) can be seen. The large peaks at m/z = 1618.7 and 1547.6
correspond to C-terminal fragments AYDGELEH6 and YDGELEH6 respectively.
To avoid a time consuming HPLC purification of the macrocycle, the oxidation reaction
was achieved by adding ArtGox and FMN directly to the macrocyclisation reaction
mixture. In nature the cyanobactin oxidase and macrocyclase domains are usually part
of the same protein and so it was expected each domain would tolerate the same reaction
conditions in vitro. The oxidation reaction was left overnight and analysed by MALDI-
TOF-MS. Oxidation of both thiazolines to thiazoles was identified via a loss of 4 Da
(Fig. 5.7).
Figure 5.7: Oxidation of 4MALDI-TOF-MS of (a) 4 and (b) 1 following incubation
of ArtGox.
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5.3.2 Development of a One-pot in vitro Synthesis of Cyanobactins
Synthetic ITACITACAYDGE (BioSyn) was initially incubated with AcLynD and
AcMicD in gel filtration bu↵er (Appendix A) as described for LynD (section 3.2.4)
to form ITACThHITACThHAYDGE (5) and ITMeOXACThHITMeOxACThHAYDGE (6)
respectively. Under these reaction conditions, AcLynD completed the cyclodehydration
of both cysteine residues to thiazolines as expected (Fig. 5.8). However the use of
AcMicD resulted in a mixture of products containing 4, 3, and 2 heterocycles overnight
(Fig. 5.8). Following iterative rounds of optimisation of the reaction conditions (data not
shown), the reaction bu↵er was changed from gel filtration bu↵er to one-pot reaction
bu↵er (Appendix A) and the reaction conditions altered to those described (section
5.2.4). These optimised conditions resulted in more e cient processing by AcMicD, such
that the major compound was 6 - a species containing 4 heterocyles following overnight
incubation (Fig. 5.8). However a large amount of AcMicD is needed to achieve the
transformation (30 µM), compared to AcLynD (5 µM). Work in the lab is ongoing to
further optimise the heterocyclisation reaction of leaderless peptide substrates, and is
not within the scope of this chapter.
Figure 5.8: ITACITACAYDGE + AcLynD/AcMicD MALDI-TOF-MS of (a)
ITACITACAYDGE + AcLynD under standard reaction conditions in gel filtration
bu↵er gives predominantly a product with 2 heterocycles (5) (b) ITACITACAYDGE
+ AcMicD under standard reaction conditions in gel filtration bu↵er gives a mixture of
compounds with 4, 3 and 2 heterocycles (c) ITACITACAYDGE + AcMicD under new
reaction conditions in one-pot reaction bu↵er gives predominantly the desired product
with 4 heterocycles (6).
Following the formation of 6, there is a choice as to which enzymatic reaction, either
macrocyclisation or oxidation, should be incorporated as the second step in a one-pot in
vitro synthesis of 1. Little is known about the relative order of the macrocyclisation and
oxidation reactions in nature, with both hypothetically possible after heterocyclisation
and neither necessarily, a prerequisite of the other [28]. However, the cyanobactin
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macrocyclisation reaction is very slow on thiazoline-containing peptides in vitro [43,55] and
it is conceivable that oxidation of thiazolines to thiazoles on the linear peptide, provides a
more optimal substrate for the macrocyclase, resulting in a favourable rate acceleration
of macrocyclisation. To test this hypothesis, three one-pot synthesis strategies were
devised: (1) sequential addition of AcD, oxidase and macrocyclase; (2) simultaneous
addition of AcD and oxidase, followed by addition of the macrocyclase; (3) sequential
addition of AcD, macrocyclase and oxidase (Fig. 5.9) Of these strategies, strategy (3)
follows the same enzymatic order of the previous in vitro synthesis, and so is expected
to work, thus acting as a control [47].
Figure 5.9: Three possible strategies for the one-pot synthesis (a) Strategy (1)
sequential addition of AcMicD, ArtGox and PatGmac. (b) Strategy (2) simultaneous
addition of AcMicD, ArtGox, followed by addition of PatGmac. (c) Strategy (3)
sequential addition of AcMicD, PatGmac and ArtGox.
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For strategies (1) and (2), ArtGox (20 µM) and FMN (200 µM) were added to
the reaction mixture (substrate peptide + AcMicD) and incubated at 27 °C for a
total reaction time of 32 h (16 h per transformation) in an attempt to generate
ITMeOXACThzITMeOxACThzAYDGE (7) from 6 . Reaction progress was monitored using
MALDI-TOF-MS (Fig. 5.10).
For strategy (1) a mass decrease of 2 Da per thiazole (m/z = 1254.5) relative to the
starting material indicated the oxidation reaction was complete (Fig. 5.10). For strategy
(2), the completely processed peptide 7 (m/z = 1254.5) was observed, but as a minor
product (Fig. 5.10). The major product was identified as a species containing only three
heterocycles, two of which were oxidised. i.e. both cysteines were processed completely,
while one threonine remains unprocessed. (m/z = 1272.5, Fig. 5.10). Prolonged
incubation of the reaction did not alter the ratio of the products (data not shown).
These data suggest that the rate of heterocyclisation is slow compared with the rate
of oxidation and that once a modified peptide has been oxidised it cannot be further
processed by the heterocyclase. Therefore, under current reaction conditions, to form
an exclusive product, the heterocyclisation reaction must be left to complete before
subsequent enzymes are added to the reaction. Therefore strategy (2) was dismissed as
a route to the one-pot in vitro synthesis of cyanobactins.
For strategies (1) and (3), the macrocyclase enzyme was added to the oxidised and
reduced substrates 7 and 6 respectively, as described (section 5.2.4). After 24 h the
reaction was monitored using MALDI-TOF-MS (Fig. 5.10). For strategy (3), the
reaction had progressed as expected, showing predominantly cyclic product 4 (m/z =
705.4) with some starting material 6 (m/z = 1258.5) present (Fig. 5.10). However
for strategy (1), no cyclic peptide product 1 (m/z = 701.3) was observed (Fig. 5.10).
After extended incubation (up to 1 week), 1 was observed, but the starting material
7 was still the major species (Fig. 5.10). This suggests that the thiazole containing
peptide is a poor substrate of the macrocyclase. Interestingly, when this experiment was
repeated using AcLynD in place of AcMicD to generate ITACThzITACThzAYDGE (8),
turnover by PatGmac was observed at a rate comparable to that of the two-thiazoline
containing peptides (Fig. 5.10). Therefore the ability of PatGmac to process 8, but
not 7, cannot simply be due to the chemical and electronic di↵erences introduced
by the aromatic thiazole, relative to the thiazoline, but due to significant changes
in the overall conformation upon thiazole formation, when two additional oxazoline
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rings are present. Further work towards confirming this hypothesis and understanding
cyanobactin oxidation are ongoing, but are not within the scope of this thesis. As
strategy (1) is only compatible with peptide substrates processed with AcLynD but not
AcMicD, and so is not universally applicable to all substrates, it was also dismissed, and
so strategy (3): macrocyclisation before oxidation was deemed to be the order of the
enzymatic transformations in a one-pot in vitro synthesis.
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Figure 5.10: Order of biotransformation reactions MALDI-TOF-MS of (a)
product(s) of heterocyclisation and oxidation reactions as per strategy (1), (b) products
of heterocyclisation and oxidation reactions as per strategy (2), (c) macrocyclisation
reaction of 6 as per strategy (3) after 24 h. A significant peak of product 4 is observed.
(d) macrocyclisation reaction of 7 as per strategy (1) after 24 h. No product 1 is
observed. (e) macrocyclisation reaction of 7 as per strategy (1) after 7 d. A hint of
product 1 is observed. (f) macrocyclisation of 8 as per strategy (2) after 5 d. Product
cyclo[ITACThzITACThz] (9) is observed; starting material 8 is not. (g) Oxidation of 4
to give 1 as per strategy (1).
As with the original in vitro synthesis, addition of ArtGox (20 µM) and FMN (200
µM) to the macrocycle was su cient to achieve complete oxidation of both thiazolines
to thiazoles, forming 1 from 4 following incubation at 27 °C for 16 h, as determined
by MALDI-TOF-MS (Fig. 5.10). Confirmation that the final product was the desired
1 was achieved with MSMS analysis (Fig. 5.11). This one-pot in vitro synthesis
(sequential addition) method was successfully employed without the addition of the
oxidase domain, and also using AcLynD, with and without the oxidase, to generate three
additional products: Cyclo[ITMeOXACThHITMeOxACThH] (4) cyclo[ITACThzITACThz]
(9) and cyclo[ITACThHITACThH] (10) (Fig. 5.11).
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Figure 5.11: One-pot in vitro synthesis products MSMS fragmentation of (a) 1
(b) 4 (c) 9 (d) 10.
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5.3.3 Purification of One-pot in vitro Synthesis Products
The one-pot in vitro synthesis products require purification from a complex mixture of
proteins, small molecules, salts and other peptides. The high concentration of multiple
enzymes in the reaction mixture, coupled with a low concentration of the product ( 90
µM) make direct HPLC purification of the reaction mixture impractical. Accordingly,
a rapid, robust and straightforward isolation of the cyclic peptide product(s) from the
enzyme mixture, and subsequent concentration of the product, is required before HPLC
purification. The chemical composition of cyanobactins make them characteristically
hydrophobic, and so we reasoned a simple two-phase extraction method might o↵er
such a solution, if an organic solvent, which when mixed with the reaction mixture
selectively extracts and retains the cyclic peptides from the aqueous reaction mixture,
can be found. In search of a suitable extraction solvent, a test reaction was set
up, which for simplicity concerned only the macrocyclisation reaction. The substrate
peptide VGAGIGFPAYDG (made in-house by Dr Brunello Nardone) was incubated
with PatGmac. The completed reaction was divided into five samples, and each sample
was extracted with a di↵erent solvent: ethyl acetate (EtOAc), diethyl ether (Et2O),
dichloromethane (DCM), chloroform (CHCl3) and n-butanol (n-BuOH). SDS-PAGE
analysis confirmed that all solvents successfully retained PatGmac in the aqueous phase
(Fig. 5.12). However only n-BuOH could extract all the cyclo[VGAGIGFP] (11) into
the organic phase, as determine by MALDI-TOF-MS (Fig. 5.12).
To examine the viability of n-BuOH as an extraction solvent for the initial isolation
of one-pot in vitro synthesis products from more complicated reaction mixtures, the
extraction experiment was repeated with product 1. The reaction mixture and n-BuOH
were mixed in a 1:1 ratio. Upon mixing a large emulsion formed at the interface between
the two phases. Centrifuging the sample at 4000g for 10 min reduced the emulsion and
separated the two phases. The two phases were pooled separately and the aqueous phase
was extracted a further two times with equal volumes of n-BuOH, the organic phase was
pooled and kept separately in each case. Analysis by MALDI-TOF-MS confirmed 1 to
be in the organic phase, and was completely absent from the aqueous phase (Fig. 5.13).
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Figure 5.12: Extraction of cyclic peptide products (a) SDS-PAGE of PatGmac
after extraction of 11 using various solvents - the aqueous (aq) and organic (org) phases
were analysed for each solvent. For DCM and CHCl3 samples of the emulsion at the
interface between the two phases (Int) were also analysed. (b) MALDI-TOF-MS of
organic (top) and aqueous (bottom) phases following extraction of 12 (mW = 698.4
Da) from the reaction mixture using n-BuOH.
Figure 5.13: Extraction of 1 MALDI-TOF-MS of organic (top) and aqueous
(bottom) phases following extraction of 1 (mW = 700.3 Da) from the reaction mixture
n-BuOH. The peak at m/z = 723.3 in the organic phase, and accordingly its absence
from the aqueous phase indicates 1 is successfully extracted from the reaction mixture
using n-BuOH. The peak at m/z = 741.3 in the n-BuOH fraction corresponds to a
species containing three heterocycles, likely arising due to acid catalysed heterocycle
ring opening under MALDI conditions.
For all products made to date in this lab, products were always found in the organic
phase from the first extraction, and sometimes in the organic phase from the second
third extractions. After three extractions, macrocyclic products were never identified in
the aqueous phase.
The organic phase containing 1 was dried by rotary evaporation and re-solubilised in
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an equal volume of methanol and water for HPLC purification as described (section
5.2.6). Compound 1 eluted from the RP-HPLC C18 column as a single peak at
retention time (TR) of 34.6 min, as identified by MS (Fig. 5.14). A second peak, at
TR = 37.4 min was observed, and corresponds to an unknown compound of m/z =
697.2. It was suspected this compound was cyclo[ITMeOXzACThzITMeOxzACThz] (12), a
quadruple oxidised product of the ArtGox reaction, where the oxazolines were oxidised
to oxazoles. Attempts to acquire MSMS data were intractable, so the identity of 12
was instead confirmed by NMR (Fig. 5.14). Due to a limited amount of material, a
13C NMR spectrum was not obtained and so the quaternary carbons have not been
assigned. Despite this we are confident the identity of 12 is correct. The presence of 12
was surprising for two reasons: firstly, no hint of 12 had previously been identified by
MALDI-TOF-MS (Fig. 5.10); secondly, while natural cyanobactins containing oxazoles
as well as thiazoles exist [64,65], no products of the arthrospiramide pathway (where from
ArtGox originates) contain oxazolines or oxazoles [112], and so ArtGox was not expected
to catalyse oxazoline oxidation. Instead, it was suspected the activity of the cyanobactin
oxidase enzymes reflected that observed for the heterocyclases, where di↵erent enzymes
are responsible for di↵erent chemistries, and so it was thought a di↵erent enzyme would
be needed to achieve this transformation (section 1.4.3). The ratio of the products 1
and 12 of approximately 70:30 (Fig. 5.14) indicate that oxazoline oxidation is not an
occasional side reaction, and that by adjusting the conditions of the oxidation reaction
it should be possible to drive the reaction towards oxazole formation, making 12 as an
exclusive product. Similarly, the reaction conditions must also be altered to favour only
thiazoline oxidation, in order to generate 1 as an exclusive product, thus maximising the
yield of the desired product in each case. Importantly, if this oxidation reaction can be
controlled to give macrocycles containing thiazoles, or thiazoles and oxazoles, it increases
the chemical diversity accessible through the one-pot in vitro synthesis, without the need
for additional enzymes.
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Figure 5.14: Characterisation of one-pot products RP-HPLC purification of 1
extracted from one-pot synthesis reaction. Product elutes at TR = 34.6 min as identified
by MS. A second one-pot synthesis (TR = 37.4 min; m/z = 697.2) thought to be an
alternative reaction product 12. Insert shows a zoom of the product region. (b) One-
pot reaction scheme showing possible products formed under these reaction conditions.
(c) 1H NMR spectrum of 12. Peak integrals are shown below the spectrum. (d) zoom
of 1H NMR spectrum of 12 showing assigned peaks. (e) COSY NMR spectrum of 12.
(f) 1H-13C HSQC spectrum of 12.
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Table 5.1: 1H NMR, COSY, 1H-13C HSQC analysis (500 MHz, MeOH) of
12.
Amino acid Atom 1H chemical shift 13C chemical shift
Ile NH 8.39, d, J = 8.7 -
↵CH 5.08, m 51.5
 CH 2.09, m 38.9
 CH2 1.46, m; 1.25 m 24.9
 CH3 0.86, d, J = 6.9 15.3
 CH3 0.89, t, J = 7.4 11.4
MeOxz  CH3 2.59, s 11.6
Ala NH 8.14, d, J = 8.3 -
↵CH 5.47, m 44.9
 CH3 1.76, d, J = 6.9 19.0
Thz CH 8.23, s 125.5
5.3.4 Controlling the Oxidation Reaction
To try to determine ArtGox reaction conditions that result in only thiazoline oxidation,
the rate of the oxidation reaction was examined in more detail. Macrocycle 4 was
incubated with 5, 10 or 20 µM ArtGox, and 200 µM FMN, and the reaction was
monitored every hour by MALDI-TOF-MS. Both thiazolines were completely oxidised
(-4 Da) after only 3 h with 10 and 20 µM ArtGox, and after 4 h with 5 µM ArtGox,
indicating the initial reaction conditions of 20 µM ArtGox for 16 h were excessive and
unnecessary (data not shown). Analysis of 4 incubated with 5 µM ArtGox and 200
µM FMN for 4 h via HPLC-MS revealed these reaction conditions resulted in only the
thiazole containing product 1, with a peak observed at TR = 34.6 min, and no hint of
the oxazole containing product detected (Fig. 5.15).
To encourage oxazole formation, 4 was incubated with 40 µM ArtGox and 1 mM FMN
for 48 h. This time, using HPLC-MS, the major product was identified as the oxazole-
containing macrocycle 12 (Fig. 5.15). To determine whether it was the extra enzyme,
the extra FMN, or the longer incubation time that was the key driving force for oxazole
formation, four new oxidation reactions of 4 were set up under the following conditions:
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(1) 20 µM ArtGox, 200 µM FMN; (2) 20 µM ArtGox, 1 mM FMN; (3) 40 µM ArtGox,
200 µM FMN; (4) 40 µM ArtGox, 1 mM FMN. The reactions were monitored by HPLC
after 24 and 48 h. After 24 h reaction (1) contained approximately a 70:30 mixture of
1 and 12, while the ratio observed for reactions (2), (3) and (4) were 65:35, 25:75 and
25:75 respectively (Fig. 5.15). After 48 h the ratio of products 1 to 12 in reactions (1-4)
were 60:40, 20:80, 5:95 and 5:95 respectively. These data show that simply extending
the incubation time (48 h vs 24 h) is not su cient to drive oxazoline oxidation under
standard conditions (20 µM ArtGox, 200 µM FMN). Extra FMN (1 mM vs 200 µM)
does contribute to oxazoline oxidaiton, but not as significantly as extra enzyme (40 µM
vs 20 µM). The requirement of extra enzyme to achieve complete oxazoline oxidation
would suggest that oxazoline is a poor substrate for the enzyme. In summary, it would be
prudent to adopt conditions of reaction (4) as the strategy to drive oxidation of oxazoline
to completion, and generate 12 as an exclusive product. In this way, by varying the
oxidation reaction conditions, in conjunction with the use of either AcMicD or AcLynD,
it is possible, using the one-pot in vitro synthesis method, to generate five di↵erent
products from a single starting peptide enabling easy, cost-e↵ective diversification.
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Figure 5.15: Controlling the oxidation reaction (a) RP-HPLC chromatograms
of 4 subjected to various oxidation reaction conditions to form either 1 or 12. (a) 5
µM ArtGox, 200 µM FMN, 4 h (blue); 40 µM ArtGox, 1 mM FMN, 48 h (red). (b)
reaction 1, 24 h (blue); reaction 2, 24 h (red); reaction 3, 24 h (green); reaction 4, 24h
(pink). (c) reaction 1, 48 h (blue); reaction 2, 48 h (red); reaction 3, 48 h (green);
reaction 4, 48 h (pink).
5.3.5 Quantitation of One-pot in vitro Synthesis Products
Quantitation of the cyclic peptide products of the one-pot in vitro synthesis is a non-
trivial task. The retention of water and bu↵er salts when peptides are vacuum or freeze-
dried to a powder mean that the quantity and yield of the pure product cannot simply
be determined using an accurate mass balance [113]. Furthermore natural cyanobactins,
and thus many of the desired analogues do not contain tryptophan residues, precluding
quantitation using the Beer-Lambert law at A280. An alternative method would be
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to quantify products by HPLC compared to standard curve, but this is unfeasible due
to the lack of authentic standard. One solution is to quantify the pure cyclic peptide
products by NMR. Quantitative NMR (qNMR) relies on the fact that the intensity of
a signal (a peak in an NMR spectrum) is directly proportional to the number of nuclei
evoking the signal, and thus the concentration of the sample [114]. The concentration
of the analyte in question can be determined through comparison with an internal
reference standard of known concentration [115]. Importantly the standard to be used
as the internal or external reference is not an authentic standard, which might be
expensive, of limited availability or does not exist; but small molecules readily available
in high purity, easily weighable, highly soluble in di↵erent NMR solvents, and provide
a unique, distinct set of signals [115]. Development of the ERETIC method (Electronic
REference To access In vivo Concentrations) provides a reference signal electronically,
and so the reference standard can be measured externally of the analyte sample,
allowing the sample to be recovered [116]. Thus qNMR provides a non-destructive, rapid
and universally applicable method of quantitation, which can form part of standard
structural characterisation protocols. qNMR is used routinely in the pharmaceutical
industry [114] and has previously been used to quantify cyanobactin production in vivo [57].
To validate the use of qNMR for the one-pot in vitro synthesis, cyclo[VGAGIGWP]
(13) was synthesised and purified and described, from the starting peptide VGAGIG-
WPAYDG (made in-house by Dr Brunello Nardone). The inclusion of a tryptophan
residue allows for comparison between the concentration of 13 as calculated by qNMR
and that determined by UV-absorbance at 280 nm.
HPLC-purified 13 (95 %) was freeze-dried to give 5.6 mg of white powder. The entire
sample was solubilised in 500 µL d6-DMSO. Using a theoretical extinction coe cient of
5 500 M-1 cm-1 (as calculated by ExPASy ProtParam part of the ExPASy server [117]) the
concentration of 13 was determined to be 13.74 mM, equating to 5.063 mg of compound.
The solution of 13 was then diluted to 600 µL with d6-DMSO for qNMR analysis. A
solution of 10 mM anthrinalic acid (14) was prepared as an external reference standard.
qNMR spectra were recorded for both 13 and 14. An ERETIC reference of 10 mM
was generated by integrating one of the well-defined and isolated benzyl-hydrogen peaks
(correlating to 1H) from the qNMR spectrum of 14 (Fig. 5.16). The concentration of
13 was then calculated by integrating the distinct peak of the indole nitrogen (1H) from
its qNMR spectrum and comparing the value with that of the ERETIC reference. This
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gave a concentration of 13 equal to 11.49 mM, (Fig. 5.16) which corresponds to 5.081
mg. The total amount of 13, as determined by UV-absorbance and qNMR are in good
agreement with each other, giving 5.063 and 5.081 mg respectively, suggesting qNMR
can be relied upon as a method to quantify cyclic peptides and cyanobactin analogues
made via one-pot in vitro synthesis.
Figure 5.16: Quantitation of 13 qNMR spectra of (a) 14 and (b) 13. The proton
used for quantitation is shown on the structure and in the qNMR spectra in green. N.B.
13 was found to exist as two conformers, giving rise to doubling of peaks. Due to this,
both indole peaks (as highlighted) were integrated together for accurate quantitation.
Chapter 5. One-pot in vitro Synthesis of Diverse Cyclic Peptides 155
5.3.6 One-pot in vitro Synthesis of Patellamide D Analogues to
Determine Structure-activity Relationships of Pgp Inhibition
In collaboration with Dr Andrew Bent, Scottish Enterprises and Ripptide-Pharma, a
series of patellamide D analogues were designed in an attempt to determine structure-
activity relationships (SAR) governing Pgp inhibition. A diversification strategy was
designed to investigate two key structural elements, which are conserved in natural
patellamdes, by varying (1) the number and type of heterocycles; and (2) the intervening
amino acids between the heterocycles at positions 1, 3, 5 and 7 (Fig. 5.17).
Figure 5.17: SAR diversification strategy By varying the number and type of
heterocycles, and the interveneing amino acids, the SAR for patellamide mediated Pgp
inhibition can be investigated.
Therefore positions 2 and 6 were fixed to be either serine/threonine or proline, while
positions 4 and 8 were fixed to be either a cysteine or a proline residue. Any one or two
of positions 1, 3, 5 and 7 were then varied. Using such a strategy, ten starting peptides
were designed and processed with di↵erent enzyme combinations to give twenty-one
discrete macrocyclic products, including patellamide D as a positive control and one
linear product to act as a negative control. All starting peptides were ordered from
BioSyn. The starting peptides, enzyme transformations and the resulting final products
can be seen in Table 4.2. Structures of all the compounds can be seen in Fig. 5.18. All
the compounds listed in Table 4.2 and Fig. 5.18 were solubilised in the minimum possible
volume of d6-DMSO, and identity was confirmed by MS and MSMS, purity assessed by
HPLC and quantities determined by qNMR. Data can be seen in Appendix B.
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N. B. Accurate quantitation by NMR requires the NMR spectra to be assigned, and thus
the NMRmust be clearly resolved and of good quality. The qNMR for the compounds, as
seen in Appendix B, are of variable quality and so the quantitation can only be considered
approximate. Although only approximate, this quantitation method is preferred to
quantitation based on the amount of dried solid, which contain varying amounts of
water, which in our experience in the lab range from 10 - 60 %. Peaks deemed suitable
for quantitation were identified tentatively based on the chemical shift, splitting pattern,
and integration of the 1H NMR spectra, and those used for each compound can be seen
in Appendix B.
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Table 5.2: Compounds for SAR
Starting
peptide
sequence
Biotransformation
enzymes Product
ITACITFCAYD AcLynD, PatGmac cyclo[ITACThHITFCThH] (15)
AcLynD, PatGmac, ArtGox cyclo[ITACThzITFCThz] (16)
AcPatD, PatGmac, cyclo[ITMeOxACThHITMeOxFCThH] (17)
AcPatD, PatGmac, ArtGox cyclo[ITMeOxACThzITMeOxFCThz] (patellamide D; 18)
ITACIPFCAYD AcLynD, PatGmac cyclo[ITACThHIPFCThH] (19)
AcLynD, PatGmac, ArtGox cyclo[ITACThzIPFCThz] (20)
ITNCITACAYD AcMicD, PatGmac cyclo[ITNCThHITMeOxACThH] (21)
AcMicD, PatGmac, ArtGox cyclo[ITNCThzITMeOxACThz] (22)
ITACITFPAYD AcLynD, PatGmac cyclo[ITACThHITFP] (23)
IPACIPFCAYD AcLynD, PatGmac cyclo[IPACThHIPFCThH] (24)
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AcLynD, PatGmac, ArtGox cyclo[IPACThzIPFCThz] (25)
ITACITACAYD AcLynD, PatGmac cyclo[ITACThHITACThH] (10)
AcLynD, PatGmac, ArtGox cyclo[ITACThzITACThz] (9)
AcMicD, PatGmac cyclo[ITMeOxACThHITMeOxACThH] (4)
AcMicD, PatGmac, ArtGox cyclo[ITMeOxACThzITMeOxACThz] (1)
ISACITACAYD AcLynD, PatGmac cyclo[ISACThHITACThH] (26)
AcLynD, PatGmac, ArtGox cyclo[ISACThzITACThz] (27)
IPACITFCAYD AcMicD, PatGmac cyclo[IPACThHITMeOxFCThH] (28)
AcMicD, PatGmac, ArtGox cyclo[IPACThzITMeOxFCThz] (29)
ITACHTFCAYD AcLynD, PatGmac cyclo[ITACThHHTFCThH] (30)
AcLynD, PatGmac, ArtGox cyclo[ITACThzHTFCThz] (31)
IPAPIPFPAYD PatGmac IPAPIPFP (32)
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Figure 5.18: SAR compound library Molecular structures of compounds 1, 4, 9,
10 and 15-32 made via one-pot in vitro synthesis to investigate SAR of Pgp inhibition.
The natural compound, patellamide D (18) is highlighted by a blue box.
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Once characterised, the twenty-two compounds listed in Fig. 5.18 and Table 4.2 were
subjected to the Pgp-GloTM assay (Promega). The assay was first validated using a
known Pgp inhibitor, cyclosporin A (CsA) as a positive control [31]. For this initial
experiment, five Pgp + ATP reactions were prepared: (1) Pgp only, (2) Pgp + 100
µM Na3VO4, (3) Pgp + 200 µM verapamil, (4) Pgp + 50 µM CsA and (5) Pgp + 200
µM verapamil + 50 µM CsA. Each reaction was set up in triplicate and an average
luminescence signal for each reaction was calculated. The relative ATPase activity was
determined by subtracting the average luminescence signal for each reaction from that
calculated for the Na3VO4 control sample; ergo the ATPase activity of the Na3VO4
reaction is 0 (Fig. 5.19). In this way a basal ATPase activity of the untreated Pgp
membrane fraction of 180 relative light units (RLU) was determined. Addition of 200
µM verapamil increased the Pgp ATPase activity approximately 4 fold. Addition of 50
µM CsA in isolation did not a↵ect the ATPase activity, however when both 50 µM CsA
and 200 µM verapamil were added to the Pgp reaction, the verapamil stimulated ATPase
activity was significantly reduced, returning to approximately basal level, confirming
CsA inhibits the transport of verapamil across the membrane by Pgp. By varying the
concentration of CsA in the Pgp + 200 µM verapamil reaction, a dose response curve
was generated and an IC50 = 4.09 +/- 1.25 µM was calculated (Fig. 5.19), which is
consistant with literature reported values [118–120].
To further validate the assay, the experiment was repeated using 18 (patellamide D) in
place of CsA (Fig. 5.19). As before the addition of 200 µM verapamil to Pgp resulted
in a 4 fold increase in ATPase activity compared with the untreated sample. This
time, the addition of 50 µM 18 in isolation was mildly stimulatory, and increased the
ATPase activity approximately 1.5 fold. However the ATPase activity in response to
18 was unchanged in the presence of verapamil, indicating 18 also significantly inhibits
verapamil-stimulated ATPase activity. The dose-dependant inhibition of Pgp by 18 was
measured, giving an IC50 = 8.53 +/- 1.22 µM (Fig. 5.19), which is in good agreement
with previous observations [24,25].
To ensure that the observed inhibition of Pgp by both CsA and patellamide D, two
structurally unrelated cyclic peptides was genuine, the Pgp-GloTM assay was repeated
using linear peptide IPAPIPFP (32). Peptide 32 can be thought of a functionless
cyanobactin analogue (free N and C-termini, absence of azol(in)e heterocycles, all l-
amino acids) and so should act as a negative control. The ATPase activity observed
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Figure 5.19: Pgp-GloTM Assay validation (a) The e↵ect of CsA on ATPase
activity of Pgp; basal activity (untreated Pgp) is shown in yellow; 200 µM verapamil
treated Pgp (ver) is shown in green; 50 µM CsA and both 50 µM CsA and 200 µM
verapamil treated Pgp are shown in red. (b) Dose response of the addition of CsA
on 200 µM verapamil stimulated ATPase activity of Pgp. (c) The e↵ect of 18 on
ATPase activity of Pgp; basal activity (untreated Pgp) is shown in yellow; 200 µM
verapamil treated Pgp (ver) is shown in green; 50 µM 18 and both 50 µM 18 and 200
µM verapamil treated Pgp are shown in blue. (d) Dose response of the addition of 18
on 200 µM verapamil stimulated ATPase activity of Pgp. Error bars represent +/- 1
standard error.
for the addition of 50 µM 32 is, within error, the same as the basal level (Fig. 5.20).
Similarly, upon addition of 50 µM 32 to a reaction containing 200 µM verpamil, the
observed activity was, within error, the same as that of verapamil alone (Fig. 5.20).
The drastically di↵erent response of 32 compared with 18 and CsA, is encouraging, and
suggests the assay will be suitable to identify a range of responses for structurally varied
compounds.
Compounds 1, 4, 9, 10, and 15-31 were screened for their ability to inhibit the ATPase
activity of Pgp stimulated by 200 µM verapamil at 50, 5 and 0.5 µM. Reactions were
set up in triplicate over three, ninety-six well plates. In addition, each ninety-six well
plate contained the following control reactions in triplicate (nine replicates in total): (1)
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Figure 5.20: Linear peptide 32 as a negative control The e↵ect of 32 on ATPase
activity of Pgp; basal activity (untreated Pgp) is shown in yellow; 200 µM verapamil
treated Pgp (ver) is shown in green; 50 µM CsA and 200 µM verapamil treated Pgp is
shown in red; and 50 µM 32 and both 50 µM CsA and 200 µM verapamil treated Pgp
are shown in purple. Error bars represent +/- 1 standard error.
Pgp only, (2) Pgp + 100 µM Na3VO4, (3) Pgp + 200 µM verapamil, (4) Pgp + 200 µM
verapamil + 50 µM CsA, (5) Pgp + 200 µM verapamil + 5 µM CsA, (6) Pgp + 200
µM verapamil + 0.5 µM CsA, (7) Pgp + 200 µM verapamil + 50 µM 32. The relative
ATPase activity of Pgp in the presence of 200 µM verapamil and 50, 5 and 0.5 µM of
each test compound and for the control reactions can be seen in Fig. 5.21. Note control
reaction (2) (Pgp + 100 µM Na3VO4) is not included, as the activity is always 0 RLU
by default.
These data revealed that the structurally varied compounds 1, 4, 9, 10, and 15-31
display a range of activities towards the ATPase activity of Pgp. The range in activity
is most noticeable when the compounds are screened at 50 µM, but it is still evident at
5 µM. Compounds 20, 24, 25, 28, and 29 were identified as hit compounds (Fig. 5.22).
Looking at the structures of these compounds, some similarities become immediately
obvious. All compounds contain at least three heterocycles (azol(in)e or proline) and
the intervening residues (positions 1, 3, 5 and 7) correspond to the native sequence of
patellamide D.
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Figure 5.21: SAR compound screen The e↵ect of compounds 1, 4, 9, 10, and
15-31, CsA and 32 on ATPase activity of Pgp stimulated with 200 µM verapamil at
(a) 50 µM, (b) 5 µM and (c) 0.5 µM. Basal activity (untreated Pgp) is shown in yellow;
200 µM verapamil-treated Pgp (ver) is shown in green; CsA and 200 µM verapamil-
treated Pgp is shown in red; 18 and 200 µM verapamil treated Pgp is shown in blue;
50 µM 32 treated and 200 µM verapamil treated Pgp is shown in purple (note 32 was
only screened at 50 µM); Pgp treated with 200 µM verapamil and test compounds 1,
4, 9, 10, and 15-31 (except 18) are shown in orange. The upper and lower dashed
lines highlight 200 µM verapamil stimulated ATPase activity and basal ATPase activity
respectively. Error bars represent +/- 1 standard error.
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By looking closely at the Pgp-GloTM assay data, and by making pairwise comparisons
(when available) it is possible to build up a set of structural-activity relationships that
explain these observations (Fig. 5.22). (1) The importance of Phe Vs Ala (Fig. 5.22):
The starting peptides ITACITFCAYD and ITACITACAYD give rise to a family of
compounds 15, 16, 17, 18 and 10, 9, 4, 1 respectively, which di↵er within their
respective pair by only a Phe/Ala substitution at position 7. In all examples, exchanging
Phe at position 7 with Ala corresponds to a reduction in e cacy, indicating Phe is
important for activity. (2) The importance of the number of heterocycles (Fig. 5.22):
By comparing a subset of the compounds (18, 20, 25, 28) which contain three or
more heterocycles (azol(in)e or proline) with a subset of compounds containing only two
heterocycles (16, 23, 10, 26), it becomes apparent that the compounds with the greater
number of heterocycles are significantly more active at both 50 and 5 µM. Furthermore
substitution of oxazoline with proline retains good inhibitory strength, suggesting
the conformational consequence of the five-membered ring is more important for an
interaction with Pgp than the electrochemical properties of the oxazoline ring. These
observations are consistant with the identification of compounds 20, 24, 25, 28, and
29 as hit compounds. (3) The importance of Thz vs ThH (Fig. 5.22): Throughout the
data there is a general trend that compounds containing the oxidised Thz heterocycles
confer better inhibition than their counterparts with reduced ThH heterocycles. This
trend is epitomised by the examples in Fig. 5.22, particularly when the compounds are
screened at 50 µM. Although this trend does not apply to all the compound pairs within
the screen, it is followed more often than not, and so is likely an important factor in
activity.
The dose-dependent inhibition of Pgp by the three oxidised hit compounds 20, 25 and
29 were measured and gave IC50 = 6.62, 1.68 and 5.08 µM respectively (Fig. 5.23).
These data reinforce the idea that oxazoline can be adequately substituted with proline,
and in these cases actually result in more e cacious compounds, compared with the
natural compound 18 (IC50 = 8.53). In fact the most potent of the three compounds,
compound 25, has both oxazoline residues substituted with proline residues. The least
active of these three, compound 20, contains an unprocessed threonine residue, while in
the more active 29, the remaining threonine residue has been processed to oxazoline.
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Figure 5.22: SAR analysis (a) Identification of compounds 20, 24, 25, 28, and 29
as hit compounds at 50, 5 and 0.5 µM shown in orange. Basal activity (untreated Pgp)
is shown in yellow; 200 µM verapamil treated Pgp (ver) is shown in green; 50, 5 and
0.5 µM CsA and 200 µM verapamil treated Pgp are shown in red; 50, 5 and 0.5 µM 18
and 200 µM verapamil treated Pgp are shown in blue. (b) Activity of Phe-containing
compounds compounds 18, 17, 16, 15 (red) vs Ala-containing compounds 1, 4, 9, 10
(blue). (c) Activity of compounds containing three or more heterocycles 18, 20, 24,
28 (red) vs compounds containing two heterocycles 16, 23, 10, 26 (blue). (d) Activity
of Thz containing compounds 18, 1, 20, 29 (red) vs ThH containing compounds 17,
4, 19, 28 (blue). Basal activity (untreated Pgp) is shown in yellow; 200 µM verapamil
treated Pgp (ver) is shown in green.
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From these data alone, further SAR rules can be proposed. (1) Proline is more e cacious
than oxazoline (25 is the best compound tested, and all three compounds are more active
than 18), and (2) four heterocycles are more potent than three heterocycles (29 >20).
However the e↵ect of rule (1) is more significant than that of rule (2) (20 >18). Further
work is required to test these hypotheses and to investigate these SARs more thoroughly.
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Figure 5.23: Dose-dependant Pgp inhibition of hit compounds Dose response
of addition of (a) 20, (b) 25, (c) 29 on 200 µM verapamil stimulated ATPase activity
of Pgp. Error bars represent +/- 1 standard error.
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5.4 Conclusions
The one-pot in vitro synthesis provides a route to the production of natural and
unnatural, highly modified cyclic peptides, which is amenable to both scale and
diversity. The modified one-pot method maintains the flexibility of the original in vitro
synthesis [47], however it does not require multiple purification steps, making it much
faster and more e cient. Additionally, as the need for trypsin proteolysis has been
dispensed with, the one-pot in vitro synthesis can, in principle incorporate lysine and
arginine residues into the final products. A major strength of the in vitro synthesis
is the a ability to produce multiple products from a single starting peptide, simply by
changing the combination of enzymes or altering the reaction conditions. Using the
biotechnological toolkit described in this thesis, it is currently possible to produce up
to five products from a single precursor peptide (Fig. 5.24). This toolkit, and thus
product diversity can be expanded by incorporating other, cyanobactin PTM enzymes,
including various prenyl-transferase enzymes [57,59], and potentially PTM enzymes from
other RiPPs.
The compatibility of the one-pot in vitro synthesis with synthetic substrates combines
the e ciency and the economical and environmental advantages of biotechnology with
the flexibility of chemical synthesis, and can be used to introduce diversity into peptidic
macrocycle sca↵olds beyond amino acids [58]. The ease of preparation of the one-pot
method make it suitable for the manufacture of small, focused libraries, based on a
known starting point; as demonstrated by the synthesis of greater than twenty analogues
of patellamide D. Other method developments detailed in this chapter also contribute to
the overall e ciency of cyclic peptide production and analysis. The developed extraction
procedure using n-BuOH selectively isolates peptide macrocycles from complex mixtures
of enzymes, co-factors and linear peptides. It provides a straightforward means to access
purer product, which is potentially applicable on a multi-well format, and so compatible
with library production. Additionally the validated-qNMR methodology provides a
universally applicable method to quantify synthesis products which lack a fluorophore,
and so cannot be accurately quantified by other means.
By synthesising over twenty analogues of patellamide D via the one-pot in vitro synthesis,
and testing them using the Pgp-GloTM assay for their ability to inhibit the ATPase
activity of Pgp, it has been possible to assign some preliminary structural-activity
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Figure 5.24: One-pot in vitro synthesis products Using the current
biotechnological toolkit described in this thesis it is possible to produce up to five
products from a single starting peptide.
relationships for Pgp inhibition. In summary: substituting phenylalanine at position 7
with alanine greatly reduced e cacy, and compounds with more than two heterocycles
(azol(in)e or proline) confer the best activities. Interestingly oxazoline moieties can be
substituted with proline residues without loss of activity, and thiazole heterocycles are
generally more active than thiazoline. Moreover three analogues, containing a mixture
of prolines and thiazoles, more potent than the natural compound have been identified.
5.5 Future Work
Attempts to optimise the one-pot in vitro synthesis reaction conditions are ongoing, with
the need to reduce the amount of enzyme required to accomplish each biotransformation
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of paramount importance when operating on a larger scale. One possible solution
is to immobilise the enzymes onto beads. This would not only simplify downstream
purification of the products, but potentially enable the enzymes to be recycled, reducing
the need to regularly purify large amounts of protein.
Work is underway to combine the one-pot in vitro synthesis and solid-phase peptide
synthesis, ultimately on the one bead one compound scale. This would enable a route
to larger library design, and potentially the identification of new, biologically active
peptide macrocycles.
Further work is required to test the SAR hypotheses proposed in this chapter, and the
work can be expanded to test more compounds containing a greater range of amino acids,
to more thoroughly assess SAR of Pgp inhibition. Additionally alternate functionality
can be tested, including oxazole rings and prenylated residues. Ultimately bespoke
macrocycles with increased e cacy can be designed, synthesised and tested.
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Appendix A - Media and Bu↵er
Compositions
Minimal medium 19 mM (NH4)2SO4, 22 mM KH2PO4, 22 mM
Na2HPO4, 9 mM NaCl
Autoinduction medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 mL
H2O / L culture). Media supplemented with 1 mM
MgSO4, 0.5 % glycerol, 0.05 % glucose, 0.2 % ↵-
lactose, 25 mM (NH4)2SO4, 50 mM KH2PO4, 50 mM
Na2HPO4
G-DUF lysis bu↵er 150 mM NaCl, 20 mM Bis-tris pH 6.8, 20 mM
imidazole pH 8.0, 0.1 % Triton X-100, 3 mM BME
G-DUF elution bu↵er 150 mM NaCl, 20 mM Bis-tris pH 6.8, 250 mM
imidazole pH 8.0, 0.1 % Triton X-100, 3 mM BME
Desalt bu↵er 150 mM NaCl, 20 mM Bis-tris pH 6.8, 20 mM
imidazole pH 8.0, 3 mM BME
Desalt bu↵er 2 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM
imidazole pH 8.0, 3 mM BME
Gel filtration bu↵er 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP
Urea lysis bu↵er 8 M Urea, 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20
mM imidazole pH 8.0, 3 mM BME
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Urea elution bu↵er 8 M Urea, 500 mM NaCl, 20 mM Tris-HCl pH 8.0,
250 mM imidazole pH 8.0, 3 mM BME
General lysis bu↵er 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM
imidazole pH 8.0, 3 mM BME
General elution bu↵er 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM
imidazole pH 8.0, 3 mM BME
One-pot storage bu↵er 150 mM NaCl, 10 mM Bicine pH 8.5, 1 mM TCEP
Peptide column bu↵er 150 mM NaCl, 20 mM Bicine pH 8.1
One-pot reaction bu↵er 150 mM NaCl, 50 mM Bicine pH 9.0
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